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Aim: There was continued interest in developing more efficient new
chelating agents for metal radionuclides mostly used for positron
emission tomography (PET) imaging. We focused on the develop-
ment of convenient syntheses of acyclic siderophore derivatized with
four N-hydroxy-N-methyl succinamide pendant arms called 4HMS
and its bifunctional analog, 4HMSA, for zirconium-89 (89Zr) and
gallium-68 (68Ga) complexation. The aim of this project was to assess
the suitability of 4HMS and 4HMSA for 89Zr and 68Ga-PET.
Methods & Results: 4HMS and 4HMSA were prepared through mul-
tiple steps starting with a spermine backbone to offer both chelating
agents with high overall yield (72-58%). Both chelating agents exhib-
ited strong selective coordination of 89Zr and 68Ga and offered a very
fast labelling kinetic at room temperature as compared to DFO and
DOTA/NOTA analogs. Achievable molar activity for 68Ga-4HMSA is
almost 10 and 3 times higher compared to 68Ga-DOTA and NOTA
analogs. Molar activity of 89Zr-4HMS is approximately 16 fold higher
compared to 89Zr-DFO. Both radio-complexes were stable in saline,
serum, as well as against transchelation and transmetallation. 68Ga-
4HMSA showed high stability in mouse plasma in vitro and in vivo
over 1h and 89Zr-4HMS chelator also showed high stability in mouse
plasma over 7 days. Biodistribution and imaging studies were per-
formed in balb/C mice. The background activity in various tissues
was low at 1h post-injection (p.i.) for 68Ga-4HMSA with a rapid elim-
ination mainly through the kidneys and liver. At the same time point,
the activity was largely found in kidneys for 89Zr-4HMS chelator. At
24 h p.i. most of the 89Zr-4HMS chelator was cleared from all organs
and the low amount of activity in kidneys and bone is consistent
with the clearance of the intact complex. Finally, the conjugation of
unprotected 4HMSA to peptides of biological interest was complete
within ~4 h with overall yields of 50-60%.
Conclusion: 4HMSA and 4HMS show an outstanding promise as
68Ga and 89Zr chelators. In terms of Zr4+ chelation and stability,
4HMS ligand has proven to be a superior chelator compared to
DFO.© The Author(s). 2018 Open Access This article
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifOP02
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Aim: Pretargeting approaches for antigen targeting combining the
excellent target affinity and selectivity of antibodies with the advan-
tages of using short-lived radionuclides such as gallium-68 have
attracted increasing interest. Among them especially the bioorthogo-
nal inverse-electron-demand Diels-Alder (IEDDA) reaction between
radiolabelled tetrazines (Tz) and trans-cyclooctene (TCO) antibody
conjugates has emerged as an effective two-step approach. Here we
present an attempt to improve IEDDA pretargeting by preparing
multimeric Tz-ligands based on a Fusarinine C (FSC) chelating scaf-
fold for gallium-68 with 3 primary amines for functionalization and
evaluating its targeting efficiency.
Methods: FSC was partially acetylated, resulting in Monoacetyl-
(MAFC) and Diacetyl- FSC (DAFC). Tz functionalization was performed
by reaction with NHS-PEG5-Tz with FSC (resulting in the trimer FSC-
(PEG5-Tz)3), MAFC (resulting in the dimer MAFC-(PEG5-Tz)2) and
DAFC (resulting in the monomer DAFC-(PEG5-Tz), starting from its
ferric complex with final iron removal by EDTA, HPLC purification
and characterization by MS. 68Ga-labelling was performed in acetate
buffer (pH 4.5) at high s.a., resulting complexes were characterized
by HPLC, protein binding, log P and stability was assessed. Rituximab
was functionalized with NHS-TCO according to published procedures
(Rtx-TCO). Binding of Tz-conjugates to TCO was assessed on Rtx-TCO
immobilized 96well plates as well as after binding of Rtx-TCO vs Rtx
to Raji cells expressing CD20 followed by incubation with 68Ga-Tz-
conjugate. Biodistribution was studied in normal balb-c mice.
Results: Mono- di and trimeric Tz-FSC conjugates were prepared in
high yields and could be radiolabelled with gallium-68 at high s.a. re-
vealing good stability in PBS solution and serum, protein binding
exceeded 50% for FSC-(PEG5Tz)3, MAFC-(PEG5Tz)2, DAFC-(PEG5Tz),
log p values were below -1. In vitro binding to TCO revealed signifi-
cantly enhanced binding of the di-and trimeric constructs vs. the
monomeric DAFC-(PEG5Tz) both towards isolated Rtx-TCO as well as
after binding of Rtx-TCO to CD20 expressing cells (monomer 4.01 ±is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 2 of 380.24%; dimer 7.75 ± 0.56%; trimer 15.9 ± 0.88%). Biodistribution
showed a similar profile with rapid renal excretion and moderate up-
take in liver and kidneys (<10% ID/g), blood levels increased from
the mono to the trimer from 1%-3%ID/g 1h p.i.
Conclusion: Our preliminary results show that the preparation of
polyvalent Tz-conjugates based on a chelating scaffold is feasible. In
vitro results revealed enhanced binding of di- and trimeric constructs
vs. the monomer similar to the affects seen in receptor targeting li-
gands, biodistribution data revealed favourable biodistribution for
these pretargeting constructs. Proof of tumour targeting in vivo in re-
spective animal models is currently ongoing.Fig. 1 (abstract OP02). Scheme: Synthetical pathway of tetrazine
modified FSC-based pretargeting agentsOP03
99mTc-radiolabeling of a poorly soluble protein, a variable heavy
chain antibody domain targeting pancreatic β-cells
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Aim: VH-13 is a single monomeric variable heavy chain antibody do-
main of a Lama IgG. It will be tested for pancreatic beta cells mass
using small animal nuclear imaging. However, VH fragments are
known to aggregate in isolation, in the absence of the light-chain
partners. The aim of this study was to find the best conditions to ra-
diolabel VH-13 with technetium-99m to avoid the potential forma-
tion of aggregates during the radiolabeling process.
Methods: VH-13 contains a poly-His tag in C-terminal position that is a
specific site suitable for labeling with Tc-99m using the tricarbonyl
method. 99mTc-tricarbonyl precursor was prepared before its incubation
with VH-13 in different conditions of concentration, temperature and in-
cubation time. Due to the appearance of aggregates during radiolabel-
ing or purification, we first studied different concentrations of several
excipients to decrease their formation: 0.2, 10 and 100 mM of arginine
(pH=7 or 12), 5% of tween-80 (w/w), 10 and 20% of heparin (w/w), 1 M
of acetone or 4% of DMSO (v/v). In a second time, 2 variants of VH-13
were designed with mutations in the VH-VL interface of the protein to
improve the solubility. All radiolabeling parameters were then adjusted.
All of radiolabeled products were analyzed by radio-HPLC.
Results: The presence of arginine at 100 mM allowed to avoid the
appearance of aggregates. But whatever the pH conditions, arginine
was radiolabeled with Tc-99m. 10 or 20 % of heparin decreased the
aggregation, quality control before purification showed a high radio-
chemical purity (RCP), but more than 80% of the radiolabeled prod-
uct remained on the purification columns, probably because of a
very light aggregation remaining. Adding DMSO was not compatible
with the radiolabeling procedure with a RCP < 50%. Finally, the two
mutants of VH-13 were radiolabeled and purified successfully. The
RCP of radiolabeled products was higher than 95%.Conclusion: Among all the tested excipients, 100 mM of arginine inhib-
ited the aggregation of protein during radiolabeling. Nevertheless, it
was also radiolabeled and greatly decreased the labeling yield of VH-
13. The synthesis of the two novels mutants including a mutation in
the VH-VL interface of protein finally represented the best solution to
reduce the aggregation and to allow a successful radiolabeling.
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Aim: 111In labelled radiopharmaceuticals are extensively used for WBC la-
belling in routine clinical practice. 64Cu (T1/2: 12.7h and 89Zr (T1/2: 78.4h)
are alternative radiometals for synthesis of radiopharmaceuticals used for
cell labelling that could enable long-term PET “in vivo” cell tracking with
several attractive clinical applications. The aim of study was to prepare
64Cu and 89Zr tracers (oxine, tropolone) applying synthesis and concen-
tration on an anion exchange column and radiolabel cells (WBCs, RBCs).
Methods: Small volumes (1-2 mL) of tracers (oxine, tropolone) in PBS of
suitable radiochemical (n-octanol extraction) purity and activity (64Cu ≤102
MBq, 89Zr ≤3MBq) were prepared on the anion exchange column (SepPAK
QMA) using a previously described method. Cells were radiolabelled,
WBCs using modified (incubation time 20 min) EANM recommended
111In-oxine WBCs labelling method. Labelling efficiency, cell viability,
assessed by Trypan Blue exclusion assay and labelling stability (efflux of
radioactivity) was determined at different time points after radiolabelling.
Results: Synthesis and concentration on SepPAK QMA resulted in 89Zr-
tropolone with > 79.1% yield, pH 7.0-7.5 and extraction into octanol
>94.5%, for 89Zr-oxine solution 27.9-70.6% with pH 7-7.9 and extraction
> 80%. For 64Cu-tropolone >92.5% yield was achieved, pH between 6.9-
7.4, extraction into octanol of >89.1%, for 64Cu-oxine 55-91.1%, pH 6.9-
7.5 and extraction >90.6%. Labelling efficiency of RBCs with 89Zr-tropo-
lone was 45-50%, with 89Zr-oxine above 64.5%. Labelling efficiency of
WBCs was above 81.1% with 64Cu-tropolone independent of cell num-
bers, for 64Cu-oxine up to 68% highly dependent on the amount of cells
available. Viability of 64Cu-tropolone radiolabelled WBCs before and im-
mediately after the labelling was 92% and 85%, respectively 240min
after labelling 88% and 81%. Labelling stability of WBCs 240min after
cell radiolabelling was above 68% and remained constant up to 48h
after labelling. Viability of 64Cu-oxine radiolabelled WBCs immediately
after the labelling was 71% (90% unlabelled WBCs) and 70% 240min
after labelling (85% unlabelled WBCs). Labelling stability of WBCs
240min after cell labelling was above 91% but decreased to 78.1% 48h
after labelling. Preliminary μPET studies in animal infection models with
64Cu-WBCs showed expected accumulation in infected tissue.
Conclusion: The applied on-column synthesis and concentration
method enables formation of PET tracers (oxine, tropolone) with good
yields, quality and in small volumes suitable for cell radiolabelling. 89Zr
and 64Cu tracers radiolabel cells with sufficient stability and viability,
this way making this approach highly promising for routine clinical use.
OP05
Synthesis of 18F-AmBF3-losartan and preliminary in vitro evaluation
as a novel AT1R PET radioligand in Oncology
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):OP05
Fig. 1 (abstract OP06). Scheme of the synthesizer including the
self-constructed unit for the formulation of the second tracer
Fig. 2 (abstract OP06). Exemplary RP-HPLC chromatogram for the
separation of [11C]Harmine and [11C]DASB in a single run
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 3 of 38Aim: Angiotensin II type 1 receptor (AT1R) is a G protein-coupled recep-
tor recognized as a promising cancer therapeutic target. AT1R expres-
sion has been reported to drive tumor development and progression
for several cancers. Losartan, an AT1R inhibitor widely used for the treat-
ment of hypertension and congestive heart failure, has been shown to
inhibit cancer cell proliferation and angiogenesis. Moreover, losartan
derivatives labeled with fluorine-18 (18F) and carbon-11 were reported
for AT1R imaging by positron emission tomography (PET); however,
they were mostly employed as AT1R PET renal tracers. The present
study reports the synthesis of ammoniumethyl-trifluoroborate-losartan
(19/18F-AmBF3-losartan), a new AT1R PET radioligand for cancer imaging.
Methods: 19F-AmBF3-losartan was prepared via a copper-catalyzed
alkyne-AmBF3 and azide-modified losartan cycloaddition at 45
oC for
two hours, followed by semi-preparative HPLC purification. Then, 19F-
AmBF3-losartan (25 nmol, 15.3 μg) was radiolabeled with fluoride-18
(555-925 MBq) via an 18F–19F isotope exchange reaction in aqueous
phase at 80 oC for 20 minutes and purified by solid phase extraction
using a C18 Light Sep-Pak cartridge. In vitro AT1R binding studies
were performed at 4 oC for one hour using AT1R-positive MDA-MB-
231 breast cancer cells, AT1R-expressing CHO AT1R cells, and AT1R-
negative CHO cells. The in vitro studies were conducted in presence
or absence of the AT1R blocker losartan potassium (100 μM). AT1R ex-
pression in cells was confirmed by quantitative real-time reverse
transcription polymerase chain reaction (RT-PCR).
Results: Losartan potassium was converted into tetrazole-protected
losartan, azido-modified tetrazole-protected losartan, azide-modified
losartan and 19F-AmBF3-losartan with 83%, 77%, 96% and 52% yields,
respectively. Mass spectrometry confirmed their identities. 18F-AmBF3-
losartan was manually prepared in ~35 minutes, with 11 – 18 % radio-
chemical yield, > 97% radiochemical purity, and 1.8 – 2.9 GBq/μmol
specific activity. The identity of 18F-AmBF3-losartan was confirmed by
co-injection with the cold compound on analytical HPLC. In vitro studies
showed that uptake of 18F-AmBF3-losartan increased in AT1R-express-
ing MDA-MB-231 and CHO AT1R cells in comparison to control AT1R-
negative CHO cells. Pre-incubation with losartan potassium effectively
blocked 18F-AmBF3-losartan binding to AT1R-expressing cells.
Conclusion: We developed a facile radiolabeling method to synthesize
18F-AmBF3-losartan that showed specific binding to AT1R-expressing
cells in vitro. These results demonstrate that 18F-AmBF3-losartan might
be a promising tracer for imaging AT1R-expressing tumors.
References
1. Liu Y, An S. Ward R, Yang Y, Guo X, Li W, Xu T,[2016], Cancer Lett.
376:226-239
2. Liu Z, Lin K, Bénard F, Pourghiasian M, Kiesewetter DO, Perrin D, Chen X,
[2015], Nat. Protoc. 10: 1423-1432
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Time is Money and Radiation Burden - a carbon-11 ‘two-in-one-
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Aim: The use of positron emission tomography (PET) for specific mo-
lecular examinations is increasing steadily and therefore the demand
for selective and specific PET-tracers is rising accordingly. Currently,
only one tracer per synthesizer can be produced (non-cassette
based) within a time frame of approximately 2 h and a radiation bur-
den of approximately 1 h. A minimum decay time of 6 half-lives
(around 2 h) between two carbon-11 productions within the same
hot-cell is essential. Therefore, in clinical routine (8 h day) only two
syntheses of carbon-11 labeled compounds per day are possible.
Consequently, the number of examinations with 11C-labeled tracers
is extremely limited (number of productions; high synthesis costs
and few production runs due to number of hot cells and synthe-
sizers). To improve this situation, the aim of this study was thesimultaneous production of two 11C-PET-tracers using a ‘two-in-one-
pot’ reaction reducing time, cost, and radiation burden. Exemplarily,
this simultaneous production was successfully performed for two
commonly used brain PET-tracers, [11C]Harmine and [11C]DASB.
Methods: Production runs were performed using a commercially
available GE Tracerlab FX C Pro. 1 mg of the precursors, MASB and
Harmol, were dissolved in DMSO and 5 M NaOH was added to the
solution. [11C]CH3I was subsequently bubbled through the precursor
solution. After a reaction time of 2 min at 100°C, the crude dual-
tracer mixture was purified by means of semi-preparative HPLC. The
synthesis module was expanded with a self-constructed semi-
automated formulation unit (Fig. 1) to ensure parallel SPE-purification
and formulation of both tracers after HPLC (Fig. 1).
Results: Both PET-tracers were prepared simultaneously in a ‘two-in-
one-pot’ reaction (n = 3) and successfully purified using one single
HPLC run. Radiochemical yield was 2.0 ± 0.3 GBq (2.3 ±0.5% not cor-
rected for decay; based on [11C]CO2 @EOB) for [
11C]DASB and 2.0 ± 0.7
GBq (2.2 ± 0.8%) for [11C]Harmine, respectively. Hence, both products
were received in the same amount (ratio 1:1). The qualities of both
tracers complied with the European Pharmacopoeia monographs.
Conclusion: We herewith describe the first simultaneous production
of two 11C-PET-tracers in a ‘two-in-one-pot’ reaction. Both products
were in full accordance with quality control parameters fulfilling the
standards for parenteral human application. This simultaneous radio-
pharmaceutical preparation lead to a significant reduction of radi-
ation burden, reduction of amount of operator time (-50%), cost
reduction (-46.2%) and, subsequently, to considerable gain in overall
efficiency of the production process.
Table 1 (abstract OP08). See text for description
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18F-labelled BODIPY-steroid hormone conjugates as potential
bimodal PET and fluorescence receptor imaging agents
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Aim: 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) has been
used as a fluorescent probe to label a variety of different ligands. BOD-
IPY derivatives have also been radiolabeled with radionuclides for the
development of bimodal PET and fluorescent imaging agents. Previ-
ously we reported the synthesis of BODIPY-estradiol and androgen con-
jugates as potential fluorescent probes for receptor imaging in breast
and prostate cancers.1 Relative binding affinities of a series of BODIPY-
estradiol conjugates revealed that only the analog featuring an eight
carbon spacer between the two entities showed good receptor binding
affinity.2 We recently confirmed by in vitro fluorescence imaging that
this analog localizes through a receptor-mediated process on cancer
cells that over-express the estrogen receptor.3 As a continuation of
these studies, we evaluated various routes to prepare the analogous
bimodal 18F-labelled BODIPY-steroid conjugates.
Method & Results: 18F-labeled 4-iodophenyl substituted BODIPY was
first prepared by the SnCl4-assisted
18F-19F isotopic exchange method
(50-70%).4 This radiolabeled moiety was subsequently conjugated in
high yield to the C17α-position of estradiol and androgen derivatives
under Sonogashira cross coupling reaction conditions using Pd-
catalyst, base and CuI. Direct labelling of the conjugates using SnCl4-
assisted 18F-19F isotopic exchange method resulted in the simultan-
eous addition of a Cl-atom to the C17α-ethynyl group and a poor
molar activity.
Conclusion: Our studies confirm the potential to prepare 18F-
labelled analogs of BODIPY-steroid conjugates. We are currently
evaluating an alternative approach using 4-dimethylaminopyridine
BODIPY as precursor to allow the efficient incorporation of 18F to po-
tentially generating higher molar activity conjugates suitable for
receptor-based bimodal imaging studies.
References
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Copper-mediated radiofluorination of aryl pinacol boronates in the
presence of pyridinium sulfonates
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Aim: Nowadays copper-mediated radiofluorination of arylboronic
acids pinacol esters (ArylBPin) found ample application for 18F-labeling
of various electron-rich arenes.1 The improvement of this methodology,
in particular, 18F-recovery step, has been in focus of the recent re-
searches.2,3 The suggested use of aqueous solutions of non-ionic bases
for 18F-elution was efficient, however in non-aqueous solutions these
weak bases cannot reach sufficient degree of protonation for 18F-recov-
ery. Non-aqueous solutions of 4-dimethylaminopyridinium sulfonatesmay constitute an amenable alternative. These salts may serve both as a
source of co-ligand for Cu(OTf)2py4 catalyst, increasing its efficiency,
4
and as appropriate PTC agents.
Methods: Following earlier suggested procedure2 an aqueous
[18F]fluoride was loaded onto an anion exchange cartridge from the
male side (OASIS WAX 1cc, 30 mg, preconditioned with 0.5 M
NaHCO3 and water). The cartridge was rinsed with 1 ml of i-PrOH in
the same direction and dried by compressed air. [18F]Fluoride was
eluted from female side with 25 μmol of 4-dimethylaminopyridinium
tosylate (4-DMPTs) or 4-dimethylaminopyridinium triflate (4-DMPTf)
in 0.5 mL of DMA into the vial containing 5.3 μmol of Cu(OTf)2py4
and 17.9 μmol of ArylBPin precursor in 0.5 ml of DMA. The mixture
was heated (110 °C, 20 min) in a sealed vial under air. After cooling
radiochemical conversion (RCC) was determined by radioTLC.
Results: Both sulfonates provided similar 18F-elution efficiency (EE),
however higher RCC were achieved using triflate salt. Notably, with this
protocol relatively small amount of precursor and catalyst was required.
Its feasibility was confirmed for a series of model aromatic substrates.
Conclusion: Easily accessible 4-dimethylaminopyridinium triflate has
shown to be suitable 18F-eluting agent for alcohol-enhanced Cu-
mediated radiofluorination. The developed procedure is very simple,
avoids any solvents evaporation steps and easy adaptable to auto-
mation. Work is now in progress to adapt this procedure to the prep-
aration of clinically relevant radiotracers. Research support: RFBR
grant № 16-54-12062\16.
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Development of biocompatible and functionalised polymer
nanoparticles for the specific vectorisation of an imaging agent
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Aim: Nanomedicine, the application of nanotechnologies to the med-
ical domain, is a fast-growing research field, especially the production
of nanoparticles enabling encapsulation then controlled and targeted
release of molecules of interest, such as a cytotoxic drug. Diagnostic
could also benefit from the use of such nanovectors containing one
or more imaging agent(s) (fluorescent dye, contrast agent, radio-
nuclide) to image a tumour.
Fig. 1 (abstract OP10). See text for description
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 5 of 38Methods: Benzyl polymalate and its derivatives (pegylated and bio-
tinylated) were prepared according to the method previously de-
scribed. (1) Different techniques have been used to formulate the
nanoparticules and to incorporate an imaging agent (DiD-Oil, fluores-
cein amine and a 99mTc-based radiotracer). The resulting nanoparti-
cles were characterised using various techniques (DLS, zetametry,
AF4, TEM, EDS). Preliminary in vitro studies have also been done.
Results: Prepared nanoparticles were monodisperse and stable. To en-
capsulate fluorescent DiD-Oil and lipophilic 99mTc-SSS radiotracer, nano-
precipitation method was not suitable and had to be modified. (2) The
resulting nanoparticles were also monodisperse and stable, with a
slightly higher diameter. Electron-dispersive spectroscopy coupled to
TEM demonstrated the presence of sulphur in the nanoparticles, thus
confirming the encapsulation of the radiotracer. Various peptides have
been grafted through streptavidin and their affinity to different hepa-
toma cell lines was tested.
Conclusion: We have developed a family of nanoparticles based on de-
gradable, biocompatible and functionalisable polymers, enabling the bind-
ing of specific targeting agents (eg. peptides) and incorporating an
imaging agent, either for optical or scintigraphic imaging. These objects de-
serve further investigation to gain a deeper understanding on their proper-
ties and in vivo behaviour. Direct grafting of the most promising peptides
is underway. Encapsulation of a therapeutic radiotracer is also planned.
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Aim: Monoclonal antibodies have been widely exploited for both
diagnostic and therapeutic purposes. For antibody radiolabeling with
Cu-64, a bifunctional chelator is required which can seize the radio
metal quite robustly into its cavity. Thus development of cross-
bridged chelator is in need. Unlike the other biomolecules (e.g., pep-
tide, aptamer), antibody radiolabeling condition is tricky and needs
sophisticated and mild labelling conditions which limits the applica-
tion of cross-bridged chelator in immuoPET. We report a new kind of
cross-bridged macrocyclic chelator (PCB-TE2A-alkyne), which can be
converted to any copper free clickable moiety or any functional
group for antibody conjugation (Fig. 1). It thus enables a general
platform for antibody tagging with Cu-64.
Methods: The propylene cross-bridged chelator was modified to differ-
ent clickable moieties and various functional groups in a single step
prior to radiolabeling. To confirm its applicability radiolabeled chelator
was then conjugated to trastuzumab and biodistribution and microPET
imaging was done in NIH3T6.7 tumor-bearing BALB/c nude mice.
Results: Starting from cyclam the PCB-TE2A-alkyne was synthesized
in five consecutive steps with 32% overall yield. It was then modified
to different functional groups, viz., tetrazine, NHS-ester, maleimide, in
a single step in excellent yield. Modifications to different functional
groups did not require any HPLC purification. In further, the tetrazine
modified chelator was radiolabeled with Cu-64 in high yield and con-
jugated to trastuzumab within 10 minutes at room temperature.
Conclusion: A versatile propylene cross-bridged macrocyclic chelator for
radiolabeling of heat-sensitive antibody with Cu-64 was demonstrated.Acknowledgements
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Aim: Pseudomonas aeruginosa (P.a.) is an increasingly prevalent oppor-
tunistic pathogen that causes a variety of life-threatening nosocomial
infections, especially in immunocompromised hosts. The diagnosis of
infections caused by P.a. can be challenging due to inconvenient diag-
nostic methods, which are often slow, invasive or lack sensitivity and/or
specificity. Novel diagnostic tools are urgently needed. One of the
novel diagnostic strategies for the specific detection of P.a. infections
could be utilization of radiolabelled siderophores. Siderophores are
small molecules produced by many microorganisms to scavenge essen-
tial iron. Replacing iron in siderophores by suitable radiometal could
open approaches for targeted imaging of infection. Here we report on
the preclinical evaluation of Ga-68 labelled pyoverdine, siderophore
produced by P.a., for specific diagnosis of P.a. infections.
Methods: Radiolabelling of pyoverdine isolated from P.a. with Ga-68
was performed using acetate buffer. Radiochemical purity was ana-
lyzed by RP-HPLC and ITLC-SG. Protein binding, partition coefficient
and stability values of 68Ga-pyoverdine in human serum and in the
excess of competing chelator and metal were determined. In vitro
uptake was tested in various microbial cultures. Ex vivo biodistribu-
tion was studied in normal Balb/c mice. Uptake of 68Ga-pyoverdine
by P.a. in vivo was studied in respiratory and muscle infection animal
models using PET/CT imaging. In vivo specificity of 68Ga-pyoverdine
for P.a. was compared with other radiopharmaceuticals.
Results: Pyoverdine was labelled with 68Ga with high (>95%) radio-
chemical purity. The resulting complex showed hydrophilic properties
(log P = -3.07±0.08), low protein binding (<3% up to 120 min incuba-
tion) and ~95% stability in human serum. In vitro uptake of 68Ga-pyo-
verdine was highly dependent on iron load and type of microbial
culture. In P.a. cultures high uptake under iron-deficient conditions was
observed that could be blocked. Furthermore in all other tested micro-
bial cultures the uptake of 68Ga-pyoverdine was significantly lower. In
normal mice 68Ga-siderophore showed rapid renal excretion and low
blood values (0.09±0.01 %ID/g) even at a short time period (90 min)
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 6 of 38after application. PET/CT imaging in infected animals displayed specific
accumulation of 68Ga-pyoverdine in infected tissues and better distribu-
tion than other, clinically used radiopharmaceuticals.
Conclusion: We have shown that pyoverdine can be labelled with
Ga-68 with high affinity and radiochemical purity. 68Ga-poverdine
displayed suitable in vitro characteristics and excellent pharmacokin-
etics. The high and specific uptake of 68Ga-pyoverdine by P.a. was
confirmed both in vitro and in vivo, proving its potential for specific
imaging of Pseudomonas infections.
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Aim: Invasive pulmonary aspergillosis (IPA) mainly caused by Asper-
gillus fumigatus (AFU) is a major cause of mortality in immunosup-
pressed patients mainly due to the lack of sensitive and specific
diagnostic procedures. AFU secrets the siderophore triacetylfusari-
nine C (TAFC) to sequester iron for acquisition and uptake via the
MirB transporter. This system is essential for AFU virulence and is
highly upregulated during infection. We have shown that TAFC can
be radiolabeled with 68Ga thereby exhibiting excellent targeting
properties in an AFU infection model [1]. Here we aimed to modify
TAFC and investigate the influence of introduced substituents on
preservation of AFU-targeting characteristics in vitro and in vivo by
μPET/CT imaging.
Methods: TAFC derivatives with various substituents (different
carbon chain lengths, charges, fluorescent dye) were synthesized
starting from the deacetylated forms of TAFC, characterized by
HPLC and MS and radiolabeled with 68Ga. Stability, protein binding
and logP values were determined. In vitro uptake by AFU was
performed in iron-depleted and iron-replete cultures. Selected
compounds with highest, lowest and comparable uptake ratio to
TAFC were studied regarding their biodistribution behaviors in
normal BALB/c mice as well as via μPET/CT imaging in healthy and
AFU-infected Lewis rats.
Results: 15 different TAFC derivatives with varying substitutions were
synthetized in high yields and could be labeled with 68Ga at high specific
activity. Lipophilicities as expressed in logP were -0.38 to -3.80
([68Ga]TAFC -2.1). In vitro uptake studies revealed retained recognition by
the MirB transporter with reduced uptake efficiency with increasing num-
ber of substitutions (mono-, >di, > tri). Introduction of fluorescent dye
(FITC) allowed imaging of uptake and processing of TAFC analogs. Three
selected compounds, [68Ga]DABuFC, [68Ga]TPFC and [68Ga]FSC(suc)3, dis-
played low protein binding and were stable in PBS and serum. Biodistri-
bution behavior and image contrast by μPET/CT of [68Ga]DABuFC was
comparable to [68Ga]TAFC whereas [68Ga]TPFC showed higher uptake in
intestine. The derivative with the lowest in vitro uptake, [68Ga]FSC(suc)3,
displayed no signal in μPET/CT image of infected Lewis rats.
Conclusion: This study shows the possibility of TAFC modification
without losing its in vitro and in vivo properties to target AFU via spe-
cific recognition of the MirB transporter. Substitution of one acetyl
group of TAFC by functionalities such as fluorescent dyes opens al-
ternative strategies for theranostics of infectious diseases.
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Aim: The current “gold standard” chelator to label antibodies with
89Zr for immunoPET is desferrioxamine (DFO). Preclinical studies have
shown that the 89Zr-DFO complex is partly unstable in vivo, resulting
in release of 89Zr and subsequent accumulation in mineral bone tis-
sue. This bone uptake may prevent the detection of bone metasta-
ses, and hampers accurate estimation of the radiation dose to the
bone marrow in dose planning for radioimmunotherapy. Therefore,
there is a need for a more stable 89Zr chelator. Here we report DFO-
cyclo*, a preorganized extended DFO derivative introducing an octa-
coordination, and investigate the stability of its 89Zr complex over
the unsaturated hexacoordinated 89Zr-DFO complex in vitro and
in vivo.
Methods: DFO-cyclo* was prepared by coupling of a cyclic hydroxa-
mate group to DFO. Trastuzumab was conjugated with DFO-cyclo*-
pPhe-NCS or DFO-pPhe-NCS and radiolabeled with 89Zr. Stability of
the labeled antibody conjugates was evaluated in human plasma
and in PBS with a 1000-fold molar excess of EDTA or DFO at 37°C up
to 7 days. The immunoreactive fraction, IC50 and internalization cap-
acity of 89Zr-DFO-cyclo*-trastuzumab or 89Zr-DFO-trastuzumab were
evaluated in vitro using HER2-expressing SK-OV-3 cells. The in vivo
distribution of 89Zr-DFO-cyclo*-trastuzumab and 89Zr-DFO-trastuzu-
mab was investigated in mice with subcutaneous SK-OV-3 xenografts
by ex vivo tissue analyses and PET/CT imaging.
Results: Labeling efficiencies exceeded 99% and specific activities >
150 MBq/mg were reached for both 89Zr-DFO-cyclo*-trastuzumab
and 89Zr-DFO-trastuzumab. When challenged with an excess of
EDTA or DFO at 37°C for 7 days, 89Zr-DFO-cyclo*-trastuzumab
showed significantly higher stability than 89Zr-DFO- trastuzumab:
99 ± 1% vs. 61 ± 1%, and 55 ± 3% vs. 44 ± 3%, respectively. Immu-
noreactive fractions of 65% and 61% and IC50 values of 2.89 nM
and 2.93 nM were found for 89Zr-DFO-cyclo*-trastuzumab and 89Zr-
DFO-trastuzumab, respectively. Internalization after 2 h was signifi-
cantly higher for 89Zr-DFO-cyclo*-trastuzumab (26.6 ± 1.1%)
compared to 89Zr-DFO-trastuzumab (22.4 ± 1.5%) (p < 0.005). Bone
uptake (%ID/g) was significantly lower for 89Zr-DFO-cyclo*-trastuzu-
mab compared to 89Zr-DFO-trastuzumab in knee (3.6 ± 0.4% vs. 5.9
±0.6%), femur (2.2 ± 0.2% vs. 3.4 ± 0.3%), and sternum (3.5 ± 0.4%
vs. 4.5 ± 0.4%) at 72 h after injection (p < 0.005). Tumor uptake and
blood clearance did not differ significantly.
Conclusion: 89Zr-DFO-cyclo*-trastuzumab shows improved in vitro
and in vivo stability compared to 89Zr-DFO-trastuzumab. In immuno-
PET, less radiation exposure to bone marrow, improved bone metas-
tasis detection and improved radioimmunotherapy dose planning
may be achieved using DFO-cyclo*.
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Aim: The labelling of autologous WBCs is a standard clinical practice
for the scintigraphic detection of infectious or inflammatory disease.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 7 of 38The mechanism of cell labeling is based on the lipophilic complex
formed upon reconstitution, which can freely cross the cell mem-
brane and once in the cytoplasm, is transformed into a secondary
complex. However, some efflux from cell has been reported, causing
errors of interpretation in the scintigraphic studies, since the activity
detected does not always correspond with true cellular uptake. In
this sense, it is postulated by some authors that the conversion to
secondary complex is reversible, and over the time, a percentage of
the primary complex tends to appear and elute from cells.
Methods: Leukocytes (≈108) from healthy human volunteers (n = 5)
were labelled following guideline, splitted into two aliquots of 0.5 cc
in plasma and saline and incubated under stirring at 37°C, for 2h and
4h. After incubation, samples were centrifuged at 2000xg and the
supernatant was analyzed by HPLC in a C18 (4 μm, 3.9x150 mm) col-
umn with a gradient mobile phase of 0.05M sodium acetate/tetra-
hydrofuran at a flow rate of 1.5 ml/min. The percentages of primary
and secondary complex and free 99mTc pertechnetate were deter-
mined by their retention time (tr). 99mTc-HMPAO-human leukocytes
(n = 3) were mechanically lysed and extracted in 0.5 ml of water for
injection, centrifuged at 2000xg and analyzed as described.
Results: Percentages of 17.8±0.7 of free 99m Tc pertechnectate (tr =
1,5 min) and 82.1±0.7 % of secondary complex (tr = 4,5 min) were
found in saline at 2 and 4 h. Results in plasma were of 21.7±2.1 %
for 99mTc free pertechnectate and 78.3 ± 2.1% for secondary com-
plex. No primary complex was detected (tr = 8 minutes) at any time
of incubation. Cell extracts showed percentages of 8.1±1.1 % of free
99m Tc pertechnectate and 92.1±1.2% of secondary complex. No pri-
mary complex was detected.
Conclusion: While secondary complex was detected inside and out-
side the cells, primary complex was absent in extracts and effluxes at
any time of study. The percentage of 99m Tc pertechnetate is prob-
ably due to oxidation during the incubation period. According to our
results, the activity detected in cell effluxes is related to the exit of
secondary complex, rather than the exit of primary complex after re-
versibility of the original conversion inside the cell.
References
1. De Vries EF, Roca M, Jamar F, Israel O, Signore A. 2010. Eur J Nucl Med
Mol Imaging. 37(4):842-8.
2. Neirinckx RD, Burke JF, Harrinson RC, Forster AM, Andersen AR, Lassen
NA. 1988. J Cereb Blood Flow Metab. Vol 8(Suppl 1): 1-11.
3. Kao CH, Wang YL and Wang SJ. 1992. J Nucl Med Technol; 20(4):224-7
4. Hung JC, Corlija M, Volkert WA. 1988. J Nucl Med.29(9):1568-76
OP15
In vivo imaging of mGluR1 neuroreceptor kinetics in mouse brain
with [11C]ITDM microPET
Š. Korat1, D. Bertoglio1, J. Verhaeghe1, I. Munoz-Sanjuan2, C. Dominguez
2, L. Liu2, L. Mrzljak2, S. Staelens1, L. Wyffels1
1Molecular Imaging Center Antwerp, University of Antwerp, Antwerp,
Belgium; 2CHDI Foundation, Princeton, New Jersey, USA
Correspondence: Š. Korat
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):OP15
Aim: Glutamate, the predominant central nervous system excitatory
neurotransmitter, binds to Group 1 metabotropic glutamate recep-
tors: mGluR1 and mGluR5. mGluR1 levels are the highest in extra-
striatal areas, such as thalamus and cerebellum. Therefore, mGluR1
PET ligands could present a potential biomarker for glutamateric sys-
tem in these extrastriatal areas involved in the pathophysiology of
Huntington’s disease.
Methods: We validated [11C]ITDM as a PET probe for imaging the kin-
etics of mGluR1 in mouse brain. [11C]ITDM was prepared by modifica-
tion of a previously described method1 in a module (Comecer
Netherlands) adapted for automated production. In a cooled solution
containing the arylstannane precursor (1.9mg), K2CO3 (2.1mg), CuCl2
(1.5mg), Pd2(dba)3 (1.3mg) and P(o-tol)3 (1.7mg) in DMF purged with
N2, [
11C]MeI was bubbled, followed by reaction at 65°C for 5min. The
mixture was purified by reverse phase semi-preparative HPLC
(tR=8.5min), using MeCN:H2O:Et3N (6:4:0.01, V/V/V) as mobile phase
(2.7mL/min) followed by sterile formulation into ethanolic salinecontaining 0.5% ascorbic acid, using a C18 Sep-Pak cartridge. For
in vivo evaluation, WT Q175DN mice (n = 9; 11 months old) were intra-
venously (i.v.) injected with [11C]ITDM (5.69±2.4MBq; injected
mass=0.87±0.33μg/kg) and dynamically scanned for 90min (Siemens
Inveon μPET/CT). To validate target engagement, blocking and dis-
placement studies with mGluR1 antagonist YM-202074 (20mg/kg; i.v.;
2min before and 30min after tracer injection, respectively) were per-
formed. Total volume of distribution (VT) (from 2TCM) was calculated
noninvasively using an image-derived input function (IDIF) in several
brain regions.
Results: [11C]ITDM was successfully implemented with a synthesis
time of 34min from EOB (end of bombardment) including formula-
tion, molar activity (AM) of 122.4±22.2GBq/μmol at EOS (end of syn-
thesis), radiochemical purity of >99% and decay corrected
radiochemical yield of 3.7±1.5% (based upon [11C]CO2). VT quantifica-
tion of [11C]ITDM PET imaging confirmed tracer uptake primarily in
cerebellum (9.1±2.1mL/cm3) and thalamus (8.2±2.1mL/cm3). Further-
more, YM-202074 administration showed significant blockade and
displacement of [11C]ITDM in all investigated brain regions, confirm-
ing target engagement of mGluR1.
Conclusion: [11C]ITDM was successfully implemented in high purity
and good AM. Our initial in vivo evaluation confirmed [
11C]ITDM se-
lective binding to mGluR1 in all brain regions, having repercussions
for reference region selection.
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Aim: P-glycoprotein transporters (P-gp) at the Blood-Brain barrier
(BBB) are efflux pumps that play an important role in protecting the
brain against harmful substances. The expression and function of
these proteins is of great interest in neurodegenerative diseases and
drug resistance. Its function can be measured in vivo with positron
emission tomography (PET) using the novel tracer 5-(1-(2-[18F]fluor-
oethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-
5,6,7,8-tetrahydronaphthalen, [18F]MC225. Preclinical PET scans are
performed under anesthesia, and in most longitudinal studies the an-
imals are repeatedly anesthetized. However, the potential effect of
anesthesia on P-gp function has not been explored yet using this
tracer. Therefore, the aim of this study is to assess the effect of a pre-
exposure to anesthesia on P-gp function in rats with [18F]MC225.
Methods: Six rats were anesthetized with isoflurane for 90 minutes.
Five other rats were not subjected to anesthesia. One week later, all rats
underwent a dynamic PET scan (60 min) with arterial blood sampling.
[18F]MC225 with a dose of 32±6 MBq and a molar activity higher than
29000 GBq/mmol was injected into a tail vein as a bolus of 1ml/min.
After tracer injection, blood samples (0.15 ml) were collected to meas-
ure radioactivity in whole blood and plasma, besides the parent
fraction of the tracer and its radioactive metabolites. The images were
processed with PMOD software, and registered to a tracer-specific brain
template. A total of 16 regions inside the brain were selected from a
Wistar brain rat atlas. The volume of distribution (VT) which reflects P-
gp function was calculated by Logan analysis using plasma activity cor-
rected for metabolites as input function.
Results Significant differences in VT of the whole brain were ob-
served (p=0.002) between the 2 groups. In control animals, VT of the
whole brain was 11.04±1.25, whereas in animals pretreated with
anesthesia it was 7.89±1.25, a decrease of 29%. Moreover, significant
decreases in VT were found between groups in all the brain regions
analyzed such as amygdala, hippocampus, hypothalamus, midbrain.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 8 of 38Tracer concentration in whole-blood and plasma, and the rate of me-
tabolism were not significantly different between the groups.
Conclusion: Our results suggest that anesthesia has a prolonged ef-
fect on P-gp function at the BBB, lasting at least one week. The
group with additional anesthesia displayed a significant decrease of
tracer uptake in brain indicating an up-regulation of P-gp.
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Aim: GABA (4-aminobutanoic acid) is the major inhibitory neurotrans-
mitter in the central nervous system. GABAB receptors are G-protein
coupled receptor subtypes that play an essential role in various cen-
tral and peripheral disorders. Molecules that modulate GABAB recep-
tors are of great medicinal interest for the possible treatment of
many disorders and conditions including autism, alcohol depend-
ence, anti-nociception, spasticity, fragile X syndrome, Down’s syn-
drome, Austin’s disease and retinal ganglion cell degeneration. A PET
radiotracer for quantification of GABAB receptors is not available yet.
Our goal is to develop a PET radiotracer for imaging GABAB receptors
that would provide a significant advance in the understanding of
autism and other GABAB-related CNS disorders. It could also facilitate
novel GABAB drug development.
Methods: New GABAB agonists, fluoropyridylmethoxy analogues of
baclofen, were synthesized. The in vitro potency of these new
compounds was determined commercially. The most potent com-
pound of the series, (R)-4-amino-3-(4-chloro-3-((2-fluoropyridin-4-
yl)methoxy)phenyl) butanoic acid (1), was radiolabeled with 18F.
The regional brain distribution of the radiolabeled [18F]1 was stud-
ied in CD-1 male mice.
Results Substitution of the aromatic ring of R-baclofen with the
fluoro 4-pyridyl ether moiety resulted in an increase (>10 times) of
the GABAB agonistic properties. The baclofen analog [
18F]1 was radi-
olabeled via the corresponding bromo-precursor with a radiochem-
ical yield of 12-18%, specific radioactivity in the range of 330-515
GBq/μmol and radiochemical purity greater than 97%. In the animal
experiments [18F]1 entered the mouse brain (1% ID/g tissue)
followed by washout. The accumulation of [18F]1 in the mouse brain
was inhibited (35%) by pre-injection of a selective GABAB agonist,
suggesting that the radiotracer binding is partially mediated by
GABAB receptors.
Conclusion: New GABAB agonists, fluoropyridylmethoxy analogues of
R-baclofen, were synthesized and radiolabeled with 18F. The mouse
experiments with the most potent compound of the series, [18F]1,
demonstrated the feasibility of ex vivo quantification of GABAB recep-
tors in the animal brain; however, its specific binding was insufficient
for translation to human subjects. Our future research on GABAB PET
imaging will target radiotracers with improved specific binding and
greater blood-brain barrier permeability.
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):OP18Aim Antibodies targeting transporters can function as carriers for the
delivery of drugs in the brain for detecting and treating diseases of
the central nervous system at the molecular level. Presently there is a
need to develop efficient non-invasive method to validate the trans-
port of these antibodies across the blood brain barrier (BBB). In this
study, we investigated the potential of novel radiolabeled antibodies
for measuring their engagement at the BBB. We compared different
modes of delivery (Intravenous (IV), intra-arterial (IA)) to estimate
their brain uptake and assess their biodistribution profiles.
Methods: The antibodies were conjugated to NOTA chelator for
64Cu-radiolabeling. The new [64Cu]NOTA-antibody conjugates were
tested in normal rats using both IA and IV modes of administration
with or without pre-injection of unlabeled material and were com-
pared to a control [64Cu]NOTA-antibody.
Results We showed that the injection in the right carotid artery of
our new 64Cu-NOTA-antibody conjugates resulted in a brief but im-
portant radioactivity exposure in the right brain hemisphere, which
persisted after exsanguination. The right to left hemisphere ratios
remained constant across the different concentrations of unlabeled
conjugates and exceed that obtained with the control 64Cu-NOTA-
antibody.
Conclusion: This study demonstrates that our new [64Cu]NOTA-anti-
bodies allow for a transitory and specific brain uptake. These success-
ful results are promising for the use of bi-specific radiolabeled
antibody that can engage a target within the brain.OP19
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Aim: Cyclic nucleotide phosphodiesterases (PDEs) are a class of intra-
cellular enzymes that inactivate the secondary messenger molecules
cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP). Thus, PDEs regulate the signaling cascades
mediated by these cyclic nucleotides and affect fundamental cellular
processes, such as proliferation, differentiation, migration, survival,
and apoptosis. Accordingly, they are promising therapeutic targets.
Since PDE2A was found to be related to a variety of tumors, it is our
aim to synthesize novel PDE2A inhibitors based on the benzoimida-
zotriazine (BIT) moiety that might be a prospective lead compound
for the development of an F-18 labelled ligand for PDE2A imaging
with PET.
Methods: Based on BIT key intermediates (Fig. 1a), a small series of
novel fluorinated BIT derivatives was successfully prepared (overall in
7-10 steps) and the affinities towards PDE2A and other PDE subtypes
were estimated. The most promising compound, BIT1, was radiola-
belled by using the corresponding nitro precursor. The reaction was
optimized by choosing different solvents, amounts of precursor,
modes of heating (conventional or microwave), temperatures, and
reaction times. Afterwards, best conditions (Fig. 1b) were trans-
ferred to an automated synthesis module (TracerLab FX2 N, GE
Healthcare). The radiotracer was isolated by semi-preparative HPLC
(Reprosil-Pur AQ column, 250×10mm, 46 % ACN/aqu. 20 mM
NH4OAc, flow 5.5 ml/min) followed by purification with a Sep-Pak
C18 Plus light cartridge and formulation in isotonic saline containing
10% ethanol.
Results BIT1 showed a high affinity towards PDE2A (IC50 PDE2A3
= 3.33 nM) and selectivity over other PDE subtypes. [18F]BIT1
was successfully synthesized with a radiochemical yield of 51.9 ±
1.3 % (n = 3), molar activities between 46 – 100 GBq/μmol and
radiochemical purities of ≥ 99%.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 9 of 38Conclusion: Radiofluorination of a novel PDE2A ligand [18F]BIT1 was
obtained with appropriate radiochemical yield and molar activity.
First biological investigations are planned to estimate the potential
of [18F]BIT1 as imaging agent for PDE2A.
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Aim: MiRNA are single stranded RNAs of 18-22 nucleotides and they
have been found to be promising diagnostic and prognostic markers
for several pathologies, such as tumors, neurodegenerative, cardio-
vascular and autoimmune disease. In the present work the develop-
ment and characterization of the first anti-miRNA 64Cu-radiolabeled
probes based on peptide nucleic acids for a potential non-invasive
molecular imaging in vivo of giant cell arteritis are described.
Methods: MiR-146a and miR-146b-5p were selected as targets because
they have been found up-regulated in this disease. Anti-miR-PNA and
scramble-PNA probes were synthesized and linked to carboxyfluores-
cein or DOTA. The affinity of the probes for the targets was assessed by
circular dichroism and melting temperature. Differential uptake and
functional activity of fluoresceinated anti-miRNA probes were tested on
BCPAP and A549 cell lines, expressing different levels of miR-146a and
-146b-5p. DOTA anti-miRNA probes were then labelled with copper-64
to function as non-invasive molecular imaging tools and their stability
and uptake were assessed in the same cell lines.
Results From circular dichroism studies it was possible to note that
both PNA sequences (anti-miR-146a and -146b-5p) were able to
recognize both miRNA sequences. The scrambled PNA sequence did
not show any ability instead. Fluorescence of both BCPAP and A549
cells treated with anti-miR PNAs was higher than that of cells treated
with the negative control scrambled-PNA. 64Cu-DOTA-anti-miR-146a
PNA showed an almost doubled uptake in BCPAP cells with respect
to the A549 cells after 42 hours. Conversely, the uptake of the 64Cu-
DOTA-anti-miR-146b-5p PNA was comparable in the two cell lines.
The uptake of the 64Cu-DOTA-scramble PNA was really low in both
the cell lines and can be assigned to unspecific binding.
Conclusion: The experiments confirmed that anti-miR-146a PNA can
selectively bound the miRNA target and its uptake is higher in
miRNA overexpressing cells in vitro. 64Cu-anti-miR-146a PNA might
be further investigated for non-invasive PET imaging of miR-146a
and miR-146b-5p overexpressing diseases.OP21
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Aim Trastuzumab-DM1 (T-DM1; Kadcyla) is an antibody drug immu-
noconjugate (ADC) composed of the humanized IgG1 HER2 antibody
trastuzumab linked to emtansine (DM1), a potent microtubule inhibi-
tor. Our objective was to determine the correlation between the
tumour uptake of 89Zr-DFO-T-DM1 assessed by imaging and biodistri-
bution studies with the cytotoxicity of T-DM1 in vitro and in vivo
response.
Methods: A panel of cell lines with different HER2 expression were
treated in vitro with increasing concentrations of T-DM1 or trastuzu-
mab (0-100 μg/mL) for 72 hours and the threshold of HER2 expres-
sion required for cytotoxicity was compared in clonogenic assays. In
order to study the delivery of T-DM1 to tumours, we constructed T-
DM1 labeled with the positron emitter 89Zr. Imaging of tumor uptake
of 89Zr-T-DM1 was studied in mice bearing subcutaneous BT-474,
MDA-MB-361, MDA-MB-231, and TrR1 xenografts. Mice were injected
with a therapeutic dose of T-DM1 incorporating 89Zr-DFO-T-DM1 (10
μg, 6 ± 1.2 MBq). Mice were imaged on a micro-PET/CT system at 96
h post-injection. Tumour and normal-tissue biodistribution was deter-
mined. Another group mice of similar tumour models were treated
with T-DM1 (3.6 mg/kg) every 3 weeks or with an equivalent volume
of PBS for up to 7 weeks to determine tumour response.
Results Clonogenic assays demonstrated a significantly higher cyto-
toxicity of T-DM1 on HER2 positive tumour cell lines sensitive or re-
sistant to trastuzumab. Resistant cell lines, such as TrR1 (breast
cancer) and SK-OV3 (ovarian cancer) showed significantly higher
cytotoxicity with T-DM1 at 10 μg/mL and 0.01 μg/mL, respectively.
There was a strong correlation between HER2 density measured by
flow cytometry and in vivo uptake of 89Zr-DFO-T-DM1 (incorporated
into a therapeutic dose) with r2 = 0.9892. A strong and direct correl-
ation between in vivo response (doubling time) and uptake of 89Zr-
DFO-T-DM1 obtained with r2 = 0.8202. A strong indirect correlation
was established between in vivo response (doubling time) and
in vitro % survival, r2 = 0.9208.
Conclusion: We conclude that there was a strong correlation be-
tween tumour uptake of 89Zr-DFO-T-DM1, in vitro cytotoxicity, and
in vivo response. 89Zr-DFO-T-DM1 has application for PET imaging of
the delivery of T-DM1 to tumours in patients with HER2-positive BC.
Imaging may inform on which patients are likely to benefit from T-
DM1 treatment.
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Aim: Neuropeptide Y receptors subtype Y1 (NPY1) are overexpressed
in primary breast carcinomas and metastases and consequently radi-
olabelled agonists for these receptors would allow in vivo targeting
of tumours for diagnostic and therapeutic purposes. With the aim to
develop a potential 99mTc breast cancer imaging agent based on the
NPY1 structure we developed a short analogue (MA-Cys-Tyr-Arg-Leu-
Arg-BPA-Nle-Pro-Asn-Ile-OH) containing the active sequence of the
peptide with the addition at the amino-terminal end of a cysteine-
Fig. 1 (abstract OP23). See text for description
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 10 of 38mercaptoacetic acid moiety to coordinate the radiometal through
the formation of a 3+1 nitrido complex.
Methods: Labelling was performed in two steps, namely: the
preparation of a Tc(V)N precursor by reduction of pertechnetate (2,5-
12,5mCi) with SnCl2 (0,1mg) in the presence of succinic dihydrazide
(1mg) for 20 minutes followed by incubation (1 hour,80°C) of the
nitrido precursor (in 1mL) with the peptide (100μg), tris(2-cyanoethyl)
phosphine (0,5mg) and hydroxypropyl-gamma cyclodextrin (2mg).
Radiochemical Purity (RP) of the final product was assessed by RP-
HPLC using CH3CN/0,1%TFA and H2O/0,1%TFA as mobile phases.
Lipophilicity was determined with n-octanol and phosphate buffer
(0.1M, pH=7.4). Plasmatic protein binding (PPB) was measured by size
exclusion chromatography. Stability in plasma and in labelling milieu
was assessed by HPLC at 2 and 4 hours after labelling, respectively.
Cysteine challenge (100 fold molar excess) was also performed.
Cellular uptake, internalization and membrane binding studies were
performed using t MCF-7(ATCC® HTB-22TM) cells.
Results Labelling of the peptide yielded a single species with a reten-
tion time of 11.4 min and a RP>90%. The complex was stable in reac-
tion milieu and human plasma. Challenge with cysteine revealed no
ligand exchange for up to 2 hours. Physicochemical evaluation
showed a log P of -0.4+0.1 and a PPB of 16+2%. A cellular uptake of
3.1±0.2 (at 4 hours) was obtained. Internalization and membrane
binding studies showed that 15.2% of the activity is bound to the
membrane and 84.8% is internalised.
Conclusion: A 99mTc-with agonist was obtained high RP, good stabil-
ity and adequate physicochemical properties. In vitro characterization
showed a promising uptake in MCF-7 cells. To establish whether it is
a good diagnostic agent for breast cancer, it is necessary to deepen
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Aim: The theranostic use of mingastrin (MG)-based radioligands tar-
geting cholecystokinin-2 receptor (CCK2R) expression in tumours is
restricted by high kidney uptake or low enzymatic stability. Recently
we have reported on the possibility to stabilise MG analogues
against degradation by introducing specific amino acid modifications
in the C-terminal receptor binding sequence (Trp-Met-Asp-Phe-NH2).
In this study we have further refined our approach leading to a
highly promising new targeting probe.
Methods: The new MG analogue DOTA-MGS5 was designed based
on a combination of the substitutions applied in peptide derivatives
previously developed by our group (1). The in vitro and in vivo char-
acterisation after radiolabelling with In-111 and Lu-177 included sta-
bility analyses of the radioligands incubated in rat tissue
homogenates and after injection into BALB/c mice. Receptor inter-
action in terms of receptor affinity and cell uptake was analysed
using A431 human epidermoid carcinoma cells transfected with hu-
man CCK2R (A431-CCK2R) and mock-transfected cells (A431-mock).
The targeting potential was evaluated by small animal dual modality
single photon emission computed tomography (NanoSPECT/CT) as
well as ex vivo biodistribution studies in tumour bearing BALB/c nude
mice up to 4 h after injection.
Results DOTA-MGS5 and the complexes with different natural
isotopes showed a high CCK2R affinity in the low nanomolar range.
Interestingly, 111In-DOTA-MGS5 showed a particularly high internal-
isation (>40% and >80% after 1 h and 4 h respectively) into A431-CCK2R cells. The somewhat lower resistance against enzymatic deg-
radation observed in rat tissue homogenates did not translate into a
similar effect in vivo. Even though the stability in blood of 111In-
DOTA-MGS5 was comparable to other radioligands previously stud-
ied (>80% intact peptide after 10 min), the tumour uptake with
values of 23.5±1.3% IA/g at 4 h p.i. was incredibly high, leading to
extraordinary performance in NanoSPECT/CT. Also for 177Lu-DOTA-
MGS5 a similar stability in blood (>80% after 10 min) and tumour up-
take (24.5±3.1% IA/g at 4 h p.i.) was found combined with favourable
tumour-to-organ ratios of >3 for stomach and >6 for kidneys.
Conclusion: The combination of substitutions from earlier investiga-
tions allowed us to further improve our concept of stabilising MG ana-
logues in the receptor-specific C-terminal sequence. 177Lu-DOTA-MGS5
with its extremely high tumour uptake seems to be the long-awaited
theranostic probe for targeting CCK2R expression in tumours.
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Aim: Magnetic nanoparticles (MNPs) have the application potentiality
in innovative diagnostic and therapeutic modalities because of their
multifunctionality [1,2]. MNPs coated with two hydrophilic bisphos-
phonate ligands, i.e., methylene diphosphonate (MDP) and 1-
hidroksietan diphosphonate (HEDP) were synthetized and labeled
with 99mTc. The aim was to examine if the above nanosystems, can
be used as theranostic nanoagents, for hyperthermia application and
nuclear diagnostic imaging.
Methods: The bisphosphonate coated MNPs were synthesized
using co-precipitation method [3]. The heating ability for cancer
hyperthermia therapy application was quantified through the spe-
cific power absorption (SPA) measurement. Radiolabeling of both
bisphosphonate-coated Fe3O4 nanoparticles with
99mTc were car-
ried out using SnCl2 as a reducing agent.
99mTc-MNPs were
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 11 of 38additional used for in vitro stability studies in saline and human
serum and in vivo biodistribution studies in normal Wistar rats.
Results: The obtained SPA values for Fe3O4-MDP and Fe3O4-HEDP are
presented in Table 1. Radiolabeling of both bisphosphonate-coated
Fe3O4 nanoparticles with
99mTc was performed at high yields without
purification (> 95 %). Incubation of both radiolabeled preparations in
saline and serum showed that the bisphosphonate-iron oxide bonding
was very stable with only 10 and 15 % of 99mTc detaching from the iron
oxide after 24 h, respectively. The highest uptake was observed at 1 h
p.i. in the liver followed by the spleen (Fig. 1).
Conclusion: The obtained results of specific power absorption dem-
onstrate potential therapeutic applications of Fe3O4-MDP and Fe3O4-
HEDP. Such radiolabeled biocompatible bisphosphonate MNPs with
high labeling yield (> 95 %), in vitro and in vivo stability, showed the
great promise as theranostic nanoagent which combines magnetic
hyperthermia and SPECT imaging.
References
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3. Massart R, Cabuil VJ, [1987], Chim Phys 84: 967-973Table 1 (abstract OP24). SPA values of the aqueous dispersion of
MNPs in the applied magnetic field, 23.9 kA/m
MNPs SPA (W/g)
252 kHz 397 kHz 577 kHz
Fe3O4-MDP 67.3 143 183
Fe3O4-HEDP 55 78.5 131
Fig. 1 (abstract OP24). Biodistribution results of (a) 99mTc-Fe3O4-
MDP and (b) 99mTc-Fe3O4-HEDP MNPsOP25
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Aim: Despite its desirable half-life and high-energy Auger electrons,
67Ga therapy has been neglected due to lack of suitable chelators
and targeting molecules. With the advent of 68Ga-PET, excellent new
chelators allow us to re-evaluate 67Ga for therapy. Previously, we
showed that 67Ga causes DNA damage in cell-free systems and and
cell kill in non-targeted cell studies. Here, we expand this work by
targeting 67Ga to breast cancer cells using trastuzumab and compar-
ing toxicity to well-described Auger electron emitter, 111In.
Methods: Trastuzumab, dialysed against 50 mM EDTA, washed and
recovered in metal-free HEPES buffer, was conjugated with tripodal
tris(hydroxypyridinone) (THP) (3.23 mg trastuzumab, 0.8 mM H3THP-Ph-SCN; 260 μL) and purified by size exclusion chromatography
(SEC). DOTA-trastuzumab was also prepared similarly. DOTA-
trastuzumab was labelled with 111In chloride at 40°C, pH 5.5 for two
hours whereas THP-trastuzumab was labelling with 67Ga chloride at
room temperature, pH 6.5, for 15 minutes. SEC purification was per-
formed when labelling efficiencies were <95%. Radiopharmaceuticals
(0.19 MBq/μg) were tested for their internalisation and effects on via-
bility (dye exclusion) and clonogenicity of Her-2-positive (HCC1954)
and –negative (MDA-MB-231) cell lines. Microautoradiography of cells
in 18% gelatine was also performed.
Results Labelling efficiencies for 67Ga-THP-trastuzumab and 111In-
DOTA-trastuzumab were 90% and 98%, respectively, giving 0.26±0.08
and 0.61±0.11 MBq/μg. At 4nM, 67Ga-THP-trastuzumab showed sig-
nificantly higher cell binding uptake (10.69±1.32%) than 111In-DOTA-
trastuzumab (6.15±1.64%; p=0.01) although the proportions interna-
lised were equal; 62.08±1.43% and 60.78±15.45%, respectively. At
100nM however, cell binding percentages were equal: 1.15±0.98%
67Ga-THP-trastuzumab and 0.83±0.85% 111In-DOTA-trastuzumab.
Controls 67Ga-THP-Ac and 111In-DOTA did not bind HCC1954 cells
and binding of 67Ga-THP-trastuzumab and 111In-DOTA-trastuzumab
in MDA-MB-231 cells was minimal (<0.2%). Microautoradiography
showed that radioactivity bound to individual cells within the popu-
lation varied considerably (from <10 to >90 silver grains per cell). Via-
bility and clonogenicity decreased with increasing radiolabeled
trastuzumab concentration, bound per cell. Radiopharmaceutical
treatment of MDA-MB-231 cells or non-internalised activity in
HCC1954 cells did not affect cell viability or clonogenicity. In
HCC1954 cells, the surviving fraction after treatment at approxi-
mately 0.1 Bq/cell 67Ga-THP-trastuzumab, reduced to 0.38±0.13, more
than for 111In-DOTA-trastuzumab (0.55 ± 0.16; p=0.03).
Conclusion: 67Ga-THP-trastuzumab and 111In-DOTA-trastuzumab both
bind specifically HER2-positive cells and reduce their viability and clo-
nogenicity. This shows 67Ga holds promise as a therapeutic radio-
nuclide as a targeted radiopharmaceutical however non-
homogeneous uptake amongst cells needs further investigation.
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Aim: Magnetic nanoparticles (MNPs) have been intensively used for a
wide variety of biomedical applications. Only few reports on the
in vivo biodistribution of functionalized MNPs with potential uses in
magnetic hyperthermia (MHT) therapy are available [1, 2]. Radiola-
beled MNPs coated with hydrophilic phosphate ligands, i.e., imidodi-
phosphate (IDP) and inositol hexaphosphate (IHP), were developed
as multifunctional agents to localize both radioactivity and magnetic
energy at a tumor site.
Methods: MNPs were synthesized by co-precipitation of ferric and
ferrous salts in a basic solution [3, 4]. The heating ability of MNPs
was quantified through the specific power absorption (SPA) measure-
ments. The MNPs were labeled with 37 MBq 90YCl3, at room
temperature for 1 h and were used in in vitro stability studies in sa-
line and human serum and in vivo biodistribution studies in normal
Wistar rats.
Results The SPA values obtained for synthesized MNPs (46–81 W g-1)
in different physiological media indicated their possible application
in hyperthermia treatment (Fig. 1). Both types of coated MNPs were
90Y-labeled in a reproducible high yield (>98 %) and exhibited high
in vitro stability in saline and human serum. The results of
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 12 of 38biodistribution, showed high uptake in the liver and spleen as well
as in vivo stability up to 72 h. (Fig. 2).
Conclusion: 90Y-coated MNPs were radiolabeled for two purposes: to
use the radiotracer to obtain an accurate biodistribution profile of
the MNPs and to produce potential radiotherapeutical agents. Both
90Y-labeled phosphate-coated MNPs exhibited favorable properties
that justify further investigations toward their potential use in com-
bined radiotherapy–hyperthermia cancer treatment.
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Fig. 2 (abstract OP26). Biodistribution results of (a) 99Y-Fe3O4-IDP
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Fig. 1 (abstract OP27). HPLC analyses of the mixture of sugars
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Aim: Quality Control (QC) of PET tracers is the most labor-intensive
part of clinical tracer production. Tracer-QC system is being used in
the US for complete automation of QC for FDG production meeting
the requirements set by United States Pharmacopeia. Here we
present the technology developed to address European Pharmaco-
peia requirements for radiochemical and chemical purity.Methods: A QC automation system has been developed that consists
of Tracer-QC device integrated with an HPLC. The HPLC includes a qua-
ternary pump, UV-Vis detector and a radioactivity detector. Notably, no
electrochemical detector is included. An innovative coupling was devel-
oped that provides for automated HPLC injection of the radioactive
sample by a pipette from the deck of Tracer-QC robot. The above de-
scribed system is enabled by a consumable cartridge that incorporates
all reagents needed for analysis of color, clarity, residual kryptofix, etha-
nol, acetonitrile, bacterial endotoxin, radioactivity concentration, radio-
chemical purity (including 18F-fluoride and 18F-FDM), half-life, residual
concentration of Cl-DG. Pre-column derivatization of sugars with PMP
reagent was utilized to quantify Cl-DG content. Robotic component of
Tracer-QC system allows for precise and fast mixing of the liquids.
Results The system presented here allowed for quantification of all im-
purities commonly analyzed in the production of FDG in Europe, while
keeping the analysis time under 45 minutes. The derivatization and sep-
aration method was optimized to separate derivatized Cl-DG, Glucose,
FDM and FDG with resolution exceeding Pharmacopeia requirements
(Fig. 1). Limit of quantification of Cl-DG was determined to be 15 ppm,
Limit for detection for 19F-FDG is ~1 ppm. 18F-FDG was fully converted to
18F-FDG – PMP derivative which was detected on the radiation detector.
TLC analysis confirmed that 18F-FDG – PMP is the only radioactive prod-
uct of the derivatization, with no competing decomposition.
Conclusion: These developments enabled an automated QC platform
that contains all hardware needed for analysis of FDG as well as other
18F-based tracers. On this platform all analyses and sample manipula-
tions are performed automatically, providing for maximum walk-away
time – the user sets up a consumable cartridge and adds one sample.
Then they only need to come back to collect the complete report. It is
expected that such systems will have a dramatic impact in both routine
production and development of new PET tracers.
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Aim: The implementation of recently introduced metal-mediated
“late-stage” approaches for nucleophilic n.c.a. 18F-labelling of non-
activated aromatics into routine production of the radiotracers is
currently on-going. These new strategies employed or copper (II)1
catalysts that combined with stannyl- or Ni-based2,3 precursors.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 13 of 38Moreover, classical kryptofix is often replaced by tetraethylammo-
nium hydrogen carbonate (TEAHC)2,3. Therefore there is an urgent
need in the development of simple analytical methods to control the
removal of these toxic impurities from the final preparations until the
allowable limits. Here we suggest the application of capillary electro-
phoresis (CE) for simultaneous determination of Cu, Ni, Sn and
TEAHC in the analytical sample.
Methods: CE analysis was performed using «Capel-105M» system that
equipped with UV spectrophotometric detector. The sample was
loaded via electrokinetic injection (10 s, 25 kV) under following condi-
tions: column 60 cm × 75 μm; background electrolyte: benzimidazole
20 mmol/L + acetic acid 40 mmol/L; UV 230 nm, separation voltage 25
kV, 20 °C. Stock solutions of Ni2+, TEAHC, Cu2+ and Me3SnCl in normal
saline at a concentration of 10, 1000, 100 and 200 ppm respectively
were prepared. Calibration standards were than prepared by serial dilu-
tion of the stock solutions. Before analysis the samples were fourfold di-
luted by deionized water. Under these conditions the retention times
(RT) for Ni2+, TEAHC, Cu2+ and Me3SnCl were 4.4, 5.0, 5.6 and 7.8 min.
All the peaks were well distinguished from that of sodium (3.9 min).
Results The conditions for simultaneous determination of toxic im-
purities in the buffer solution by CE technique CE analytical proced-
ure have been developed. Our data (Fig. 1) show that the suggested
method had a high sensitivity with detection limit for impurities ac-
cording to ICH Guideline of Elemental Impurities Q3D.
Conclusion: New analytical CE method was proposed for routine
quality control of the radiotracers, synthesized via metal-mediated re-
actions. The method is fast, simple, reliable and can be easy adapted
to any CE equipment. This research was supported by RFBR grant №
16-54-12062\16.
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Aim: Breakthrough of Ge-68, and the yield of Ga-68 are important as-
pects of Ge-68/Ga-68generator function. At the Western Cape
Academic PET/CT Centre, SnO2-based Ga-68 generators produced by
iThemba LABS are used. These generators are eluted with 0.6 M or 1 M
HCL and Ge-68 breakthrough has been observed. The aim of this study
was to evaluate the influence of the age of the generator, the number
of elutions performed, and the interval between elutions on Ga-68 yield
and Ge-68 breakthrough in order to optimise use of Ga-68.Methods: Elution records of 7 generators, used between January
2013 and July 2017 were reviewed. The first 5 generators were
eluted with 1 M HCl, and the last 2 generators with 0.6 M HCl. Ge-68
breakthrough was measured after decay of eluted Ga-68. The age of
the generator and the time interval between elutions were calculated
and plotted against breakthrough and yield.
Results The number of elutions per generator ranged between 28 and
151, and the generators were used for periods ranging from 166 to 372
days. Yield within the first month were between 119 % and 133 % of
the nominal Ge-68 activity on the column for generators eluted with 1
M HCl, and 107 to 110 % for those eluted with 0.6 M HCl. By 160 days
the yields had decreased to 106 % to 110 % with 1 M HCl elutions and
80 % to 99 % with 0.6 M HCl eluant. Three generators, including those
eluted with 0.6 M, showed Ge-68 breakthrough within the first 10 days
of use. By 160 days age, the Ge-68 breakthrough varied between 0.02
% and 1.0 %, with the lower acidity eluant giving the second highest
value. There were no correlation between interval between elutions
and Ge-68 breakthrough and Ga-68 yield.
Conclusion: Due to irregular intervals between elutions, it is difficult
to compare elution yield at various ages of generators. All generators
however clearly functioned poorer with increased use. The increasing
Ge-68 breakthrough, and especially breakthrough early in the life-
span of the 2016 and 2017 generators is worrying, as it creates long-
living radioactive waste. Elution with a less acidic eluant seems to
provide a slightly lower yield but also lower Ge-68 breakthrough.
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Aim: Development of 68Ga radiophamaceuticals (RPs) requires a lot
of tests to be made during labeling conditions optimization, stability
evaluation, etc. It is critically important not only to evaluate radio-
chemical purity (RCP) value, but to know exact value of every radio-
chemical impurity content. There’s no doubt that TLC analysis is the
most convenient method for the determination of all the radiochem-
ical species content, given that the TLC system is adequate. Previ-
ously new method for determination of RCP of 68Ga-RPs was
developed [1]. The method is handy, fast and informative with a
good correlation with pharmacopoeial and other frequently used
methods. The method allows to determine 68Ga-colloid, unbounded
68Ga and labeled molecule content with a single strip. The method
can be routinely used with 68Ga-PSMA-617, 68Ga-DOTA/NODAGA-
RGD/TOC/-TATE, etc. However the method has a drawback: some-
times adequate chromatographic separation is not available with
acyclic chelators (DATA/HBED-CC/DTPA, etc.). Also molecular weight
has an impact on Rf of the complexes (main peak shift can be about
±0.3 Rf). The aim of this study is to develop a new method allowing
to overcome these drawbacks.
Methods: 68Ge/68Ga generator (Cyclotron Ltd, Obninsk, Russian Fed-
eration) was used. All chemicals and solvents were of high-purity or
pharmaceutical grade and were purchased from Sigma-Aldrich or
Panreac. Radiopharmaceutical precursors (PSMA-617, DOTA/
NODAGA-RGD/TOC/-TATE, etc.) were purchased from ABX. iTLC-SG
strips of different manufacture periods were used (Pall/Varian/
Thermo). PET-MiniGita (Raytest) radio-TLC scanner was used for ana-
lysis of radioactivity distribution.
Results The decision was made to develop a method, which allows
to obtain retention factors as follows: Rf=0.0-0.1 for 68Ga-colloid,
Rf=0.5-0.6 for unbounded 68Ga and for labeled molecules Rf=0.9-1.0.
This separation pattern was obtained for labeled compounds listed
above using mixtures with w:o = 1:1 or 1:3 (w – water, saline; o –
acetonitrile/ethanol/methanol). The presence of small amount of acid
(TFA/HCl/HNO3, ect.) is essential. This amount should be kept very
precise to provide pH 1.6±0.4. The most informative peak separation
can be obtained with saline:acetonitrile mixture (1:1 ÷1:3) containing
0.06-0.08% TFA. Experiment details and critical features will be pre-
sented. This system is applicable for the most of 68Ga-RPs under
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 14 of 38study. It was found that chromatographic pattern is not the same
when using iTLC-SG strips of different manufacture periods. This fact
should be carefully taken into account.
Conclusion: New highly effective TLC method for 68Ga labeled com-
pounds analysis was developed. The method is applicable during
pharmaceutical development and routine clinical practice.
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Aim: Over the past years, many different PET agents have been de-
veloped to investigating on Prostate Cancer (PC) to make the non in-
vasive approach a reality, in order to replace the biopsy and the
related complications. The PC is the more common cancer that affect
the male population. Due to the high incidence of this pathology are
mandatory to investigate on a fluorine-18 tracer that give the possi-
bility to overcame the gallium-68 tracers limitations.[1] The aim of
this study is to optimize an automatic synthesis for [18F]FPSMA1007
on Ge FASTLab® module, in a stable high yield with a wide range of
inlet activity, and setting up a faster, efficient and EU Pharmacopoeia
compliant quality control to shorten the time of product realize. [2]
Methods: The synthesis method is based on one step synthesis using
a new precursor commercialized by ABX and is tuned on Ge FAS-
TLab® synthesizer. All the reagents are included on a single use cas-
sette. The [18F]Fluorine was trapped on QMA and eluted with a
mixture of TBAHCO3/ACN or K222/ACN/K2CO3 and after drying at
125°C on synthesis reactor, the ABX precursor dissolved in DMSO
was added to proceed with the nucleophilic [18F]-Fluorination. The
reaction mixture was heated up at 95°C for 10 min after the reaction
step the mixture was cooled at 35°C to starting the purification step
followed by formulation. The total process takes place on 37 minutes.
HPLC analysis was performed on an Agilent 1260 Infinity HPLC
equipped with an Agilent 1260 UV detector and a Raytest gamma-
ray detector, controlled with Gina Star software V.5.9. The analysis
was performed on a 4,6x100 Eclipse Plus C18 3.5μm (Agilent) in iso-
cratic conditions using CH3CN and 0.1 % TFA (70/30, run time 15
min). TLC analysis was performed on Merk Silica Gel 60 on PET (10x5
cm, developed over 2/3 of the plate), mobile phase MeOH/NaCl 0.9%
a Perkin Elmer Cyclone. Other analysis were performed according to
European Pharmacopoeia “Radiopharmaceutical Preparations”.Results Two different elution solution was used to compare the final
process yields, at the same time, high activity runs were performed,
in different inlet activity range, to evaluating the yield and product
stability in final formulation. For stability study a range of 1-2.5 GBq/
ml radioactive concentration was evaluated at room and at 40°C for
up to 12h. According to final product formula specification the syn-
thesis yield was stable on range 30-50 % at the inlet activity range
(55-170 GBq) with a very high Am ( 800-3500 GBq/ 훍mol) at EOS. The
radiochemical purity for all the runs was > 96 % and chemical impur-
ities were < 0.1 mg/V. The new HPLC/TLC method allow to make the
quality control in terms of general indications of European
Pharmacopoeia Monographs.
Conclusion: All the synthesis performed by using the K222 elution
solution shows slightly lower yield compared to TBA, at the same
time any difference, in quality control profile and stability were
found, all the products collected were stable and in high chemical/
radiochemical purity. The HPLC and TLC methods setup allow to per-
form a complete purity evaluation on less than 15 min.
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Aim: Radioiodine and astatine are increasingly studied for thera-
peutic or diagnostic purposes in nuclear medicine [1]. Particularly,
211At (t1/2 = 7.2 h, α-emitter) is a promising radioisotope for targeted
α-particle therapy. To associate these radiohalogens to cancer target-
ing biomolecules (peptides, antibodies), the conventional approach
consists in performing the radiohalogenation of a precursor bearing
a N-Hydroxysuccinimidyl (NHS) ester function for conjugation to the
biomolecule [2]. However this approach requires basic aqueous con-
ditions leading to competitive hydrolysis of the NHS ester, resulting
in sub-optimal conjugation yields (<50%). To overcome this issue, we
have initiated the investigation of click chemistry based bioorthogo-
nal conjugation approaches aiming at increasing the coupling yields
and improving the radiolabelling procedure.
Methods: A series of bifunctional precursors bearing clickable
functionalities (tetrazine, azide or alkyne) were specifically designed
for radiolabelling with radioiodine and 211At. Bioorthogonal ligation
kinetics of the labelled prosthetic groups were evaluated on model
peptides bearing the complementary clickable functions (trans-
cyclooctene (TCO), bicyclononyne (BCN), alkyne) for identification of
the best system, and transferred to antibody radiolabelling.
Results All ligation reactions tested on model peptides produced
quantitative yields from less than 1 minute to 9 hours with the fol-
lowing reactivity order: [tetrazine-TCO] > [copper(I) catalyzed alkyne-
azide] > [tetrazine-BCN] > [azide-BCN], as expected from literature
data[3]. The fastest system [tetrazine-TCO] was then tested on an
anti-CD138 mAb, providing quantitative radiolabelling yields (>99%)
without need of purification within less than a minute, confirming
the high efficacy of this approach. Immunoreactivity against CD138
was preserved (80 ± 2%).
Conclusion: The results obtained highlight the higher efficiency of
click chemistry in comparison with the conventional approach. They
open perspectives for quantitative radiolabelling with reduced
conjugation time that may facilitate the transfer of 211At-labelled
antibodies to clinical applications. Assessement of the in vivo behav-
iour of such radiolabelled biomolecules is now in progress to fully
validate this promising approach.
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Aim: The 5-year survival for PnCa patients is only 6% due to late-
stage diagnosis and inadequate treatment options. There is an ur-
gent need for new treatment strategies. Human epidermal growth
factor receptor (EGFR) is overexpressed on up to 90% of PnCa tu-
mours. Panitumumab is an antibody against EGFR that can be modi-
fied with a NOTA chelator for radiolabeling with 177Lu to treat PnCa
cells as a radioimmunotherapy agent (177Lu-RIT). This study aims to
determine the RBE of 177Lu-RIT compared to γ-radiation and examine
EGFR positivity as a predictor of PnCa response to 177Lu-RIT.
Methods: Flow cytometry: EGFR density was measured on AsPC-1,
PANC-1, MiaPACA-2, and Capan-1 cell lines. Cells were incubated
with panitumumab for 60 min, then with Alexa Fluor 647 anti-human
IgG immunoconjugates for 30 min at 4°C, then run on a flow cyt-
ometer. Clonogenic survival assays: Cells were treated with γ-radiation
(0-8Gy) or 177Lu-RIT (0-3MBq/72nM) then seeded in into 6-well plates
and allowed to grow at 37°C, 5% CO2, for 14 days. Then colonies
were fixed/stained and counted. Subcellular fractionation: Cells were
treated with 177Lu-RIT (1MBq/72nM) for 1, 3, 4, and 24 hours. Radio-
activity associated with cell surface, cytoplasm, and nucleus was
separated then measured in a γ-counter.
Results EGFR density was +++, +++, +, and ++, for AsPC-1, PANC-1,
MIAPaca-2, and Capan-1 cells, respectively. Clonogenic survival after
γ-radiation was reduced to 10% (D10) for AsPC-1, PANC-1, MIAPaca-2,
and Capan-1 cells at 3.2 Gy, 5.0 Gy, 4.0 Gy, and 2.5 Gy. 177Lu-RITcaused D10 at 3.1MBq, 1.1MBq, 6.0MBq, and 1MBq for AsPc-1, PANC-1,
MIAPaca-2, and Capan-1 cells, respectively. Subcellular fractionation
studies showed that PANC-1 had the highest nuclear localization of
177Lu-RIT and results from these studies allowed microdosimetry to be
performed to convert MBq to Gy. The D10 after
177Lu-RIT was 16.9 Gy,
5.7 Gy, 23.3 Gy, and 8.2 Gy for AsPc-1, PANC-1, MIAPaca-2, and Capan-1,
respectively, resulting in RBE of 0.2, 1.0, 0.2, and 0.3.
Conclusion: RBE of 177Lu-RIT is less than γ-radiation and varies signifi-
cantly between PnCa cell lines with no correlation to EGFR density. EGFR
positivity is not an adequate predictor of response to RIT with 177Lu-RIT.
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Aim: Breast cancer (BC) remains the most common invasive cancer
diagnosed among women and the second most frequent cause of
cancer-related death in women worldwide. The majority of BC cases
are hormone-responsive and approximately 75% express the estro-
gen receptor (ER), a well-established biomarker for prognosis and
guiding treatment of patients. ER has also been used as a target for
BC imaging. In spite of the improved BC survival rate due to endo-
crine therapies that modulate ER action, resistance to treatment is a
major clinical concern. Thus, new molecular imaging agents and
more effective therapies are needed to improve BC management.
Theranostics is particularly suitable for that purpose as the ER status
profiling acquired by imaging can be used to targeted treatment.
Peptides containing the LXXLL sequence have demonstrated high ER
affinity and could be of potential value to develop targeted radio-
pharmaceuticals. Thus, our goal was to assess the potential value of
a radiolabelled LXXLL peptide as theranostic agent for BC. For that
purpose, we have selected from the literature a peptide with recog-
nized ER affinity and have radiolabelled it with two different radionu-
clides, 111In and 125I.
Methods: A LXXLL-peptide was synthesized and conjugated to the
bifunctional chelator DOTA by microwave-assisted solid phase syn-
thesis. The peptide conjugate was radiolabelled with 111In. 125I-label-
ling was performed by direct radioiodination in the histidyl residue
using the oxidative method of chloramine-T. ER binding affinities
were evaluated by a fluorescent polarization assay with the corre-
sponding inactive In(III) complex or iodinated peptide. Cellular up-
take was assessed in MCF-7 (ER+) and MDA-MB-231 (ER-) human
breast cancer cells. Biodistribution was assessed in tumor-bearing
Balb/c mice induced with MCF-7 cells and microSPECT imaging stud-
ies are underway.
Results: The LXXLL peptide was successfully radiolabelled with both
radionuclides with high radiochemical yield and purity at high spe-
cific activity. Chemical identity was ascertained by comparing its
HPLC profile with that of the inactive congeners. Inactive LXXLL-
peptide derivatives retained ER binding affinity. Both radiolabelled
peptides have showed rapid and high uptake in MCF-7 cells (ER+).
Biodistribution studies in tumor- bearing mice indicated high in vivo
stability, fast blood clearance and high uptake in ER rich organs and
MCF-7 xenografts.
Conclusion: The favourable biological performance of radiolabelled
LXXLL peptides in cellular and tumor-bearing mice models suggests
their potential as theranostic agents.
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Aim: The present study was designed to develop and validate methods
for biological quality control (bacterial endotoxin and sterility testing) for





90Y. These RCPs are considered to be
active pharmaceutical ingredient (API) for various radiopharmaceutical for-
mulations. The validation of biological quality control procedures for RCPs
is a mandatory requirement for small scale radiopharmaceutical prepara-






90Y, Lysate(λ:0.03EU/mL), Tris-base (0.25/0.2/0.4/2N), Ca++
and Mg++ free PBS(PO4
- ion concentration: 7.8nM). Cultures of S.aur-
eus, P.aeruginosa, B. subtilis, C.albicans.
Methods: The endotoxin limit(EL) for RCPs was fixed at 5EU/mL, based
on the volume used for radiosynthesis and alert limit. BET assays were
performed by gel-clot method. Maximum valid dilution (MVD) was cal-
culated considering the sensitivity of lysate and EL. Sterility testing was
validated by direct inoculation method using FTM and SCD media. Posi-
tive controls for S.aureus, P.aeruginosa, B.subtilis, C.albicans were set up
at bacterial concentration <100 CFU (serial dilution- spread plate
method) and corresponding negative controls were set up with and
without RCPs. Positive and negative controls of RCPs were set up con-
sidering single patient dose (125-150 and 50-100 mCi of RP in a volume
of 0.5 and 2.0mL meant for therapeutic and diagnostic radiopharma-
ceutical formulations respectively).
Results In BET assay, 177LuCl3 and CH3COO
90Y exhibited inhibition due
to extreme pH conditions. Inhibition could be resolved by neutralizing
with endotoxin negative (<0.25EU/mL) 0.25N Tris-base at first dilution.
68GaCl3 exhibited enhancement due to presence of excess Na
+ and in-
hibition because of extreme pH. The enhancement in BET test was re-
solved using endotoxin negative PBS as diluting agent instead of LRW
and inhibition was taken care of by neutralization with 0.25N Tris-base.
BET assay of Na99mTcO4, Na
188ReO4 and H
18F, did not demonstrate any
inhibition. In sterility testing, luxuriant growth was observed for positive
control culture in the presence of 1-2 mL (50-100 mCi) of Na99mTcO4,
Na188ReO4and H
18F following incubation for 48 hours. Growth of all
these microorganisms was inhibited (<100 CFU) in 0.5-1.0 mL
68GaCl3,
177LuCl3 and CH3COO
90Y. However, inhibition was reversed on
neutralization with sterile Tris-buffer (0.2/0.4/2N). This was also con-
firmed by counting CFU by spread plate method. No growth was seen
in any of these RCPs in negative controls.
Conclusion: The procedures for quantification of endotoxin limit and
sterility tests of various RCPs used in radiopharmaceuticals formula-
tions was standardized and validated.
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vides proton beam of 16.5 MeV, with varying beam current from 1μA
to 75 μA. This cyclotron has liquid and gaseous irradiation target cav-
ities for production of non-metallic radioisotopes viz 18F, 11C,13N etc.
In order to extend the utility of the cyclotron for producing medically
useful isotopes viz 64Cu, 111In etc using the solid targets, a prototype
semi-automated solid target assembly has been designed and fabri-
cated indigenously. In this study the feasibility of this target for ir-
radiation, to produce 64Cu was tested. Materials: Natural Ni powder <
150 μm, 99.999% trace metal basis purchased from Aldrich, ORION
gamma-ray spectrometer coupled with a high purity Ge-detector
Methods: A proton beam of 2 μA was irradiated for 30 min on nat-
ural Ni (electroplated in-house with thickness 120 μm). The param-
eter such as the vacuum, He pressure, γ field and neutron flux was
observed at regular time intervals during irradiation. After irradiation,
target disc was transferred into a lead capsule. The γ spectrum of ir-
radiated sample was recorded with HPGe detector. Quantity of 64Cu
produced was calculated by analysing the spectrum using InterWin-
ner 7.0 software.
Results The vacuum was found to be stable indicating proper sealing
of the solid target assembly with cyclotron port. The He gas pressure
was constant showing no leak of coolant from the target assembly.
The γ field and neutron flux measured was found to be 38 mR/h and
236 n/cm2/s respectively during the irradiation. The HPGe spectrum
showed a peak at 1.34 MeV corresponding to 64Cu along with other
peaks. The quantity of 64Cu produced was estimated to be 29 μCi at
the EOB.
Conclusion: The indigenously developed solid target assembly was
found to be compatible with GE-PET trace 800 cyclotron, having only
liquid and gaseous target cavities. The target was successfully tested
for irradiation at 2μA current for 30 m time duration with natural Ni
target. This indigenous target can be used for production of higher
amount of 64Cu while using enriched 64Ni with high current.
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Aim: Polydimethylsiloxane (PDMS) is a cheap and easly available ma-
terial for microfluidic devices for radiopharmaceutical synthesis. Lit-
erature describes interactions of this material with [18F]Fluoride
(references 1,2,3,4). Some authors discard PDMS and others suggest
the use of fluoropolymer thin films to reduce [18F]Fluoride adsorp-
tion. The aim of this work was to evaluate [18F]Fluoride retention and
elution in a PDMS reactor chamber, when it is under heating and
vacuum, normaly used for [18F] PET radiosynthesis.
Methods: Ten 30 μL reactor chambers of PDMS microchips for PET
radiopharmaceuticals were tested to evaluate possible adsorption
phenomena. No cover films were used, so the [18F]Fluoride inter-
acted directly with the PDMS. Activities from 8 MBq to 2500 MBq of
[18F]Fluoride were assayed. First, [18F]Fluoride was preconcentrated in
a QMA resin and eluted with K2CO3 6 mg/mL. The radioactive solu-
tions (K2CO3 aqueous solution/acetonitrile 1:1) were pippeted manu-
ally into the reactors, heated until complete evaporation (100-140°C)
with vacuum (700 mbar, Sykam S1021 pump) to mimic azeotropic
distillation and nucleophilic substitution. An average temperature of
130°C was maintained during 10 minutes, measured by a coupled
termocouple. [18F]Fluoride was then eluted with water for injection
and the reactor chambers were dried with compressed air. Radio-
activity was measured after filling, evaporation and water elution in a
Comecer IBC Dose Calibrator.
Results:
Conclusion: In our experience, [18F]Fluoride was practically not
adsorbed to PDMS when this material is under heating and vacuum
conditions commonly used in [18F]Fluoride preconcentration and
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 17 of 38nucleophilic substitution. On the contrary, [18F]Fluoride was retained
and almost completely eluted with water for injection, so we can
suggest this cheap and easily available material for lab-on-chip
Radiopharmacy.
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1 8.62 7.88 6.96 0.10
2 12.58 11.08 10.20 0.20
3 28.12 26.27 22.60 1.03
4 51.80 48.84 40.70 1.70
5 66.60 59.29 50.90 1.80
6 240.05 217.6 206.88 0.74
7 802.10 726.90 672.66 18.07
8 925.30 804.22 710.45 7.05
9 1257.01 1122.7 955.34 7.03
10 2544.80 2372.1 2152.03 7.40PP04
Development and comparison of dual generator elution methods
on a MultiSyn Synthesizer (iPHASE technologies Pty Ltd) -
application to the synthesis of 68Ga-peptides
L. Morandeau1, S. Poniger2,3, A.H. Asad1, J. Ioppolo1, S. Chan1, R.I. Price1,4
1Department of Medical Technology and Physics, Sir Charles Gairdner
Hospital, Perth, WA, Australia; 2iPHASE technologies Pty Ltd, Melbourne,
VIC, Australia; 3The Austin Hospital, Melbourne, VIC, Australia; 4School of
Physics, University of Western Australia, Nedlands, WA, Australia
Correspondence: L. Morandeau
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):PP04
Aim: Increasing patient demand for 68Ga-peptides in our facility has
created the need for higher number of doses per batch produced.
We have investigated several options for dual generator elution for
the synthesis of 68Ga-DOTATATE on an iPHASE MultiSyn Synthesizer,
using two ITG 68Ge/68Ga generators.
Methods: The efficiency of three double elution methods of ITG gen-
erators using HCl 0.05M were compared:
(i) Fractionated elution: The elution profile of one ITG generator
was first determined. The most concentrated fractions from two
generators were then collected and measured. (ii) “In series”
elution: Two generators were connected in series and the
elution profile determined. The optimum fraction and rate of
elution were established.
(ii) Pre-concentration (1): the individual eluates from both
generators were passed through a Strata SCX cartridge, and the
trapped 68Ga eluted with acidified 5 M NaCl. The synthesis of
68Ga-DOTATATE was then optimised for elution methods (i)
and (iii). TLC of the crude reaction mixture was performed be-
fore purification. After synthesis, activity of all the synthesis
components were measured and decay corrected to EOS.Results: The % recovery for the three methods was determined as
follows: double elution recovered activity/sum of activity recovered
from 4 mL single elution of each generator (1-3 days prior) x 100. (i)
Fractionated elution: 87% of 68Ga was recovered in 4.5 min from the
collection of the 2-5 mL fractions from both generators. (ii) “In series”
elution: the 2-8mL fraction was collected in 6.5 min, yielding 80% of
recovered activity. (iii) The pre-concentration/elution method took
5.5 min and recovered 91% of the activity. 68Ga-DOTATATE synthe-
sis: Using method (i) the precursor (25μg) in 1.5 mL 0.25M Na-acetate
buffer was reacted with the 6 mL eluate (pH reaction 3.5-4) for 7 min
at 90-95°C. The RCP of 68Ga-DOTATATE before purification was
98.4% (TLC). 68Ga-DOTATATE was obtained in 83% yield (n.d.c), 13%
activity was found in the waste and was mostly accounted for the
discarded fractions. Using method (iii), the precursor in 1 mL buffer +
3 mL Trace Select water was reacted with 0.8 mL eluate (pH reaction
3.5-4). Before purification, the RCP of 68Ga-DOTATATE was 95.6%
(TLC). 68Ga-DOTATATE was obtained in 84.5% yield (n.d.c), 4.2% ac-
tivity remained on the Strata X and 6% in the waste.
Conclusion: 68Ga-DOTATATE was successfully synthesized in excel-
lent yields on a MultiSyn Synthesizer starting from the fractionated
and pre-purification double elution methods of two ITG generators.PP05
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Aim: In the last decades the Silk Fibroin Nanoparticles (SFNs) have re-
ceived considerable attention for drug delivery due their high bind-
ing capacity for various drugs and controlled drug release properties.
Up to date, multiple formulations of SFNs with different encapsula-
tion methods and drugs have been described but it is still unknown
their biodistribution in vivo after intravenous administration or tissue
injection. Our aim in this work is to label the SFNs with a radioiso-
tope to allow the visualization of the SFNs distribution in vivo. Post-
labelling approach is proposed, nanoparticles are first functionalized
with DTPA and then incubated with 111InCl3.
Methods: SFNs were prepared by a nanoprecipitation in MeOH [1].
The DTPA-functionalized silk fibroin nanoparticles (DTPA-SFNs) were
prepared by amide coupling reaction between the amine groups of
SFNs and one of the carboxylic groups of DTPA by using the EDC/
NHS activating system [2].
Suspensions of DTPA-SFNs (Zaverage = 191.1 ± 0.7 nm, PdI 0.115
and ζ= -32.1 ± 0.6 mV; pH 7.5) at concentration of 7 mg/mL were la-
belled with activities ranging from 22 to 79 MBq of 111InCl3 (Mallinck-
rodt Radiopharmaceuticals Spain, S.L.U) at room temperature up to 3
hours under stirring. After incubation, suspensions were washed
twice with deionized water. Labelling yield was calculated as radio-
activity in SFNs divided by total radioactivity (SFNs and supernatant).
Results Radiolabelling yield was 63.69±2.15 % (n = 8). Activity measured
in supernatants after washing was under 3% (n = 8). 111In labelled nano-
particles were stable in suspension along the incubation experiment.
Conclusion: The coupling of DTPA followed by incubation with 111In
chloride could be a promising method for SFNs radiolabelling. Fur-
ther studies are needed in order to optimize the radiolabelling pro-
cedure, including stability tests, cytotoxicity in cell cultures and
biocompatibility in vivo.
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Aim: Nanoparticles have recently gained great interest in biomedical
applications. Among them, silk fibroin nanoparticles (SFNs) present
excellent properties as vectors for drug delivery and several biomed-
ical applications have been recently reviewed [1]. In vivo tracking of
these nanoparticles is an actual challenge for researchers and label-
ling with radioisotopes would be an attractive alternative to other in-
vasive biodistribution studies [2]. This work describes how silk fibroin
nanoparticles (SFNs) are capable of adsorbing 99mTc compounds by
using different strategies. Radioisotope labelling of SFNs was opti-
mized in terms of radioisotope/SFNs ratio (MBq/mg SFN), time and
temperature of incubation.
Methods: SFNs were prepared by a previously described nanopreci-
pitation method [3]. Aqueous suspensions of SFNs (Zave=168.1±2.5
nm, PdI = 0.095, ζ= -21.2±0.7 mV; pH 7.5) at two concentrations (5
and 12.5 mg/ml) were radiolabeled with activities ranging from 250
to 1050 MBq of 99mTc-DTPA (Technescan DTPA, Mallinckrodt Radio-
pharmaceuticals Spain, S.L.U.) and 99mTc-HMPAO (Exametazima,
Radiopharmacy Laboratory Ltd), either at room temperature or 4 °C,
up to 3 hours under constant stirring and recovered by centrifuga-
tion and washed twice with deionized water in order to remove
weakly bounded radioisotopes. Labelling yield was calculated as
radioactivity in SFNs divided by total radioactivity (SFNs and super-
natant). Radioisotope-labelled silk fibroin nanoparticles were further
characterized in diameter (Z-Average) and Z-potential (ζ) by DLS.
Results Results of labeling yield in the assayed conditions are sum-
marized in the following figure.
Conclusion: According to our results, labelling with 99mTc-HMPAO
reaches higher yields (32.1 ±1.4 %) compared to 99mTc-DTPA (6.4±0.4 %).
Higher concentration of nanoparticles shows higher isotope re-
tention. Temperature of incubation does not significantly affect
labelling yields. On one hand, DLS measurements showed that
99mTc-HMPAO-SFNs are slightly bigger in diameter and negatively
charged than the unloaded SNFs. On the other hand 99mTc-DTPA-SFNs
are significantly bigger in diameter but are less negatively charged
than the unloaded SNFs. These are very preliminary outcomes and
further studies are needed to optimize the radiolabelling
procedure.References
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Aim: The main reason to use the nanoparticles is to make active sub-
strate not to decay at the injection site, to target impact zones, to
provide continuous active substrate oscillation and to improve the
bioeffect of administration of drug. To assist intravenously applied
anticancer drugs in overcoming barriers (such as Chemical, Biological,
Physical, and Clinical Barriers) and to improve the balance between
their efficiency and their toxicity, a large number of drug delivery
systems have been developed over the years, ranging in nature from
‘simple’ liposomes, polymers [1] and micelles, to bacterially derived
‘Minicells’ and temporally targeted ‘Nanocells’ [2].
Methods: This study deals with grafted lysine aminoacid (Lys), metacryl
derivate of a hydrophobic side chained aminoacid containing poly(2-
hydroxyethylmethacrylate) based magnetic graft-Lys-poly(HEMA) nano-
particles, and the attempts to radiolabel this compound with a appro-
priate radionuclide (such as 99mTc) and evaluate the usefulness of the
resultant radiopharmaceutical for the diagnosis and management of
malignant tumors using nuclear methods. Hydrophobic nature of the
nanoparticle, possibly increases the uptake of nanoparticle in different
organs and tissues.
Results Magnetic graft-Lys-poly(HEMA) was labeled with 99mTc and radio-
pharmaceutical potential was investigated using animal models in this
study. Quality control procedures were carried out using thin layer radio-
chromatography (TLRC). The labeling yield of radiolabeled polymer,
99mTc-m-graft-Lys-poly(HEMA), was found to be about 100%. Then, stabil-
ity and lipophility studies were done for this radiolabeled polymer. The n-
octanol/water partition coefficient (lipophilicity) of 99mTc-m-graft-Lys-poly(-
HEMA) was determined. The lipophilicity was found to be 0.17. The results
of the serum stability experiments demonstrated that approximately
100% of 99mTc-m-graft-Lys-poly(HEMA) existed as an intact complex in
the human serum within 240 min. Biological activity of 99mTc-m-graft-Lys-
poly(HEMA) was determined on female Albino Wistar rats by scintigraphy
and biodistribution studies. The biodistribution study showed high uptake
in the stomach, the pancreas, brain, ovarian, intestines and the breast.
Conclusion: In conclusion, 99mTc-m-graft-Lys-poly(HEMA), which has
diagnostic and therapeutic application potentials in nuclear medicine,
was first radiolabeled using the SnCl2 method and investigated to evalu-
ate its biodistribution. Radiolabeled m-graft-Lys-poly(HEMA) proved a
useful tool for assessing the in vivo behavior of the drug in rats.
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Aim: 68Ga-PSMA & 68Ga-DOTATATE PET/CT have been established as
a useful modality in the diagnostic imaging of prostate cancer (PCa)
and neuroendocrine tumours (NETs) respectively. Their therapeutic
“companions” 177Lu-PSMA and 177Lu-DOTATATE have also been de-
veloped for the treatment of these tumours (Nanabala et al., 2016;
Maus et al., 2014). The aim of this work was to develop the produc-
tion and quality control of 177Lu-PSMA and 177Lu-DOTATATE for clin-
ical applications. In order to avoid hand doses to staff and reduce
the risk of 177Lu contamination, we investigated the automated syn-
thesis of 177Lu-PSMA and 177Lu-DOTATATE on a MultiSyn radio-
synthesizer (iPHASE technologies Pty Ltd). The preliminary
development phase presented here was investigated with 10 GBq
per synthesis.
Methods: The syntheses were carried out on a MultiSyn automated
synthesizer located into a dedicated shielded hotcell. 177Lu-DOTA-
TATE was prepared by incubating 177LuCl3 (~10 GBq in 500μL of
0.04M HCl) with 120 μg of DOTATATE in 500μL of 0.4 M sodium acet-
ate/50μL of 20% ascorbic acid solution at 85oC for 30 min. After cool-
ing, 0.5 mL of DTPA (1 mg DTPA in 0.9%NaCl) was added. The final
product was diluted and transferred through a sterile filter (Cathivex
GV) into the final collection vial containing 25 mg of sodium ascor-
bate. Radiochemical purity as well as radiochemical stability of the
product was determined by radio-TLC and radio-HPLC methods.
Results 177Lu-DOTATATE was prepared in yield 86.7% ± 0.2% (n = 3)
with a radiochemical purity greater than 99%. The final product
passed all recommended quality control specifications (pH, sterility,
pyrogen test & bubble test). The synthesis of 177Lu-DOTATATE was
completed in ~ 45 min. A similar approach for the 177Lu-PSMA is in
progress.
Conclusion: High activities of 177Lu-DOTATATE were successfully pre-
pared in good yields using a MultiSyn radiosynthesizer, passing all QC
requirements. The automated synthesis was performed in a dedicated
hotcell for proper radiation protection. This optimised method will be
used to provide 177Lu-labelled PSMA and DOTATATE for clinical use at
Sir Charles Gairdner Hospital in 2018.
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Aim: [18F]NS12137 (3-[(6-[18F]fluoro-2-pyridyl)oxy]8-azabicyclo[3.2.1]oc-
tane) is a highly selective norepinephrine transporter (NET) tracer [1].
Recently [18F]NS12137 has been produced via electrophilic pathway [1].Herein we introduce the synthesis of protected [18F]NS12137 by a
copper-mediated 18F-labelling starting from a stannylated NS12137 pre-
cursor (Fig. 1).
Methods: Radiolabelling was performed with a partly automated syn-
thesis device, by applying a previously reported 18F-labelling proced-
ure [2]. Dry [18F]KF/K222 complex was formed by azeotropic drying of
the cyclotron produced [18F]fluoride at 120 °C. Cu(OTf)2(py)4 was
added to the reaction vessel in anhydrous MeCN at room
temperature and the reaction mixture was stirred for 10 minutes. The
stannylated precursor was added to the reaction vessel in dimethyla-
cetamide (DMA) or MeCN. When using DMA as a solvent, MeCN was
first evaporated at 120 °C. The reaction vessel was then heated at
120 °C and samples for analytical radio-HPLC were collected during
30 minutes every 5 minutes. When using MeCN as a solvent, the re-
action vessel was heated at 80 °C and samples for analytical radio-
HPLC were collected during 75 minutes every 15 minutes. Deprotec-
tion has been performed by changing the solvent (DMA to THF),
evaporating THF to dryness and then treating with 48 % HBr.
Results Protected [18F]NS12137 was successfully prepared from the
stannylated precursor via copper-mediated nucleophilic [18F]fluorin-
ation. The radiochemical yield (RCY, non-decay corrected, based on
radio-HPLC analysis of the crude reaction mixture) was up to 94% when
using DMA as a reaction solvent after 5 minutes reaction. When MeCN
was used, the RCY was up to 0.5% after 30 minutes reaction.
Conclusion: Protected [18F]NS12137 was produced with a high RCY
by the copper-mediated synthesis. The RCY obtained is higher than
with electrophilic 18F-fluorination. Future work will include deprotec-
tion and isolation of the product.
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Zirconium-89 has attracted huge interest and is used in tracing and
quantification of slow biological processes and labelling of long half-
live biomolecules such as monoclonal antibodies for pharmacokinetic
studies and clinical trials. A new Coordinated Research Project (CRP),
planned to be initiated by IAEA in late 2018 will investigate the targ-
etry, irradiation data, separation and coordination chemistry of
zirconium-89 by all participants from developed and developing
countries. A detailed work plan on conjugation and 89Zr
Fig. 1 (abstract PP09). Synthesis of protected [ F]NS12137
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 20 of 38radiolabelling of biomolecules shall be addressed. The participation
of 15 Member States for 4 years is expected in this project.
Keywords: IAEA, CRP, 89Zr, Production, Radiolabelling, Monoclonal
antibody
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Aim: Radiopharmaceutical preparations for parenteral use must com-
ply with the test for bacterial endotoxins according to the European
Pharmacopoeia [1], whereby the endotoxin test can be carried out
after release for the in-vivo application. For this purpose dedicated
endotoxin testing devices are commercially available. Some nuclear
medicine sites additional perform bioanalytical tests using an optical
microplate reader. We aimed to approve and validate a method for
endotoxin testing of radiopharmaceuticals with analysis and evalu-
ation by a microplate reader.
Methods: For endotoxin testing the quantitative kinetic chromogenic
LAL assay Kinetic-QCL, (Lonza Group Ltd, Basel, Switzerland) with a
96 well pyrogen-free microplate was used. The dynamic measure-
ments were performed with a FLUOstar OPTIMA multi-detection
reader (BMG Labtech, Ortenberg, Germany) [2]. The specific analysis
was programmed with the operating software MARS. The test mea-
sures the reaction time (y) to reach the predetermined absorbance
(threshold of 0.2 OD). 100 μl of standards (0.005, 0.05, 0.5, 5.0 EU/ml)
and unknowns were measured at 405 nm in duplicate for a total of
100 min. The endotoxin concentrations (x) were calculated by linear
regression fit with the formula log(y)=a*log(x)+b. As assay control,
spiked samples (0.5 EU/ml) of the unknowns were measured in
duplicate. To validate interfering factors, 6 samples of unknowns
(68Ga-peptides in PBS matrix, 5 % EtOH) were diluted 1:10; 1:20; 1:50
and 1:100 and measured without/with a spike in duplicate.
Results In 3 validation runs accuracy, reparability, precision, and lin-
earity were studied. All samples in the studies were valid with a spike
recovery between 75% and 100%. The correlation of the calibration
fit was >0.997 and LLOQ was found to be 0.005 EU/ml. The solvent
matrix of 68Ga-peptides showed no interferences at a dilution of
1:10. Considering this dilution, the range of the endotoxins test
stretched from 0.05 to 50 EU/ml. According to Ph. Eur. the limit for
bacterial endotoxins in 68Ga-peptides solution for injection is defined
with 175 EU per dose. Calculating 10 ml per dose the limit of 17.5
EU/ml is well covered.
Conclusion: We have demonstrated that an optical microplate reader
is well suitable to test bacterial endotoxins in retain samples of 68Ga-
peptides solutions. Up to 20 samples can be tested as bundle onto a
96 well microplate within 3 hours. After validation this analysis
method was integrated successfully into the parametric release of
our routinely prepared 68Ga-peptides.
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 21 of 38Aim: Epidermal growth factor (EGFR) receptor is over-expressed in
several solid tumors. EGFR tyrosine kinase inhibitors (EGFR-TKI)
bind to the intracellular TK domain and compete with adenosine
triphosphate (ATP), preventing thus tumor cell proliferation,
angiogenesis, and protection from apoptosis. In the present
study, we aimed towards the synthesis of potential 68Ga labeled
monomers and dimers of the EGFR-TKI pharmacophore (3-bromo-
phenyl)quinazoline-4,6-diamine pharmacophore[1,2]. 1, bearing
the complexing agent HBED-CC (N,N′-bis[2-hydroxy-5-(carbox-
yethyl)benzyl]ethylenediamine-N,N′-diacetic acid). Lead structure 1
was also linked to a 4-aminobutanoic acid 2. HBED-CC was
conjugated to the aforementioned pharmacophores (1 and 2) via
its functionalized propionic acid moieties, resulting in monomers
3 and 4 or dimers 5 and 6, respectively. Ligands 3-6 were tested
in vitro for TK inhibition, radiolabeled with 68Ga and tested
in vivo for their biodistribution profile in mice bearing A431
(human epidermoid carcinoma cell line) tumors.
Methods: The cytotoxicity of 1-6 was determined by the MTT assay
against A431 cells by treating them with varying concentrations of 1-
6 for 72 h (10 nM-1000 μΜ)1. HBED-CC analogues 3-6 (1.0 nM in
HEPES buffer 2.4 mM, 90-100 μL) were radiolabeled with [68Ga]Ga3+
eluate (40 μL, 40-50 MBq), 98°C, 10 min, and evaluated for radiolabel-
ing efficiency via radio-RP-HPLC. Tracers [68Ga]i (i = 3-6), were investi-
gated in vivo for their tumor accumulation and biodistribution in
A431 tumor-bearing SCID mice at 5, 60 and 120 min post injection.
Results In vitro MTT assays for 3-6 showed IC50 values in the μM
range. Monomer 3 (43.60 ± 7.49 μM) was significantly better than 4
(62.84 ± 6.34 μM) and 6 (68.80 ± 3.71 μM) and identical with dimer
5. Radiolabeling of 3-6 resulted in a single radioactive product [68Ga]i
(i = 3-6), while radiochemical yield ranged between 98-100%. Biodis-
tribution experiments for [68Ga]i (i = 3-6) showed tumor (A431) up-
take which ranged between 0.90-1.34 %ID/g at 5 min. Monomer 3
and dimer 6 showed a fast tumor clearance (0.49-0.34 %ID/g at 60
min p.i.), while for monomer 4 and dimer 5 tumor uptake remained
rather constant after 60 min p.i. (0.73-0.70 %ID/g). All compounds
showed extensive uptake in the intestines at 60 and 120 min p.i., ran-
ging between 23.23-43.18 %ID/g. Among the ligands studied mono-
mer 4 presented less off-target uptake in combination with the
higher tumor accumulation.
Conclusion: Four novel quinazoline monomers and dimers based on
the HBED-CC chelator (3-6) were synthesized, radiolabeled with 68Ga
and evaluated as biomarkers for EGFR-TK imaging. Among the tracers
studied [68Ga]i (i = 3-6), monomer 4 presented the best pharmacoki-
netic characteristics regarding tumor uptake and off-target accumula-
tion. Tracer 4 is being considered for further evaluation as PET tracer
for EGFR-TKI imaging.
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Aim: PSMA and GRPr are both highly expressed on prostate cancer
(PCa), and thus considered attractive targets for imaging and ther-
apy. GRPr has been also been suggested for imaging breast cancer
(BC), while on the contrary for PSMA a limited number of positive
cases has been reported. We compared two ligands linked to thechelator N,N’-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-
N,N’-diacetic acid (HBED-CC), H2N-(Ahx)-Lys-NH-CO-NH-Glu (PSMA-11)
[68Ga]1 and a GRPr antagonist, H2N-4-amino-1-carboxymethyl piperi-
dine-[(R)-Phe6, Sta13]BN(6–14) [68Ga]21,2. Both tracers were tested
in vitro in PC-3, LNCaP (both PCa), T47D, MDA-MB-231(both BC) and
in the PSMA-transduced and PSMA-overexpressing cell lines PC-3+,
T47D+ and MDA-MB-231+. In addition, a GRPr probe for fluorescence-
based flow cytometry (FACS), 3, was synthesized by the replacement
of HBED-CC with Alkyne-BDP-FL (Jena Bioscience®).
Methods: PSMA overexpression in PC-3, T47D and MDA-MB-231 cell
lines was accomplished by means of lentiviral transduction and was
subsequently confirmed by western blot in the respective cell ly-
sates. 1 and 2 were synthesized and radiolabeled with 68Ga accord-
ing to published methods3. Total cell bound [68Ga]1 and [68Ga]2
over time (0-90 min) was determined according to previously pub-
lished methods1,2. FACS analysis with 3 was also performed on the
following cell lines T47D+ (PSMA+), T47DMock (vector only), T47D
(wild type).
Results: Maximum cell binding of [68Ga]1 and [68Ga]2 (PSMA- and
GRPr-specific respectively) was achieved after 45 min of incubation
time. Cell binding of [68Ga]1 and [68Ga]2 was increased after PSMA
transduction in all cell lines tested after 1h incubation. More specific-
ally, (results are expressed as timesx above control, % given radio-
activity) [68Ga]1 (PSMA) was higher for MDA-MB-231+ (100x, ~80 %),
T47D+ (4x, ~2.5 %), PC-3+ (10x, ~13 %) than controls (Mock or
blocked with addition of 10.000-fold excess pharmacophore), while
for LNCaP it was ~66 %. Interestingly, alongside PSMA overexpres-
sion caused by the transduction the binding of the GRPr ligand was
also increased, thus [68Ga]2 was higher for MDA-MB-231+ (2x, ~3 %),
T47D+ (2x, ~9 %), PC-3+ (2x, ~30 %) than controls (Mock or blocked
with addition of 1000-fold excess pharmacophore). These observa-
tions have been also confirmed by FACS using 3 in T47D and T47D+.
Conclusion: The transduction of PSMA positively affected the
amount of cell bound ligand for both [68Ga]1 (PSMA) and [68Ga]2
(GRPr) in all PCa and BC cell lines studied. These results indicate a
possible connection between the two receptors (PSMA/GRPr); further
studies are underway to prove this hypothesis. The findings of this
study might be of high impact for the development of novel radio-
pharmaceutical treatment strategies addressing tumor heterogeneity.
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Aim: Camelid single-domain antibodies (sdAb), also called VHHs, con-
stitute a promising “new” class of imaging agent for nuclear medi-
cine. When using the tricarbonyl method for radiolabelling VHH with
Tc-99m, the optimal conditions must be specifically determined 1) by
determining the parameters such as temperature and heating times
to obtain the maximum of complexation with 99mTc but also 2) by
evaluating the effects of temperature on their secondary structure.
Methods: Five VHH (VHH-r1, VHH-r2, VHH-r3, VHH-r4 and VHH-r5)
were radiolabeled with technetium-99m using tricarbonyl method at
their C-terminal hexahistidine-tag (His-Tag). For each compound, vari-
ous parameters such as specific activity, time and temperature of in-
cubation were evaluated to determine the ones allowing for
obtaining the most elevated complexation with 99mTc. The radio-
chemical purity (RCP) was determined by HPLC before and after puri-
fication step with a NAP-5 size exclusion column. Circular dichroism
(CD) spectra were achieved from 205 to 260 nm at temperatures ran-
ging from 25°C to 85°C.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 22 of 38Results The conditions enabling to acquire the highest complexation
with Tc-99m were found to depend on the evaluated VHH. For in-
stance, they were of 45 min at 75°C for VHH-r1, VHH-r4 and VHH-r5,
of 60 min at 60°C for VHH-r2, and of 90 min at only 40°C for VHH- r3.
Similarly, conformational changes observed by CD were found to
vary between the evaluated VHHs, with maximal thermal stabilities
ranging from 40°C to 75°C. As a result, for 3 VHHs out of 5, the incu-
bation temperature had to be reduced to achieve the maximum of
complexation in order to preserve their 3D conformation (50°C for
90min for VHH-r2 and 60°C for 60min for VHH-r4 and VHH-r5). Once
successfully radiolabeled and purified (PRC>95°C), we showed that all
99mTc-VHHs had preserved affinity for their target, except for
99mTc-VHH-r2.
Conclusion: This study underlines the fact that despite their struc-
tural similarities, each VHH responds differently to the conditions of
radiolabeling with Tc-99m. Therefore, to radiolabel a VHH using
99mTc-tricarbonyl method it is very important to define optimal con-
ditions of incubation in agreement with the maximum of complex-
ation without affecting its 3D conformation.Fig. 1 (abstract PP16). See text for descriptionPP15
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Aim: Dose calibrators are medical devices used in nuclear medicine
to determine the amount of radioactivity to be administered to pa-
tients. According to Dutch Nuclear Medicine Guidelines, dose calibra-
tors should be validated for all radionuclides and geometries with a
maximum deviation of 5% with respect to the true radioactivity. This
validation requires the use of well calibrated radioactive standards or
measurements with calibrated equipment. Because this is expensive
and time consuming, validation is often limited to a comparison to
other dose calibrators. It is questionable if this limitation is justified,
especially when looking at the effect of the (type of) isotope, the
dose calibrator type/manufacturer and the geometry of the radio-
active sample.
Methods: In this study, we used and compared four different dose
calibrators (ISOMED 2000, ISOMED 2010, Capintec CRC-25R, Veenstra
VIK-202). In these, we measured activity from four commonly used
isotopes (18F, 68Ga, 99mTc and 111In) using different volumes in both
syringes and vials. Additionally, we analyzed the effect of using dif-
ferent geometries (3 different brands of syringes and 4 different
brands of vials) on the measurements in more detail on one system.
All measurements were compared to a fully calibrated gamma spec-
troscopy semi-conductor system (GR1018, Canberra) to determine
the deviation from the true radioactivity.
Results For 18F and 99mTc, the deviations were mostly within the 5%
limit on all devices and for all geometries. For 68Ga and 111In how-
ever, deviations of more than 30% from the true radioactivity and
50% between different dose calibrators were observed. Within one
type of dose calibrator, the deviations are small for all isotopes: the
standard deviation for repeated measurements is below 3%, while
the effect of varying syringes and vials is about 5-10%.
Conclusion: Even though all dose calibrators showed acceptable de-
viations for 18F and 99mTc measurements, the deviations for 68Ga and
111In are not conform legal regulations and require on-site modifica-
tions of the dose calibrator settings. Although the effect of sample
geometry was generally limited (compared to the differences be-
tween isotopes), it frequently still exceeded the 5% limit as posed in
the guidelines. We therefore advise to validate dose calibrators (at
least one per type) for every isotope and for every geometry, using a
well-calibrated standard. As this may affect the ‘medical device’ sta-
tus of the system, discussion with the manufacturer is required.PP16
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Aim: Neolignan 4’-O-methylhonokiol (MH) isolated from Magnolia
grandiflora is known to have several biological activities, including
anti-cancer, anti-inflammatory and anti-neurodegenerative effects [1].
MH has recently been shown to inhibit cyclooxygenase (COX) activity
with a higher selectivity for COX-2 (IC50=0.062 μM) over COX-1
(IC50=2.4 μM) [2]. The development of COX-2 inhibitor radiolabeled
analogs is of special interest for PET visualization of inflammation
and tumors. Therefore we suggested a MH analog labeled with
carbon-11 (4’-[11C]methoxy-5-propyl-1,1’-biphenyl-2-ol or [11C]MPbP)
as a potential PET radiotracer. Unlabeled MPbP has demonstrated a
high anti-inflammatory activity comparable to that of specific COX-2
inhibitor celecoxib in the preliminary tests on mice with a
carrageenan-induced inflammation. The present study describes the
radiolabeling procedure of [11C]MPbP.
Methods: The synthesis of [11C]MPbP was performed by two-step pro-
cedure starting from precursor with Boc-protecting group and operated
with home-made fully automated module. The radionuclide carbon-11
(T1/2 = 20.4 min) in the form of [
11C]CO2 was produced by a nuclear reac-
tion 14N(p, α)11C in a PETtrace cyclotron (GE Healthcare). [11C]CH3I was
produced using ‘wet’ method (LiAlH4/HI) and transferred under nitrogen
flow (~10 ml/min) into reaction vessel with the precursor solution (2 mg
in 1.2 ml of acetone and 0.7 М NaOH in water-ethanol solution (1:1, v/v)
as a base). [11C]-methylation reaction was performed at room
temperature in 5 min. The hydrolysis step was accomplished at 60°C with
12 M HCl in 5 min. The efficiency of O-11C-methylation as well as yield of
[11C]MPbP were determined in crude reaction mixture using radio-TLC on
Silicagel 60 F254 UV-plates with hexane/ethyl acetate (4/1) as a mobile
phase and radio-HPLC (Waters X-Bridge column 4,6x150 mm, MeCN/H2O
(60/40) as eluent with flow-1.3 ml/min). The radiochemical identity of
[11C]MPbP was evaluated by comparison with the reference compound.
Results For the first time, [11C]MPbP, a novel potential COX-2 inhibi-
tor was produced. The 11C-methylation yield was about 60% and
[11C]MPbP was resulted in 45% yield based on [11C]CH3I.
Work is now in progress to further optimize synthesis and purifica-
tion of [11C]MPbP and to investigate its biochemical characteristics
(plasma stability, lipophilicity, BBB permeability, binding affinity to
COX-2). This study was funded by RFBR according to the research
project 17-04-02119 A.
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Fig. 1 (abstract PP18). Full HPLC chromatogram of the purification
of [18F]FFMZ
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Aim: Binding of the urokinase-type plasminogen activator (uPA) to
the membrane anchored receptor uPAR is defined by its amino ter-
minal fragment (ATF) consisting of a kringle and a growth factor-
like domain (GFD). The latter is buried deep in the binding cavity
and harbours the majority of the high-affinity interactions. A cyclic
peptide (WX-360: cyclo21,29[D-Cys21]-uPA21-30[S21C;H29C]) was de-
rived from this original structure demonstrating a capability to in-
hibit tumour growth and spread [1,2]. As the uPA system is
frequently associated with the process of invasion/metastasis and a
more aggressive phenotype in a great variety of cancers, there is a
great interest in PET imaging using uPAR-directed tracers to visual-
ise the tumour’s potential for metastasis formation. Hence, this
study uses the cyclic peptide WX-360 as a starting point for the de-
velopment of new PET tracers.
Methods: Ligands were synthesised on solid phase. A competitive
bioassay based on immobilised rhuPAR was developed to assess
their binding affinities. Briefly, increasing concentrations of ligand
(0-1000 μM) were incubated in the presence of a 0.1 nM solution of
a monoclonal mouse IgG1 antibody (clone #62022, R&D Systems)
directed against the uPA-binding pocket of uPAR. Binding of a
horseradish peroxidase conjugated secondary goat anti-mouse IgG1
antibody and subsequent conversion of a chromogenic substrate
generated the signal which was read at 450 nm. A competitive cell-
based binding assay to re-evaluate the initial results is currently
being developed.
Results Saturation and competitive binding studies employing the
natural ligand uPA revealed specific binding of the primary mAb
(Kd = 1.0 ± 0.1 nM). Assay specific IC50 values of the peptide-
based, literature-known structures DOTA-AE105 and WX-360 were
in the low micromolar range while no binding was detected for
DOTA-AE105M (non-binding mutant) [3,4]. Studies on the opti-
misation of the binding motif were promising for methylation of
the central lysine residue and exchange of the disulphide bridge
for a peptide bond. Conjugation of a DOTA chelator for radiome-
tal complexation was accomplished by insertion of various linkers
at the C-terminus of WX-360, the resulting compounds displaying
similar inhibitory potentials as compared to the original structure.
Placing the chelator at the N-terminus, however, slightly reduced
the binding affinity.
Conclusion: With initial positive results, this study presents the
potential of deriving uPAR-binding PET tracers from the peptide
WX-360. The platform for compound characterisation is currently
expanded to re-evaluation of IC50 values in a cell-based assay as
well as determination of logP values and serum stabilities.
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Aim: 2′-[18F]fluoroflumazenil (FFMZ) has proven useful for benzodi-
azepine receptor imaging. Our gold was to implement the fully-
automated synthesis of [18F]FFMZ in a Tracerlab FXFN module.
Methods: Synthesis was performed via nucleophilic substitution
using the chemical precursor Tosyloxyethylflumazenil (TFMZ),
adapting the method reported by Yoon et al. [1] but avoiding
the use of gradient HPLC. Briefly, [18F]Fluoride ion was trapped in
a QMA cartridge and eluted with 1.5 mL solution of K.2.2.2. (5.3
mg/mL)/ K2CO3 (1.4 mg/mL) in MeCN/H2O (95/5). After drying of
the azeotrophic mixture, 5 mg of TFMZ in 1.7 mL MeCN/0.3 mL
DMSO were added to the reaction vessel and heated at 110°C for
12 min under intermittent purging with helium. The reaction mix-
ture was diluted with 2 mL (×2) of water and passed through an
activated Alumina cartridge to the HPLC-injection vial. Solution
was then loaded onto the HPLC-loop for purification in a semi-
preparative C18 reverse phase column (250/10 mm, Nucleosil
100-7 C18, Macherey-Nagel). Purification was performed under
isocratic elution using two mobile phases at a flow rate of 3 mL/
min: first with 100% water for 10 min then switching to 40%
MeCN in water. The collected product-fraction was diluted with
water (1:5) and loaded onto a preconditioned C18 cartridge. After
rinsing with 3 mL of water, [18F]FFMZ was eluted with 1 mL of
70% EtOH, diluted with 10 mL of physiological saline, and steril-
ized by filtration (0.22 μm Millex-FG).
Results: [18F]FFMZ was eluted at 20 min after injection as
shown in Fig. 1. Synthesis was satisfactorily accomplished
yielding the final product in radiochemical yields of 20–25%
decay corrected at the end of bombardment after a synthesis
time of 60 min (n = 5), with a radiochemical purity >99% as
determined by analytical HPLC.
Conclusion: A convenient and reliable synthesis of [18F]FFMZ was
successfully adapted in an automated module by using two suc-
cessive isocratic elutions instead of gradient HPLC. Final product
showed no radioactive or non-radioactive impurities obtaining
[18F]-FFMZ in enough quantity and quality for clinical
applications.
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Aim: The radioiodinated products are used as diagnostic or
therapeutic agents. The diversity of the labelling methodologies
that used to introduce the radioactive iodine into the target
molecule are wide enough to make the selection of a specific
route is of great interest. Several oxidant agents were used in
labelling biomolecules. Three famous ones are Chloramine-T,
Iodogen and Iodo-beads (the solid state of the Ch-T). However,
the mentioned agents are producing varies radiochemical yields
and more importantly stabilities of the produced labelling prod-
uct always questioned. The current report is detailing the
findings out of a study that was aimed in investigating several
reaction factors on the above labelling agents when used with
small molecules and short peptides.
Methods: The direct electrophilic method via Chloramine-T or
similar oxidant was used. Following the end of the reaction the
purification step was done using Sep-Pak C-18 Classic cartages
that should be activated with 3 ml water prior the purification.
Then the Sep-Pak was then washed with 1 ml water, then
collect the product (labeled peptide) in the second wash which
done by eluting with 0.5 ml MeCN and 1.5 ml mix of the HPLC
system. The radioiodinated product was isolated by Sep-Pak
and confirmed with the TLC and HPLC analysis methods.
Results Chloramine-T gives constant RCY most of the time under
all conditions except at basic PH (8.5) in which heat is required.
Iodogen gives better RCY when heated and higher PH 7.4 and
8.5 were used. The effect of the heat was clear at PH 6.5 as the
RCY was nine times higher at 60°C. Also Iodo-beads gives
higher RCY than the other two labeling agents except at PH 8.5
and 60°C, it was about 25 % (±5) less.
Conclusion: We can conclude that RCY and purity are very
dependent on the right choice of the labeling agent and
reaction conditions. However Iodo-beads give higher RCY than
the other two labeling agents which make it the targeted
intermediate oxidant reagents.
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Aim: Radiosynthesis an imaging radiotracer for a carefully selected bio-
logical process and choosing the right imaging modality become the
top aims for all biomedical researchers. Positron Emission Tomography
(PET) is the first on the list used for such investigations as it fulfils all in-
formations required for imaging of biological process. On the other
hand human cancer cells over express many peptide receptors which
can be used as molecular targets. Therefore, radiolabeled receptor-
binding peptides have emerged as an important class of radiopharma-
ceuticals for tumor diagnosis and therapy. As small peptides for recep-
tor imaging and targeted radiotherapy have advantages over proteins,
antibodies and antibody fragments as they are small and show rapid
diffusion in target tissue and they have low molecular weight which
will result in rapid clearance from blood and non-target tissues and that
in turn will result in high tumor-to-background ratios.
Methods: In a routine process a 0.1mg of nanoparticles that been at-
tached to a biological molecule (peptide) dissolved in 50μl H2O.
68GaCl3 eluent from a
68Ge/68Ga generator is used as the generator is
fractionally eluted beginning with 5.0 ml of sterile 0.1N HCl. For frac-
tional elution, the first 1.6 ml of eluate always discarded, the next 2.0
ml is collected for use and the final 1.4 ml also discarded. 200 μl of
the fractionated Ga-68 eluate (approximately 1 mCi/37 MBq) is added
to nanoparticle solution then 100μl of sodium acetate buffer (1.25M)
or ammonium acetate buffer (0.25M) is added and allowed to react
at (85-90°C) for 30 minutes, the pH of the reaction mixture should be
kept at 5.5. Following incubation, the labeled nanoparticle is then
tested for radiochemical yield and purity using Radio-TLC and HPLC.
Results: The labelled nanopatical attached to the biological molecule
is monitered by both TLC and HPLC.
Radio-TLC example of labelling reaction mixture; 68Ga-anoparticle re-
mains at the origin with retention factor of 0.00, the purity approxi-
mately 85%, and the free 68Ga migrating to the solvent front with
retention factor of 0.96.
Conclusion: New efficient methodology to label nanoparticles with
Ga-68 was developed in order to promote the development of PET-
nanoradiopharmaceuticals that in the future will overcome the limita-
tion of the regular PET-radiopharmaceuticals in use nowadays.Fig. 1 (abstract PP20). See text for description
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Aim: Melanoma is a tumor of constantly accumulative occurrence for
which novel methods of imaging and targeted therapy are generally
pursued. Developing a newly laminin class peptide that been labeled
with position emitter Ga-68 or I -124 and with SPECT emitter I-131
will be discuss. In order to evaluate the potential relevance of posi-
tron emitter labeled a laminin class short peptide with enhanced
melanoma targeting capacity, the uptake of 68Ga/124I-peptide were
investigated in SK-MEL 28 melanoma cell line. Also the same peptide
was labelled with 131I to be tested as therapeutic approach.
Methods: High performance liquid chromatography (HPLC) system
and Thin Layer Chromatography (TLC) were used for quality control
purposes. The radiochemical purity were > 99.00% (n = 5). The stabil-
ity was persistent over 6 h and amounted to > 98.55% ±0.35% (n =
15) for the 68Ga-peptide. In vitro receptor binding was performed on
the mentioed cell line and biological evaluation was done in normal
and mice bearing SK-MEL28 cell xenograft. Animal PET/CT using
68Ga-peptide and 124IGa-peptide were performed in murine models
of melanoma.
Results: As determined by HPLC, the 68Ga-short peptide efficiency
was >70% and radiochemical purities always > 99% in short reaction
time. These synthetic approaches hold substantial promise as a rapid
and efficient method amenable for automation for the labelled of
peptides with high radiochemical yield and short synthesis time. For
radioiodination direct electrophilic method were used with High RCY.
Conclusion: The uptake of 68Ga-peptide was high by pheomelanotic
SK-MEL-28 human melanoma cells. In vivo characterization in normal
mice revealed rapid blood clearance of 68Ga-peptide with excretion
by both urinary and hepatobiliary pathways. In vivo imaging using
animal PET/CT is confirming the later findings yielded a high tumor-
to-background ratio at 1 h and at 2 h. In vitro tests have shown that
significant amount of the 68Ga-peptide associated with melanoma
cell fractions. Due to its easy handling and quite high uptake by mel-
anoma cells, we expect that this peptide could be successfully used
in routine application for melanoma imaging or eventual radiother-
apy suggesting great potential for noninvasive clinical evaluation of
suspected metastatic melanoma.
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Aim: Sodium Iodide (131 I) is a radiopharmaceutical available as oral
capsule or solution, and is largely used in nuclear medicine for tyroid
scintigraphy imaging and in radioiodine therapy. Radiochemical pur-
ity (% RqP) is defined as the percent of total radioactivity in the de-
sired chemical form. The main methods to determine % RqP is paper
chromatography (PC), thin-layer chromatography (TLC) and high per-
fomance liquid chromatography (HPLC). Some compendial methods
also establish procedures for retardation factor (Rf) determination
1-2.
The objective of this work was to evaluate the mobile phase effect
on the Rf of iodide (I
-) and iodate (IO3
-) in the % RqP analysis of So-
dium Iodide (131 I).Methods: Whatman 3MM PC (1.5 × 12.5 cm), methanol and glacial
acetic acid were from Merck Millipore. Methanol and purified water
in the proportion of 50%, 70%, 75% and 85% (v/v) were the mobile
phases. Diluent solution containing 0.1 mg/mL KIO3, 0.2 mg/mL KI
and 1.0 g/mL Na2CO3, and standard solutions of 0.2 g/mL KI and 0.4
g/mL KIO3 were prepared. In the origin position of a 10 cm paper
strip, 5 μL of the diluent solution were applied. After chromato-
graphic separation in each mobile phase, the suitable standard solu-
tion was dripped on the iodate and iodide expected positions
followed by drops of glacial acetic acid to reveal the Rf of the species
with formation of a brown spot3.
Results: The American and Argentine pharmacopoeial methods
present iodate-131 as the main radiochemical impurity but differ in
the mobile phase composition and in the color development method
for iodide and/or iodate1-2. The systems advocate the use of 30 and
20 cm long stationary phases which require several hours for separ-
ation of the species, and methanol 70% and 75% (v/v), respectively.
In a 10 cm strip and 70% (v/v) methanol, the Rf for iodate was 0.5-0.7
and for iodide was 0.7-0.9; with 85% (v/v) methanol, the Rf were 0.3-
0.5 for iodate and 0.7-1.0 for iodide, respectively, taking an hour and
a half for the chromatografic run. The resolution obtained with 85%
(v/v) methanol was better when compared to methanol 70% (v/v).
Conclusion: By the use of the staining test for iodate and iodide pro-
posed by the Argentine pharmacopoeia, it was possible to improve
the % RqP analysis of Sodium Iodide (131 I), decreasing the analysis
time of more than 4 hours to an hour and a half.
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Aim: Internal contamination with plutonium (Pu), either in the con-
text of accidental occupational exposure or as a result of possible
terrorist use, continues nowadays to be a potential hazard. The
practical way to reduce Pu body burden and the associated radi-
ation risks is decorporation by chelation therapy by injection of
marketed Na3-Ca-DTPA solution. This study aimed at assessing the
efficacy of 110nm-sized liposomes encapsulating the DTPA in
plutonium-exposed rats. The comparative effects of liposomal and
free DTPA at similar doses were examined in terms of limitation of
alpha activity burden in rats receiving various treatment regimens.
Methods: Unilamellar liposomes (DSPC/Cholesterol/DSPE 69:30:1)
were used to encapsulate DTPA (25mM). For decorporation experi-
ments, rats were first contaminated by intravenous administration
of the soluble citrate form of 238Pu (4 to 10.3 kBq), before injection
of DTPA, marketed free form or encapsulated in liposomes (2.25 at
6.74 μmol/kg). Treatment schedules started at one hour (prompt
treatment) or at seven days (delayed treatment) after contamin-
ation and were given as a single injection or repeated injections. A
prophylactic single treatment was also tested given at three days
before contamination. Organs of interest (liver, bone and spleen
mainly) and excreta were collected at different times for measure-
ment of Pu alpha activity.
Results Liposomal DTPA given at 1h post-contamination reduced sig-
nificantly Pu retention by 2.5-, 1.6- and 3-fold in liver, bone and
spleen respectively, compared with free DTPA. For delayed adminis-
tration, liposome-entrapped DTPA decreased hepatic, skeletal and
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 26 of 38splenic Pu levels by, respectively 68, 39 and 74% of the levels in un-
treated control rats (only 19, 12 and 24% with a similar dose of free
DTPA). In addition, repeated injections of liposomal DTPA improved
the removal of Pu compared to single injection and the efficacy of
the prophylactic treatment was also observed.
Conclusion: The advantage of liposomal DTPA was undoubtedly dir-
ectly and indirectly due to the better cell penetration of DTPA when
loaded within liposomes, mainly in the tissues of the mononuclear
phagocytic system. The decorporation induced by liposomal DTPA
may result firstly from intracellular chelation of Pu deposited in soft
tissues, predominantly in the liver. Afterwards, the slow release of
free DTPA molecules from these tissues may enable a sustained ac-
tion of DTPA, probably mainly by extracellular chelation of Pu avail-
able on bone surfaces. To conclude, Pu decorporation can be
significantly improved by liposomal encapsulation of DTPA regardless
of the treatment regimen applied.
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Aim: According the EU GMP Guide the radiopharmaceuticals should
be manufactured in controlled areas and the premises maintained so
that the level of particles and microbiological contamination are low.
At Turku PET Centre (TPC) the production of radiopharmaceuticals is
performed in EU GMP class C clean room. Thus validation of the
clean room shall ensure that the area fulfills all EU GMP requirements
for this classification.
Methods: In order to grade our production premises, we have com-
piled a validation plan which was accepted by the quality assurance
person of TPC. The validation process according the accepted valid-
ation plan was performed by an outside contractor according to
valid standards (methods, calibrations of the measurement equip-
ment and documentation). The tests include measurements of
HEPA filter integrity, air volume flow, room differential pressure,
airflow visualization, air change rate, airborne particle levels and
viable microbial particles. The microbiological testing and measure-
ment of airborne particles were performed both at rest and in oper-
ation. For microbiological testing, active and passive air samples
using settle plates and surface samples using contact plates were
taken from spots specified in the validation plan.
Results: The contractor compiled a validation report including all
measurement records. All the requirements were fulfilled, the report
was checked and accepted by the responsible person at TPC.
Conclusion: To maintain the classification, following measurements
are performed annually: HEPA filter integrity test, air volume flow,
room differential pressure, room air change rate and airborne particle
levels. In addition, the room differential pressures are monitored
automatically all the time giving alarm when out of specification.
Microbiological sampling and measurement of airborne particles are
performed regularly according to a standard operation procedure.
Microbiological sampling is done at least once a month. Airborne
particles are measured at least once a week during end product ster-
ile filtration. While doing aseptic work, microbiological sampling and
the measurement of particles are always performed.
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):PP25Aim: 177Lu-DOTATATE (Lutathera®) indicated in endocrine tumors
PRRT should be administered according to its SPC by a slow intraven-
ous infusion (7.4GBq whitin 30min-or-50mL/h) with either the “2-
pump” or the “gravity” methods. This latter method consists in using
a saline solution placed in height and connected to the Lutathera®
vial by an infusion line, which flows the vial causing volume expan-
sion and overpressure, pushing the diluted product into a second in-
fusion line that goes to the patient. The first trials we made with this
technique showed that it was as imprecise as difficult to control. The
aim of this work was to optimize exprimentally this technique and
compare to the other ones.
Methods: A saline bag(250mLw) as placed at 2m height, connected
to an infusion line (set at 16drops/min -or-50mL/h) ending with a
22G/30mm-needle. The needle was inserted into the Lutethera vial
placed at 1,5m height. A second long 19G/88mm-needle deeply
inserted into the vial septum until touching its bottom -was
connected to the venous perfusion line going to the patient. For
radiation safety reasons, 177Lu-DOTATATE was substituted by a cold
saline solution stained by Red Ponceau and placed a Lutathera
empty vial sealed with a new rubber stopper and an alumunium ring.
The evaluation of photometric absorption replaced the radioactive
measurments. Once the assembly of this system set up, the infusion
was started, 150 mL the colored solution was graudally collected at
the line outlet in 5mL fractions which content was assessed by UV-
visible-spectrophotometry at 550nm. Measurments permitted to
evaluate 3 parameters: volumic activity of the perfusate (VAp), (in %,
AT) and residual activity in the bottle (in %, AR). Results are
expressed as mean±SD (n = 3).
Results: Collected perfusate shohwed a volumic activity wich de-
creased gradually in exponential way [Vap=A0.e(-0,062. Perfused-
Volume);R2=0.99]. Similar evolution was found in the residual activity
of the vial, which disappeared according to the same mode. Sym-
metrically, the total perfused activity gradually increased in an expo-
nential mode. After 30 minutes of infusion (infusion time requested
in the SPC), a significant amount of the product (21.0±1.1%)
remained in the vial. We calculated that to administer 99% the total
delivered activity, it was necessary to infuse a a total volume be-
tween 81mL and 86 mL. After 100mL of infusion, only 0.45±0.26%
remained in the vial.
Conclusion: While the pump infusion techniques produce uniform
and homogeneous perfusates, gravity technique was found to deliver
a variable content perfusate making difficult the control of cumula-
tive perfused activity, and perilous the planning administration of
partial activities following dose adjustments. The infusion of the en-
tire content requires at least 81mL of aline, significantly higher than
the SPC requirements.PP26
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Aim: 177Lu-DOTATATE is indicated in neuroendocine tumor PRRT. Its
therapeutic efficiency and safety are tightly related the maintenance
during all the treatment cycle of the chelate stucture integrity until
its internalisation in tumour cells. Any alteration on its structure may
lead to the complex destruction or unmettalation. These reactions
may be suspected during co-infusion of other pharmaceuticals
impacting pH, such as alkaline vehicles, or in patient freshly pre-
treated with cold somatostatin analogues which may be compettive
to the bound peptide. The aim of this work is to study chemical in-
teractions of 177Lu-DOTATATE in co-infusion conditions with various
pharmaceutical vehicles and non-radioactive somatostatin analogues.
Methods: 177Lu-DOTATATE (Lutathera®) was diluted to 1/5th in
saline, 5% Glucose, Bicarbonate 8.4% solution, Ringer-Lactate,
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or plasma enriched with 10% de octreotide. Radiochemical purity
(RPC) was determined by ITLC-SG in 0.1mol/L sodium citrate pH=3.
The labelled peptide had retention factor (Rf) of 0.1 (0.2 in plasma)
and the free radionuclide migrates at Rf=1.0. RPC was also deter-
mined using C18 Sep-Pack-Plus cartridge (Waters, USA). The free
radionuclide was eluted with 5mL of 0.1mol/L acetate buffer pH=3
and the labelled peptide with 5mL of methanol, and hydroxylated
Lu-177 remained inside the cartridge. Mixtures were then analyzed
immediately, 30min and 24h after dilution. Results were expressed
as mean±SD (n = 3-4) and RPC was considered as compliant when
it was >95%. Binary comparisons to the undiluted product were
made by a Mann-and-Whitney U test and stability over time
checked by a 1-way ANOVA (p < 5%).
Results: 177Lu-DOTATATE diluted in saline or glucose or with cold pep-
tides showed compliant RPC levels during the 24hours study duration.
In Bicarbonate and Ringer Lactate, significant amounts of unbound
Lutetium were found during Sep-Pack extraction, respectively 10.5±3.3%
and 8.9±4.2%. In plasma mixtures, significant amounts of either hydrox-
ylated Lutetium and or unbound lutetium were found only within 24h
incubation: respectively 4.9%±1.3% and 4.2%±0.6% in plasma and re-
spectively 6.3%±1.8% 4.8%±0.8% in plasma enriched with octreotide.
Conclusion: Hydroxylated Lutetium and unbound lutetium found in
plasma 24 hours post-incubation may be due to the catalytic activity of
plasma which slowly deteriorates the lutated complex. This is unlikely
to occur in vivo: Lutatate is rapidly cleared from the bloodstream within
few hours post-infusion. According to our results, the co-infusion of
177Lu-DOTATATE with alkaline pharmaceutical vehicles should be
avoided: it affects the complex stability and induces Lu-177 release.PP27
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Aim: The positron-emitting 89Zr (T1/2=78.42h) is widely studied for PET.
Monoclonal antibodies labeling is the main focus of these studies. But
should we disregard the diagnostic potential of simple 89Zr com-
pounds?! The possibility of effective diagnosis of inflammation, skeletal
disorders and even tumors using 89Zr-oxalate and other complexes was
previously demonstrated [1,2]. The aim of this study is to develop
handy procedure for production of 89Zr-oxalate in physiologically ac-
ceptable form and evaluate its potential for PET diagnosis.
Methods: All chemicals and solvents were of high-purity or pharma-
ceutical grade and were purchased from Sigma-Aldrich or Panreac.
Quality control was carried out with TLC chromatography (iTLC-SG –
50 mM DTPA solution and other eluents; PET-MiniGita radio-TLC
scanner). Dowex 1, Chelex-100 (Sigma-Aldridge), ZR (Triskem), Chro-
mafix HCO3 (Macherey-Nagel) resins were used.
89ZrCl4 in 5 M HCl
was purchased from Cyclotron Ltd, Obninsk, Russian Federation. In
vivo experiments were carried out in BALB/C mice models with differ-
ent pathologies. Wizard 2480 gamma-counter and G4 microPET
(Sofie) were used for biological evaluation.
Results: It was found that ZR resin allows to obtain 89Zr-oxalate solu-
tion with highest yield and lowest metal impurities content. Chromafix
HCO3 and Chelex-100 resins allow to obtain high purity as well. How-
ever, 89Zr-oxalate solution purified with ZR resin does not meet all the
requirement for the PET radiopharmaceutical under development. Its
virtues and shortcomings will be presented in detail. Using Chelex-100
resin allowed to develop the procedure for production of pH-neutral
isotonic 89Zr-oxalate solution with high purity and specific activity.
Radiochemical yield of the preparation and purification procedure is
≥90%. Radiopharmaceutical radiochemical purity remains ≥95% for at
least 2 weeks. 89Zr complexes with other carboxylic acids were studied
as well. Biological data indicate that 89Zr complexes with carboxylic
acids are promising visualizing agents for infection and inflammationfoci and musculoskeletal injuries. Toxicity tests were carried out as well.
Experimental results will be presented in detail.
Conclusion: Handy procedure of production of 89Zr-oxalate physiolo-
gically acceptable solution was developed. Its potential for PET diag-
nosis was evaluated.
Ethics approval: Animal experiments were carried out according to
European Convention for the Protection of Vertebrate Animals used
for Experimental and Other Scientific Purposes. The work was finan-
cially supported by Ministry of Education and Science of the Russian
Federation – State Contract № 14.N08.11.0162.
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Aim: A SnO2-based generator requires higher HCl eluent concentra-
tions than other commercially available generators. The manufacturer
of the iThemba LABS generator recommends 0.6 M HCl as eluent,
but use of 1 M HCl has been reported. There is only limited pub-
lished data on the characteristics of eluates after elution of a SnO2-
based generator with eluent concentrations lower than 0.6 M HCl.
The aim of this investigation was to compare elution efficiencies,
68Ge breakthrough and metal contaminants of 68Ga eluates using 0.2
to 1 M HCl eluents and to qualify the possible benefits over the risks
of any particular eluent over the recommended 0.6 M HCl.
Methods: 68Ga was eluted from a 1 to 2-month old 1110 MBq SnO2-
based 68Ge/68Ga generator up to thrice daily on weekdays. The gener-
ator was eluted at least 6 times in total with each concentration of HCl
(0.6 M, 0.4 M, 0.2 M, 0.8 M and 1.0 M) with rinses of 10 ml between con-
centrations. Rinses were done using the eluent intended for the subse-
quent elution. A period of at least 5 hours was allowed between
elutions. The generator was eluted with 0.5 ml fractions up to a volume
of 10 ml to construct elution profiles for each eluent. Elution yield was
calculated as percentage of nominal 68Ge activity in the generator.
68Ge breakthrough was determined in each sample. Metal contami-
nants (Zn, Fe, Cu, Ga) in eluates were determined by ICP-OES.
Results Elution yield of the generator increased from 18% with 0.2 M
HCl to 126% with 1.0 M HCl. 68Ge breakthrough increased from
0.004% with 0.2 M HCl to 0.62% with 1.0 M HCl. Fe content was fairly
consistent around 0.32 ppm; Zn increased with increasing acidity;
and Ga content remained fairly constant up to 0.6 M HCl and then
increased consistently. Cu was only detected in 1.0 M HCl eluates.
Conclusion: An increase in the HCl concentration of the eluent resulted
in increasing generator elution yields but also higher 68Ge breakthrough
and Zn content. 68Ge breakthrough could be problematic with regards
to radiation safety and radioactive waste control. In order to comprom-
ise optimal elution yield with minimal 68Ge breakthrough, 0.6 M HCl
should therefore be the eluent of choice for a SnO2-based generator.
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 28 of 38Aim: Radiolabeled peptides have become very important in nuclear
medicine and oncology in recent years mainly because they repre-
sent the molecular basis for in vivo imaging and radiopharmaceutical
therapy with high specificity and affinity for overexpressed receptors
in tumors. The objective was to evaluate the radiolabeling efficiency
of the 131I-peptides, as well as their interaction with overexpressed
receptors on tumor cells related to glioblastoma.
Methods: The EEEEYFELV peptide and its analogue DEDEYFELV both
with affinity for EGFR receptor and the fragment GRGDYV with high
affinity for the integrin receptor were synthesized accordingly to the
Fmoc protocol and purified by preparative HPLC. All the peptides
were radiolabeled with the radioisotope 131I-Na. The radioiodination
was evaluated and optimized using the methodology of Chloramine-
T. Radiochemical yield analyses of 131I-EEEEYFELV and 131I-DEDEY-
FELV peptides were performed by Whatmann 3MM using MeOH 95%
and by thin layer chromatography on silica gel TLC-SG (Al) in ACN
95% for 131I-GRGDYV peptide. The stability studies in vitro were real-
ized at 2, 24, 48 and 72 hours in room temperature and refrigerate
and in human serum at 37°C up to 24 hours. Partition coefficient and
binding to plasma proteins were determinate for all radiopeptides.
The interaction of radiolabeled peptides with tumorigenic cells was
assessed by using culture cells (C6) and brain homogenate of the
glioblastoma animal models (n = 6).
Results: The peptides EEEEYFELV, DEDEYFELV and GRGDYV were effi-
ciently synthesized, radiolabeled and showed radiochemical yield of
90.32% ± 0.30, 94.67% ± 0.27 and 97.95% ± 0.05 (n = 7), respectively.
The stability studies showed that all the peptides were stable within 72
hours when stored in the refrigerator and up to 24 hours in human
serum showing an average of radiochemical purity of 91.65% ± 1.33 (n
= 3) for all peptides. All 131I-peptides have hydrophilic features and
showed a binding percentage to plasma proteins of 59.47% ± 0.74,
57.68% ± 1.29 and 34.92% ± 2.53 (n = 3). Furthermore, the peptides
presented an interaction affinity with the tumorigenic cells of 4.48% ±
0.22; 4.40% ± 0.30 and 1.73% ± 0.38, respectively and a internalization
of approximately 45% for all fragments.
Conclusion: The peptides were efficiently synthesized and the tested
radiolabeling strategies showed successful results. Moreover, all the
peptides demonstrated affinity for the tumor cells evaluated. These
results obtained in this study are consistent to adapt in the clinical
application.
Funding: FAPESP, CAPES and FCMSCSP (FAP).
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Aim: Ubiquicidine (UBI) 29-41 is currently being investigated as a
potential infection imaging agent. All published methods for radi-
olabelling of this tracer to date describe manual processes. The
current manual method for labelling UBI 29-41 with Ga-68 has sev-
eral disadvantages, including unnecessary radiation exposure to
operators, and difficulty to meet GMP requirements. The aim of this
study was to develop an automated synthesis method for the label-
ling of Ga-68 UBI.
Methods: Ga-68 for radiolabelling was freshly eluted from an
iThemba Labs Ge-68/Ga-68 generator, using fractional elution
with 0.6M HCl. NOTA-UBI was provided by BL Biochem (Shanghai,
China). The approach to developing an automated method was
to first duplicate the manual method developed by Ebenhan et
al* using the generator, eluant and consumables available at our
PET Centre. Next, the manual method was adapted to suit a Scin-
tomics protocol, e.g. adapting volumes for the synthesis unit. The
radiolabelling yield and radiochemical purity were determined
after each labelling experiment.
Results Initial manual labelling attempts indicated that the volume
(± 0.55 ml) of sodium acetate required to adjust the pH of thelabelling mixture was too small for use in an automated synthesis
process. It was decided to use a 1.5 M HEPES buffer to adjust the elu-
ate to an acceptable pH. Eluate volumes ranging from 1.0 to 2.0 ml
were used to which 1.2 to 1.6 ml of HEPES buffer was added and the
pH measured in order to find the most suitable combination of elu-
ate volume and buffer volume to render a mixture with a pH be-
tween 3.5 and 4.0. Results indicated that 1.4 ml to 2.0 ml eluate and
1.2 ml HEPES buffer was suitable for use in the development of an
automated synthesis method. Four successful automated labellings
were performed using the HEPES buffer with an average decay-
corrected radio-yield of 88.97% and a radiochemical purity of
99.49%.
Conclusion: An automated synthesis protocol using a Scintomics
GRP Module has been successfully developed and tested. This proto-
col can be utilised for the routine synthesis of Ga-68 UBI under GMP
conditions.
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Aim: The current treatment methods such as chemotherapy have
limited effects on cancer or other cells because of using conventional
cytotoxic drugs. For this reason, using multifunctional nanoparticles
in drug delivery systems become more important.[1,2] Some drug
molecules are encapsulated nanoparticles as drug delivery sys-
tems.[3] Ampicillin is a one of effective antibiotics against Gram-
positive and Gram-negative bacteria. The present study aims to label
ampicillin loaded graphene oxide nanoflake (AMP-GO) with 99mTc
and evaluate of its in vitro binding to S. aureus and E. coli.
Methods: Graphene oxide nanoflakes were prepared according to
Hummers’ method.[4] Ampicillin was loaded onto graphene oxide
nanoflake prepared. AMP-GO was characterized by Fourier Transform
Infrared Spectroscopy (FTIR) and Scanning Electron Microscope (SEM)
techniques, and the amount of loaded ampicillin onto GO was deter-
mined by UV-Vis absorption spectroscopy. AMP and AMP-GO were
labeled with 99mTc using stannous chloride reducing agent. The sta-
bility of 99mTc-AMP and 99mTc-AMP-GO were determined in phos-
phate buffered saline (pH=7.2). The in vitro bacterial binding studies
were performed by using both radiolabeled AMP and AMP-GO to S.
aureus and E. coli.
Results Labeling efficiency of 99mTc-AMP was 92.6±5.94 % while la-
beling efficiency of 99mTc-AMP-GO was found to be 97.66±2.06%.
The stability results of radiolabeled compounds in phosphate buff-
ered saline are summarized in Fig. 1.
In vitro binding results of 99mTc-AMP/99mTc- AMP-GO to S. aureus are
seen in Fig. 2.
In vitro binding results of 99mTc-AMP/99mTc- AMP-GO to E. Coli are
seen in Fig. 3.
Conclusion: AMP and AMP-GO were labeled with 99mTc with high
yield. According to in vitro binding results, the binding efficiency
of99mTc-AMP-GO was higher to S. aureus and E. coli than 99mTc-AMP.
99mTc-AMP-GO could be promising candidate as agent infection nu-
clear imaging. Furthermore, in vivo studies of 99mTc-AMP-GO with in-
fected rats are planned to be done.
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99mTc-AMP-GO at various times after incubation in phosphate
buffered saline at room temperature. Data are presented as mean ±
standard deviation
Fig. 2 (abstract PP31). In vitro binding efficiencies of 99mTc, 99mTc-
AMP, and 99mTc-AMP-GO to S.aureus. Data are presented as mean ±
standard deviation (n = 3) *p < 0.05
Fig. 3 (abstract PP31). In vitro binding efficiencies of 99mTc, 99mTc-
AMP, and 99mTc-AMP-GO to E. coli. Data are presented as mean ±
standard deviation (n = 3) * p < 0.05PP32
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Aim: 18F is the most commonly used radionuclide for PET imaging.
Its half-life of approximately 110 min is suited for same-day imaging
of many compounds that clear quickly from the body to allow
visualization of uptake in the intended target. Recently, 18F-labeling
method using Al−F complex in aqueous solution was devised and of-
fered a straightforward 18F-labeling procedure. The radiolabeling of
various chelates with Al-18F at high temperature (~100-110oC) is well
documented in literature1. But high temperature radiolabeling is un-
suitable for heat sensitive biomolecules. So facile method for radiola-
beling at lower temperature is highly needed. We examine the
efficiency of Al-18F chelation by a variety of available macrocyclic
chelators at low temperature (Fig. 1).
Methods: 18F− aqueous solution was first treated using a Sep-Pak
cartridge equilibrated with 0.4 M KHCO3. The sample was then
loaded, washed with water and eluted with 200-μL fractions. The
radiolabeling was performed by adding 10 μL of the 2 mM Al3+ stock
solution, 10 μL of the chelator stock solution, and ~500 μCi Na18F to
a vial containing 100 μL 0.1 M ammonium acetate buffer (pH 5.5) so-
lution and 100 μL ethanol at different temperature.
Results: It was found that, chelators with TACN backbones bearing
two acetate pendant arms and one benzyl-NCS moiety (NODA-MP-
NCS) resulted quantitative labeling in a temperature as low as 30 °C
within 2 min.
Conclusion: These results represent an important step toward rapid
and efficient radiofluorination of biomolecules at room temperature.
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EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 30 of 38Aim: A key factor for the expansion of positron emission tomography
(PET) is the development of new synthetic routes for the incorpor-
ation of radionuclides. Short half-life isotopes such as carbon-11 (t1/2
= 20.33 min) particularly suffer from a limited number of labeling
strategies. In order to expand the labeling toolbox for carbon-11, a
recently discovered ultrafast cross-coupling methodology[1] was ap-
plied to the labeling of several clinically interesting tracers.
Methods: [11C]MeLi was prepared via lithium-halogen exchange by
trapping [11C]MeI in a solution of n-BuLi. The prepared [11C]MeLi was
further used in a palladium catalyzed cross-coupling reaction with
aryl bromides.
Results Using this procedure, three classes of tracers with applica-
tions in amyloid plaques imaging, breast cancer imaging and VAChT
imaging had been successfully labelled. Radiolabeled products were
obtained in good yields with high radiochemical purity (>99%).
Conclusion: A new labeling methodology was developed and suc-
cessfully applied to the synthesis of clinically interesting radiotracers.
This procedure fulfilled essential requirements for the introduction of
carbon-11, providing the target molecule in high yields and high
radiochemical purity within 30 to 40 minutes from the end of bom-
bardment (EOB).
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Fig. 1 (abstract PP34). Chemical structure of linear and cyclic
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Aim: Apoptosis, a genetically determined process of programmed
cell death, has a crucial role in various processes including normal
cell turnover, tissue homeostasis, and development. Moreover, apop-
tosis occurs in many medical disorders and hence the development
of non-invasive evaluation method is highly demanded. We have re-
ported high potential of the radiolabeled apoptosis-targeting peptide
(ApoPep-1) for apoptosis detection, however in vivo stability of radi-
olabeled peptide was not acceptable to monitor apoptosis for a long
time [1]. In this study, we prepared cyclic ApoPep-1 peptides (Fig. 1)
to compare the stability with original linear ApoPep-1. A targeting
ability of cyclic ApoPep-1 peptide for apoptosis was also investigated
in acute myocardial infarct model.
Methods: Linear and cyclic ApoPep-1 peptides were synthesized by
a standard Fmoc method and an extra tyrosine residue was added
for labeling with radio-iodine. The in vitro stability of the radiolabeled
peptides was determined in FBS, and the in vivo stability test wasperformed by blood analysis. To evaluate its targeting efficacy of
radiolabeled cyclic ApoPep-1, autoradiography was done in
isoprenaline-induced acute myocardial infarct model.
Results: All linear and cyclic peptide was synthesized and radiola-
beled with I-131 in good yield. The radiolabeled peptides showed
significant difference in vitro stability at 24 h (linear ApoPep-1: 72%,
cyclic ApoPep-1: ~95%). In vivo stability of radiolabeled linear and
cyclic peptides at 1 h showed drastic difference between linear and
cyclic peptides (linear ApoPep-1: 60%, cyclic ApoPep-1: 87%). Apop-
tosis induced in heart by myocardial infarction was clearly detected
by the radiolabeled cyclic ApoPep-1.
Conclusion: Effect of structural forms on the stability of linear and
cyclic ApoPep-1 was demonstrated.
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Aim: Arginase catalyzes the hydrolysis of arginine to ornithine and
urea, being the final enzyme of the urea cycle, which is a ubiquitous
pathway to excrete toxic ammonia from organisms. Lately, it also has
emerged as a key regulator of nitric oxide by competing with NO
synthase for the same substrate. Therefore, arginase overexpression
has been associated with a series of pathogenic processes that can
go from cardiovascular, immune-mediated or inflammatory condi-
tions to tumor cell metabolism.(1) Several research groups have been
involved in the development of small-molecule arginase inhibitors
reaching to data holding great promise. However, only recently the
drug development industry is attaining clinical trials.(2) Since the as-
sociation to PET labeling techniques has great relevance not only for
the evaluation and characterization of some of this molecules, but
also to increase the library of radiotracers available, our goal with this
work was to synthesize and evaluate the [18F]fluorinated equivalent
of a late-generation arginase inhibitor.(3)
Methods: An arylboronic acid pinacol ester-derived precursor was
synthesized in view of a Cu-mediated nucleophilic [18F]fluorination.
Radiochemical yield for the conversion of the intermediate species
was assessed by TLC-SG and/or radioHPLC. Deprotection of the
amino acid moiety was achieved by hydrolysis and the final radio-
tracer was purified by semi-preparative HPLC and obtained, after re-
formulation, as a physiological and injectable solution. Further
stability and distribution-coefficient studies were performed.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 31 of 38Results: In summary, radiochemical yield of the conversion of the
arylboronic ester-derived precursor reached ~80% when using 60 to
15 μmol (lower amounts brought significant losses in yield). Final
[18F]fluorinated compound was obtained with radiochemical purity
≥95% in an overall yield of 11% (d.c., non-automated synthesis). The
radiotracer showed stability in solution up to 4 h and an experimen-
tal log D of -0.67±0.05.
Conclusion: The [18F]fluorinated arginase inhibitor was efficiently
labeled with fluorine-18 in good yield. Preliminary in vitro studies
using R22v1 cell lines, which express Arg2, revealed a cellular
uptake of the radiotracer susceptible of being blocked after treat-
ment with arginase inhibitors. Further studies are currently being
performed in different cell lines which either overexpress Arg1 or
Arg2 to evaluate the potential of the developed radiotracer towards
arginase mapping.
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Aim: The improved signal to noise ratio and simplified kinetic model-
ing1 has presented 6-L-[18F]fluoro-m-tyrosine (6-[18F]FMT) as a valu-
able alternative to 6-L-[18F]FDOPA, a well-known PET tracer for the
visualization of dopaminergic neurons and neuroendocrine tumors.
However, clinical applications of 6-[18F]FMT have been limited by the
paucity of practical production methods. Cu-mediated radiofluorina-
tion of pinacol arylboronates (aryl-Bpin)2 enables the preparation of
radiolabeled aromatics regardless of their electronic properties using
nucleophilic [18F]fluoride. We have applied our procedure for
alcohol-enhanced Cu-mediated 18F-fluorination3,4 to prepare 6-
[18F]FMT using an easily accessible Bpin-substituted Ni-BPB-AA com-
plex as a dual-protecting framework.
Methods: Radiolabeling precursor was synthesized by alkylation of
(S)-Ni-BPB-Gly with 6-Bpin-3-MOMO-benzyl bromide prepared via
radical bromination of the corresponding toluene. Aqueous
[18F]fluoride was loaded onto a QMA vac 1cc cartidge from the male
side, the cartridge was rinsed by 1.5 mL of i-PrOH and dried with he-
lium. 18F was eluted in the opposite direction using a solution of 12.5
μmol of TBAOTf in 0.6 mL i-PrOH directly to a solution of 7.5 μmol of
Cu(OTf)2Py4, 15 μmol of I in 0.3 mL DMA. The mixture was heated in
a sealed vial at 110°C for 20 min under air. 1.0 mL of 12 M HCl was
added and the reaction mixture was heated (100oC, 10 min) furnish-
ing the crude 6-[18F]FMT which was purified by HPLC using 2% EtOH
in 0.1% AcOH as eluent. The product fraction was additionally puri-
fied using a SepPak Alumina N light cartridge.
Results: Precursor for radiolabeling was prepared in 45% yield over
two steps. The developed radiolabeling protocol provides a high 18F-elution efficiency of 86-94% and 18F-incorporation rate of > 90% (de-
termined by TLC). Deprotection afforded the desired tracer in a RCC
of 60%. 6-[18F]FMT was produced in a RCY of 32%, RCP of 97% and
enantiomeric purity > 99% within 70 min (EOB).
Conclusion: Boronated Ni-BPB-AA complexes are valuable sub-
strates for the preparation of labeled aromatic amino acids using
alcohol-enhanced Cu-mediated radiofluorination. The novel proto-
col enables the simple and efficient production of 6-[18F]FMT with-
out time consuming solvent evaporation and intermediate SPE
purification steps.
Research support: RFBR grant № 16-54-12062\16 and DFG grant ZL
65/1-1.
References
1. C. Li et al., Synapse, 2014, 68(8), 325-331.
2. M. Tredwell et al., Angew. Chem. Int. Ed., 2014, 53(30), 7751-7755.
3. J. Zischler et al., Chem. Eur. J., 2017, 23, 3251-3256.
4. B. Zlatopolskiy et al., J. Med. Chem., 2017, doi: 10.1021/acs.jmedchem.7b01245e.
PP37
Physico-chemical assessment of labeled freeze dried kits of
trastuzumab-immunoconjugates significant for breast cancer
therapy
M. Sterjova1,2, P. Džodić2, P. Makreski3, T. Ruskovska1, E. Janevik-
Ivanovska1
1University ‘Goce Delčev’, Faculty of Medical Sciences, str. “Krste
Misirkov” No. 10-А, 2000 Štip, Republic of Macedonia; 2University of Niš,
Faculty of Medicine, Department of Pharmacy, str. dr Zoran Đindić 81,
18000 Niš, Serbia; 3Institute of Chemistry, Faculty of Natural Sciences and
Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, Republic
of Macedonia
Correspondence: M. Sterjova
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):PP37
Aim: Monoclonal antibodies appears as an important therapeutic
agents for cancer treatment and have shown high complexity in the
manner of action and their biological properties. Due to the signifi-
cant potency in various malignancies and easy detection of radio-
activity with outside scintigraphy, radioimmunoconjugates have
become a part of many clinical trials. The antibody manipulation and
exposure to stress conditions during the processes of conjugation,
lyophilization and labeling, can cause disruption of the native struc-
ture of the protein. The most appropriate technique for protein in-
tegrity and purity examinations is reducing sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Attenuated total
reflectance-infrared (ATR-IR) and Raman spectroscopy as powerful,
non-destructive and easy-to-use techniques provide valuable mo-
lecular structure information and are convenient for verification of
changes in the secondary structure. The successful experience in
formulation of ready-to-use kits of rituximab-immunoconjugates, in-
spire us to use another attractive monoclonal antibody for therapy
of HER2 positive breast cancer. The same protocols, with minor ad-
justments, were implemented for structural characterization of la-
beled and non-labeled lyophilized trastuzumab-immunoconjugates
formulations.
Methods: The purified trastuzumab from Herceptin® was conjugated
with bifunctional chelators (BFCAs), p-SCN-Bn-DTPA, p-SCN-Bn-DOTA,
p-SCN-Bn-1B4M-DTPA in ratio of 1:20 and lyophilized to solid state.
The freeze dried conjugates and cold labeled samples with LuCl3 and
YCl3 were used for further examinations and physico-chemical
characterization by applying of SDS-PAGE, ATR-IR and Raman
spectroscopy.
Results Under reducing conditions migration of the trastuzumab pro-
vided separation of two bands of fragments with molecular weight
of 25 kDa for light chain and 50 kDa for heavy chain, proven with
the Wide Range, Molecular Weight marker. The same intensity of the
fragments of lyophilized and labeled conjugates with the fragments
of pure trastuzumab was indicated that there is no degradation of
the antibody. ATR-IR and Raman spectra also have indicated that all
samples have retained native structure expressed in terms of assign-
ment of the amide bands (amide I, II and III bands), characteristic for
Table 1 (abstract PP38). Radiochemical yield of [18F]MICA-304
Reaction time
Amount of precursor 10 min 20 min
4 mg 81% 55%* 76%
8 mg 78%
Click reaction mixture: 2.2 eq. CuSO4; 8.2 eq. sodium ascorbate; 1.1 eq.
bathophenanthroline disulfonate. *Using half of the amount of the click
reaction mixture
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 32 of 38IgG1 structures principally composed of β-sheets. Characteristic
amide I band at ~1670 cm-1 and amide III band (1230-1300 cm-1)
were detected in Raman spectra. IR spectra also contain the amide I
(1700-1600 cm-1), amide II (1480-1575 cm-1) and amide III bands
(1255-1244 cm-1) specific for secondary structure of the proteins.
Conclusion: The promising results from electrophoresis and vibra-
tional spectroscopy are good basis for further radiolabeling of immu-
noconjugates with 177Lu and 90Y for treatment and imaging of HER2
positive lesions.
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Aim: Apoptosis represents the most abundant type of regulated cell
death, and plays a key role in disease treatment. Many therapies tar-
geted at promoting tumor apoptosis are currently in use for the
treatment of cancer patients. Therefore, assessment of response to
anticancer therapies can be achieved by readout of apoptosis in tu-
mors. Non-invasive molecular imaging of therapy-induced apoptosis
can be achieved by using positron emission tomography (PET) radio-
tracers that specifically target hallmarks of the apoptosis process
such as the activation of caspase-3. We therefore aimed to develop
18F-labeled activity-based probes (ABPs) to selectively monitor
caspase-3 activity by PET imaging.
Methods: Our concept is based on turning selective and potent
peptide-based inhibitors into ABPs. For this Hyx-(Ahx)2-DW3-KE was
developed bearing an optimized peptide sequence (DW3) for the
selective detection and inhibition of caspase-3 in cells, and an elec-
trophilic center (warhead, KE) for covalent binding to the enzyme
active site. Radiolabeling of Hyx-Ahx2-DW3-KE with
18F was per-
formed using the copper-catalyzed azide-alkyne cycloaddition reac-
tion. The binding efficiency of the 18F-labeled ABP, [18F]MICA-304,
to human caspases will be evaluated using SDS-PAGE analysis. Ra-
diotracer metabolic stability will be evaluated in vitro. The in vitro
affinity and selectivity of the non-radioactive ABP will be profiled
against a panel of human caspases.Results “Click radiolabeling” was used to obtain [18F]MICA-304 from
[18F]fluoroethylazide in a radiochemical yield ranging from 55 to 81%
(based on HPLC analysis of the crude product, Table 1).
Conclusion: Optimal radiochemical reaction conditions were defined
to be 10 minutes at room temperature. In vitro and preliminary
in vivo data will be reported. [18F]MICA-304 is a candidate ABP for se-
lective detection of caspase-3 activity, and will be modified for
in vivo PET imaging in mouse models of apoptosis.PP39
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Aim: P Current limitations with existing 68Ge/68Ga generators have
led to a recent interest in the direct cyclotron production of 68Ga by
the 68Zn(p,n)68Ga reaction. To this end, we recently presented a new
automated two-column scheme to isolate [68Ga]GaCl3 following pro-
ton irradiation of enriched 68Zn (Nair M. et al [2017], Eur J Nucl Med
Mol Imaging 44: S119–S956). Optimization of this process was fo-
cused not only on maximizing 68Ga recovery, but also on meeting
specifications (e.g. <10 μg/GBq iron and zinc) of the European
Pharmacopoeia (EUP) generator-based [68Ga]GaCl3 monograph. A de-
tailed assessment of other chemical impurities was, however, consid-
ered warranted and forms the basis for this study.
Methods: A selection of sample retains (Zn Lot A: Feb-May, 2017; Zn
Lot B: Aug-Oct, 2017) from experiments performed on a GE PETtrace
68Ga liquid target/FASTlab system were submitted for ICP-MS analysis
(ALS Scandinavia). Samples were either irradiated (but not chemically
processed), or, samples were chemically isolated as ~2.8 mL
[68Ga]GaCl3. For the analysis of Zn, it is critical to note that the m/z =
68 channel was used, along with appropriate scaling to account for
the non-natural abundance of 68Zn. Natural isotopic composition was
assumed for the analysis of ~70 additional elements. It is also im-
perative to note that samples were taken during the development
phase, and may include sub-optimal chemistry processing and in
some cases, ACS grade reagents. This wide range of samples was
nevertheless included to provide insight to the process variability
and robustness.
Results: Data is tabulated below for both Zn and Fe (in μg/mL), as
well as 8 other impurities (in ng/mL). These additional impurities
were identified to be of interest due to known target contact mate-
rials, noted chemical variation between 68Zn lots, potential concern
for DOTA chelation competition with Ga, etc. Data is reported as
the average and standard deviation for the noted number of sam-
ples. It should also be noted that current levels of 68Zn are routinely
below 1 μg/mL, with further reduction demonstrated with add-
itional column rinsing.
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 33 of 38Conclusion: While the levels of Zn and Fe have been optimized to
meet EUP specifications, a detailed assessment of additional chemical
impurities has revealed that the starting contribution (i.e. post irradi-
ation, but pre-chemical processing) for impurities of potential con-
cern is generally quite low – e.g. at most ~1-2 μg/mL, with post-
purification reducing such impurities to the single-to-low-tens of ng/
mL range. This analysis supports the current applicability of
cyclotron-based production of 68Ga and anticipated robustness as
novel ligands and chelators are developed and introduced.Table 1 (abstract PP39). See text for description















Zn 48583 ± 365 2.8 ± 3.4 55183 ± 1066 0.73 ± 0.48
Fe 1.13 ± 0.12 0.24 ± 0.12 0.98 ± 0.13 0.18 ± 0.12
ng/
mL
Ni 1318 ± 118 18 ± 11 214 ± 35 19 ± 13
Cu 1615 ± 121 8.8 ± 6.1 1147 ± 152 4.7 ± 1.2
Co 85 ± 74 0.28 ± 0.19 3.8 ± 1.1 0.150 ± 0.055
Cr 37 ± 20 22 ± 24 46.0 ± 8.7 10.2 ± 5.2
Y 0.60 ± 0.10 0.38 ± 0.14 0.380 ± 0.045 0.283 ± 0.075
Nb 21 ± 35 0.046 ± 0.014 18 ± 35 0.14 ± 0.11
Sn 9 ± 12 1.19 ± 0.61 335 ± 192 21 ± 29
Cd 4.6 ± 3.5 0.19 ± 0.15 1940 ± 87 0.22 ± 0.12PP40
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Aim: Automated PET-tracer syntheses are essential to enable produc-
tions in a quick and robust way for (pre)clinical studies [1]. In this
study, azide-alkyne Huisgens cycloadditions of 18F-labelled azide
building blocks (azide-BB) with acetylene-ligands are used for the de-
velopment of 18F-labelled PET-tracers for diagnosis of prostate cancer
by targeting prostate specific membrane antigen (PSMA). Due to
purification issues of the azide-BB’s, the radiochemical yields (RCY) of
these click reactions (CR) were low. Automated microfluidic systems,
such as the FlowSafe, could improve these syntheses. The advan-
tages of 18F-labelling in flow-mode comprises the more dynamic mix-
ing and heating of the azide-BB precursor and [18F]fluoride, leading
to higher yields and less side-products due to shorter reaction times
and higher surface-to-volume ratios [2]. Therefore, we elaborated an
automated synthesis route for 18F-labelled PSMA-tracers (18F-PSMA-
tracer) in the FlowSafe, using a 2-steps procedure in which an azide-
BB is 18F-fluorinated in a microreactor, purified by Solid Phase Extrac-
tion (SPE) and subsequently underwent an in-batch CR.
Methods: Azeotropically dried [18F]fluoride and the precursor for
azide-BB are redissolved in acetonitrile, transferred through a 100μL
glass microreactor with a flowrate of 80μL/min at 110oC, giving an
effective reaction time of 75s. A back-pressure regulator adjusted the
pressure inside the microreactor to 5.0bar and increased the boilingpoint of acetonitrile. The intermediate is dissolved in an excess of
water and transferred to an Oasis HLB Plus-cartridge. It is eluted with
ethanol and collected in a vial containing click reagents and PSMA-
targeting acetylene-ligand. CR is performed in a batch-reactor in at
least 50% water, heated to 80oC for 20min and subsequently purified
by HPLC.
Results: Manually 18F-fluorination of the azide-BB gave a RCY of
21%. Performing the 18F-fluorination of the azide-BB in the FlowSafe
reduced radiochemical impurities from 2.7% “by hand” to 0.3%. With
the purer intermediate, the SPE purification-method was improved,
providing the azide-BB in >99% radiochemical purity and a RCY of
39%. With this purified azide-BB, a CR was performed yielding a 18F-
PSMA-tracer with an isolated RCY of 5%.
Conclusion: Automation of 18F- PSMA-tracer synthesis was success-
ful. Less side-products were formed during the 18F-fluorination of
the azide-BB in the microreactor, which simplified the purification
and led to an improved RCY. With the purified 18F-labelled azide-
BB, a novel 18F-PSMA-tracer was successfully coupled in-batch by
CR in the FlowSafe.
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Aim: [18F]-FEPPA, a radiotracer specific for TSPO (18 kDa translocator
protein), is used in PET imaging (Positron Emission Tomography) as a
biomarker of cerebral inflammation. Literature [1] describes the use
of methanol and formic acid in the mobile phase during semi-
preparative HPLC purification. Aims of this work were to implement a
radiosynthesis of [18F]-FEPPA using HPLC purification more suitable
for in vivo use and to optimize the analytical HPLC control method.
Methods: [18F]-FEPPA is synthesized by nucleophilic substitution (90°
C, 10 min) from a tosylateprecursor (N-(2-((N-(4-phenoxypyridin-3-
yl)acetamido)methyl)phenoxy)ethyl-4-methybenzene sulfonate)
followed by semi-preparative HPLC purification (mobile phase: etha-
nol/water for injection 70/30 v/v + 0.1% phosphoric acid, FEPPA re-
tention time = 13 min) on an AllInOne® radiosynthesis automate.
Chemical, radiochemical purity (RCP) and specific activity (SA) are de-
termined by analytical HPLC (Kinetex® C18 column (50 × 2.1 mm, 2.6
μm), injection volume: 5 μL, mobile phase: H2O/CH3CN 75/25 v/v at
0.6 mL/min).
Results [18F]-FEPPA radiosynthesis were carried out in 49 min with
a non-decay corrected yield enhanced from 19 to 29%. The RCP ob-
tained was greater than 99%. The mean SA was 198 GBq/μmol. The
new analytical HPLC method allowed a quality control in 7 min.
Solvent consumption and injection volume have been reduced by a
factor 12 and 4 respectively. This new control method induced a 3
fold decrease of the received dose by the operator in terms of ion-
izing radiation.
Conclusion: [18F]-FEPPA radiosynthesis was implemented with high
yields. The final product was obtained in a new formulation more
suitable for in vivo studies. Operator exposure was improved with
the new faster control method.
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Aim: Bispecific antibody (BsAb) can be obtained both chemically and
bio-engineered for imaging and therapeutic applications in nuclear
medicine(1-2). If all the described tools are satisfactory for imaging,
the in vivo instability of engineered BsAb or the poor yield of BsAb
obtained by chemically limit their use in radioimmunotherapy (RIT).
We propose in this study a new way to generate BsAb using click
chemistry tools.
Methods: The 9E7.4 IgG2a (anti-CD138) antibody was chosen for
proof of concept. 9E7.4 was first modified with 100-500 equivalents
of N-ethylmaleimide (NEM) to saturate the accessible thiol groups on
the antibody surface. The modified antibody was then purified by
gel filtration chromatography. The modified (9E7.4-NEM) and un-
modified antibodies (9E7.4) were cleaved with optimized pepsin
quantities under acidic conditions to give (Fab’)2 fragments. The
(Fab’)2 obtained were then reduced with 2-mercaptoethylamine to
generate the Fab’ fragments. These fragments were separated into
two fractions and functionalized with dibenzocyclooctyne (DBCO) for
the first fraction and with azide (N3) for the second one. Both func-
tionalized Fab’ were then mixed 1 hour or1 month after production
to obtain BsAb in order to validate their stability and their reactivity
over time. 9E7.4 IgG, 9E7.4-NEM IgG, 9E7.4 (Fab’)2, 9E7.4-NEM (Fab’2)
and BsAb were monitored by UPLC and electrophoresis for chemical
purity, and after 125I radiolabeling for antigen recognition.
Results Immunoreactivity was verified after each step described
above. For BsAb, the antibody tested had the best final yield (20%)
and the lowest aggregates percentage correscponding to a pre-
saturation with 100 eq NEM and addition of 20 eq of DBCO and 20
eq of N3 for bioorthogonal chemistry.
The results are summarized in the following Table 1.
Conclusion: We demonstrated that click chemistry can be used to
generate BsAb and that cysteine pre-saturation by NEM limits the
formation of aggregates during the antibody functionalization. The
yields obtained are comparable to those described in the literature
with phenylenebismaleimide(3). The immunoreactivity decrease is
probably due to the large spacing between the Fab’ fragments pro-
vided by the PEG chains. This problem can be solved by the use of
new click modifiers presenting a minimal distance between the frag-
ment and the click function.
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Aim: Radiopharmaceutical preparations for human purpose may con-
tain residual solvents. Headspace Gas Chromatography (HS-GC) re-
mains the standard method for the analysis of volatile solvents,
according to the European Pharmacopeia. Dimethylsulfoxide (DMSO),
dimethylformamide (DMF) and dimethylacetamide (DMA) are less
volatile solvents that are widely used in carbon-11 and fluorine-18 la-
beling. However, in that case, HS-GC quantification takes too much
time for the release of short half-lives radiopharmaceuticals. There-
fore, we developed a fast and robust Ultra High Pressure Liquid Chro-
matography (UHPLC) method for the simultaneous quantification of
those 3 solvents.
Methods: Analyses were carried out on an UHPLC (Waters) using a
BEH C18 column (Waters). Validation was performed within the re-
quirements of ICH validation guidelines (Q2A, Q2B and Q3C) and
based on Good Laboratory Practices (GLP). It consisted in the evalu-
ation of linearity, limit of quantification (LOQ), limit of detection
(LOD), selectivity, specificity, carry-over, accuracy, precision and
matrix effect.
Results The raw data were collected on six different days with a
minimum of five days of exploitable data for each solvent. Separation
of the three solvents can be achieved within 4 minutes with high res-
olutions. Solvents in samples can be quantified with good inter or
intraday accuracy and precision. LOQ is far below the permitted daily
exposure of each solvent. Selectivity and specifity were satisfactory.
No matrix effect was observed.
Conclusion: This fast UHPLC method is routinely used for the quality
control of radiopharmaceuticals produced in our facilities. Moreover,
stability of stock solutions and frozen quality controls is achieved for
at least 10 months. The use of a 98% aqueous mobile phase reduces
the risk of coelution of radiolabeled compounds which makes this
method suitable with most of them.
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Aim: Somatostatin receptor scintigraphy reveals various types of neu-
roendocrine tumors. The radiotracer historically used is Indium-111
pentetreotide (111In-DTPA-Phe-Octreotide) = Octreoscan®. It is an
analog of somatostatin’s specific membrane receptors labeled with
Indium111. A new derivative of octreotide coupled to Technetium
99m (99mTc-HYNIC-[D-Phe,Tyr-octreotide) = Tektrotyd® is marketed. In
this study, we propose to compare between these two products ac-
cording to our experience.
Methods: This comparative study focused on several criteria: method
of preparation and administration of the product, dosimetry, patient
exam preparation, image acquisition and quality. For this, we relied
on the summary of products characteristics and on the examinations
made at the department.
Results Both products require extemporaneous labeling; Tektrotyd®
nevertheless has some preparation steps in addition to Octreoscan®.
The preparations quality control is carried out for both of them by
the same method (Thin Layer Chromatography) which is convenient
for the hospital routine. The dosage varies from one product to an-
other. Therefore, for an adult, the effective dose received for the
maximum dose of 220 MBq of 111In-pentreotide is 12 mSv while 740
MBq of 99mTc-Octreotide gives an effective dose of 3.7mSv. Image
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 35 of 38acquisition is done the day of the injection for Tektrotyd® (after 4
hours) unlike Octreoscan®, where the acquisition is done after 24
hours. Patient exam preparation is done the same way for both prod-
ucts. Our physicians noticed that scintigraphy performed with Tektro-
tyd® showed a better image quality making it easier to interpret.
Conclusion: Technetium 99m is a gamma emitter (141Kev) with short
half-life (6 hours), while Indium 111 is a 94% gamma emitter
(247Kev) with a longer half-life (2.8 days). From a dosimetric point of
view, Indium 111 is much more irradiant. Thus Tektrotyd® is more
convenient to use either for patients or for the staff. Some studies
demonstrated that both products are equally effective despite all
these differences. In our department, doctors reported a better
image quality with Tektrotyd®. The fact that Tektrotyd® is presented
in the form of cold kit with Technetium 99m labeling, with less radia-
tions and better images’ quality than Indium 111, makes us chose it
for scintigraphy of neuroendocrine tumors in our department.
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Aim: 68Ga-edotreotide, PET-agent for somatostatin receptor imaging
in GEP-NET, has recently obtained a marketing authorization as a ra-
diopharmaceutical kit (SomaKit TOC®). We wanted to compare the
performance, ease of realization, radiation protection parameters of
automated labeling of DOTANOC as compared to the labeling of
DOTATOC (using SomaKit TOC) with Ga-68.
Methods: Automated radiolabeling of DOTANOC was performed on
the ModularLab PharmTracer® module (Eckert & Ziegler) with C4-
Ga68-PP cassette. Process is fully automatized and includes generator
elution, cation exchange post-processing, heating, purification on
C18 cartridge and dilution with sterilizing filtration. Manual prepar-
ation of SomaKit was performed according recommendations and
with equipment supplied by AAA. The generator is eluted with a syr-
inge pump directly into the SomaKit vial. Buffer is then added by
hand before transferring the vial to a heating block with a forceps.
Radiochemical purity (RCP) was evaluated with reverse HPLC for
DOTANOC and ITLC for SomaKit. Overall yields, including elution
yield and synthesis yield, were calculated corrected for decay in
order to compare the labeling performance. Hand radiation exposure
was evaluated using APVL-ED3 detector with two probes fixed on
the first phalanx of each middle finger.
Results Overall yields were respectively 57.0 +/- 11.3 % (n = 157) and
64.8 +/- 5.6 % (n = 35) respectively for DOTANOC and SomaKit. RCP
was always > 98 % for DOTANOC and 96.9 +/- 6.9 % for Somakit in-
clude 5 (15 %) non-compliant RCP. To note that 30 to 35 min are re-
quired between generator elution and batch release for both
process, but preparative step lasts at least 30 min for DOTANOC ver-
sus less than 10 min for Somakit. The radiation exposure measure-
ments (extrapolated for a generator at calibration) gave 70 and 132
μSv for the middle finger (left and right hand) and 179 and 152 μSv
respectively for DOTANOC and SomaKit.
Conclusion: Somakit radiopharmaceutical kit not only allowed to turn
the preparation of 68Ga-DOTATOC into a straightforward routine
process, but it also led to an increase in the overall synthesis yield com-
pared to automated DOTANOC radiolabeling. However, the lack of puri-
fication step in Somakit radiolabeling process prevents its injection to
patient in case of incomplete complexation of Ga-68. Also, process in-
cluding purification provides PRC consistently higher for DOTANOC vs.
Somakit. Shifting from an automated to a manual process in routine
also raises the question of radiation safety. This last encourageautomation of Somakit labeling which should also improve the repro-
ducibility and allow moving towards full GMP. This work is in progress.
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Aim: The value of 68Ga-PSMA-directed PET imaging as a diagnostic
procedure for recurrent prostate cancer is assessed and more particu-
larly in early biochemical relapse. Synthesis of 68Ga-PSMA-11 is rela-
tively straightforward due to HBED-CC chelation allowing significant
synthetic yield even at room temperature. Automation of 68Ga-PSMA-
11 synthesis can nevertheless be optimized to increase overall radio-
chemical yield i.e. increase of the available activity to inject more
patients by synthesis during the shelf life of gallium-68 generator.
Methods: PSMA-11 was purchased from IASON and gallium-68 chlor-
ide was obtained by elution of GalliaPharm® generator. Current prep-
aration process has been developed on the ModularLab Standard®
(Eckert&Zielger AG, Berlin) tubing synthesizer in a procedure similar
to that described by Ceci et al. Briefly, the process includes an
acetone-free cation exchange post-processing purification (Mueller
et al.), 95°C heating for 5 min in acetate buffer (2 M, pH 4.5) and puri-
fication on disposable Sep-Pak C18 Plus® cartridge (Waters SAS
France) by elution with 2 mL ethanol/water (1:1). The resulting prod-
uct is sterilized by filtration and diluted in physiological saline. Then,
the process was transferred on the ModularLab PharmTracer® (Eck-
ert&Ziegler AG) cassette-based synthesizer with the C4-Ga68-PSMA
cassette and the same steps and reagents as above. Radiochemical
purity was evaluated by reversed-phase HPLC.
Results Up to now, 62 syntheses were performed on the tubing
synthesizer. Mean observed radiochemical yields (RCY) was 86.1 +/-
4.6 % and mean radiochemical purity (RCP) was 99.0 +/- 0.9 %.
Among 10 % of the initial activity is retained on the C18 cartridge.
With this process, synthesis is completed in 14 min. Validation of the
GMP-cassette synthesis is ongoing. First results were 96.8 % RCY and
99.2 % RCP in 17 min process.
Conclusion: Optimization of the process was motivated by safety im-
provement by using GMP cassettes. Transfer from tubing to cassette
module lead also to an increase in RCY. This is explained by the op-
portunity of using a Sep-Pak C18 Light® cartridge with a lower re-
sidual 68Ga-PSMA-11 retention. In spite of the intrinsic longer time
process, the final product activity is increased and should allow to in-
ject more patient per batch.
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Aim: Prostate cancer is one of the most common cancers among
men. Prostate specific membrane antigen (PSMA) has proven to be a
useful diagnostic and therapeutic agent in radiotherapy. PSMA-617 is
currently one of the most interesting molecules that binds specific-
ally to the PSMA-receptor. 177Lu and 161Tb are beta emitting radionu-
clides with similar radiochemical properties. In addition, Tb-161 emits
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 36 of 38a high number of low energetic conversion- and auger-electrons.
Therefore, Tb-161 could be a promising radionuclide for treatment of
small tumors and metastases.
Methods: PSMA-617 was purchased from ABX, Germany, and used
without further modifications. The PSMA-617 was radiolabeled with
177Lu (ITG, Germany) and 161Tb (IFE, Norway). Cell toxicity studies
with 177Lu-PSMA-617 and 161Tb-PSMA-617 were conducted on the
cell line LVCaP (ATCC, USA).
Results In this study, PSMA-617 was labeled with Lu-177 and Tb-161
using different reaction conditions to optimize radiochemical yield and
purity. The formed complexes 177Lu-PSMA-617 and 161Tb-PSMA-617
were compared with regard to specific activity, stability and shelf-life.
Conclusion: 177Lu-PSMA-617 and 161Tb-PSMA-617 complexes have
been obtained in high radiochemical yield and purity. In the next
step, we will use an AR-positive hormone responsive prostate cancer
cell line to investigate the therapeutic efficacy of 177Lu-PSMA-617
and 161Tb-PSMA-617 in vitro.
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Aim: Breast cancer is the most common cancer in women and
causes over 500 000 deaths worldwide every year. Overexpression of
HER2 receptor tyrosine kinase occurs in 30 % of metastatic breast
cancers and correlates with poor prognosis. Trastuzumab (Herceptin®,
Roche, United Kingdom) is a recombinant humanized anti-HER2
monoclonal antibody used for treatment of HER2-positive breast can-
cer. Studies have shown that anti-HER2 radioimmunotherapy (RIT)
with 177Lu-labelled trastuzumab is effective in treatment of breast
cancer in vitro. 161Tb exhibits similar radiochemical properties to
177Lu, but also yields a significant number of short-range Auger/con-
version electrons (≤50 keV). In this study, we want to label and com-
pare the therapeutic efficacy of 177Lu-DOTA-trastuzumab and 161Tb-
DOTA-trastuzumab on the HER2-overexpressing cell line SKBR3.
Methods: Trastuzumab was conjugated with p-SCN-Bz-DOTA (Macro-
cyclics, USA) to give the DOTA-trastuzumab conjugate, which was
radiolabelled with 177Lu (ITG, Germany) and 161Tb (IFE, Norway)
under identical reaction conditions. Immunoreactivity studies with
177Lu-DOTA-trastuzumab and 161Tb-DOTA-trastuzumab on the SKBR3
cell line (ATCC, USA) are ongoing.
Results The average number of p-SCN-Bz-DOTA molecules per anti-
body was determined radiochemically to 5.4 ± 1.1. Radiochemical
yield and purity >98 % was achieved for both 177Lu and 161Tb. Qual-
ity control parameters like pH, appearance, radiochemical purity and
in vitro stability were studied. The radiolabeled preparations were
stable up to 120 h within the tested range of specific activities.
Conclusion: This study indicates that the used conjugation and
radiolabeling procedures give preparations of high stability and
high radiochemical purity. Further evaluation of the efficacy of
161Tb-DOTA-trastuzumab and 177Lu-DOTA-trastuzumab in vivo should
be pursued.
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Aim: The aim of this overview was to evaluate the regulations in
Republic of Macedonia dealing with radiopharmaceuticals withemphasis on Marketing authorisation, keeping in mind that the way
how radiopharmaceuticals is developed and introduced to the users
are completely different from what was typical for conventional
pharmaceutical products.
Specific issues: The quality of the radiopharmaceuticals is defined in
the applicable pharmacopeia monographs of individual radiopharma-
ceuticals. Regarding the processes of registration of radiopharmaceu-
ticals and production of radiopharmaceuticals according to Good
Manufacturing Practises, similar uniformity is not present in all coun-
tries. The Good Radiopharmaceutcial Practice Code was defined to
comprise the application of the GMP guidelines for Pharmaceuticals
with the relevant guidelines for radiation protection during produc-
tion, distribution and hospital handling of radiopharmaceuticals to
ensure the safety and efficacy of the product administered to the pa-
tient. Over the years the need for regulation of the radiopharmaceu-
ticals became necessary. The discussions lead to the realisation that
radiopharmaceuticals could not be considered as something extraor-
dinary, and that the same quality standards would have to apply for
these products as for conventional Pharmaceuticals. The first formal
systems for obtaining market authorisation for radiopharmaceuticals
were established in the USA, United Kingdom and Denmark. It was
obvious that the requirements 653 used for non-radioactive drugs
could not be applied directly to the radiopharmaceuticals. Most
countries have established national registration procedures to obtain
official market authorisation for a radiopharmaceutical. In Republic of
Macedonia radiopharmaceuticals are include under the general legis-
lation for medicinal products. Republic of Macedonia is a small coun-
try and use of radiopharmaceuticals is small. Therefore the interest in
registering these products is small.
Status of radiopharmaceutical regulations in Republic of Macedonia
1) Law on Medicines and Medical Devices (Official gazette No.
106/07,88/2010, 36/11, 53/11, 136/11, 11/12, 147/13, 27/14, 43/
14, 88/15) in which radiopharmaceuticals are regulated
2) Rulebook on the contents of the application, the documentation
and detailed requirements in respect of the premises, equipment
and staff for granting authorisation for production of medicinal
products (Official gazette No. 106/07,88/2010, 36/11, 53/11,
136/11, 11/12, 147/13, 27/14, 43/14, 88/15)
3) Rulebook on Good Manufacturing Practices (fully in a
compliance with EudraLex Volume 4 Good Manufacturing
Practices Annex 1 for Manufacture of Sterile Medicinal
Products 01/fully 03/2009, Annex 3 for Manufacture of
Radiopharmaceuticals, Annex 11 for Computerized Systems and
Annex 15 for Qualification and validation.
4) Law on Ionizing Radiation Protection and Safety (Official gazette
No.48/02, 135/07, 53/11, 164/13, 43/14, 149/15)
Conclusion: The Law on medicinal products and medical devices of the
Republic of Macedonia is completely in compliance with the EU regula-
tive. But, it is obvious that the requirements used for non-radioactive
drugs could not be applied directly to the radiopharmaceuticals. Several
special characteristics of the radiopharmaceuticals had to be taken into
consideration. Keeping in mind that recently in Republic of Macedonia
PET centre was established and we have our own production of radio-
pharmacuticals it is necessary to take some steps forward and make the
effort to separate radiopharmaceuticals from general legislation for me-
dicinal products. Most requirements concerning documentation of the
safety and efficacy of a non-radioactive drug must be also appled to ra-
diopharmaceuticals. But, it must be recognised that radiopharmaceuti-
cals do not have a measurable pharmacodynamic effect. In the same
time radiopharmaceuticals have a changing composition with time due
to the radioactive decay of the ultra-short lived radionculides, so some-
times it is impossible to perform quality control.
Studies of chronic toxicity would only be required in special
cases. Clinical documentation would normally be more limited
than for non-radioactive drugs. Therefore, Republic of Macedonia
must to establish national registration procedures to obtain offi-
cial market authorisation for a radiopharmaceutical, taking bear-
ing in mind that we did not have a drug legislation that did also
cover radiopharmaceuticals.
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Optimization of production of [11C]CH3I with Methylator II for
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Aim: University Institute of Positron Emission Tomography Skopje is
equipped with the Methylator II (Comecer Spa. Former Veenstra In-
struments BV.), a module designed for the production of high spe-
cific activity MethylIodide ([11C]CH3I) and/or Methyl Triflate
([11C]CH3OSO2CF3) and CarbonSynthon I (Comecer Spa.) for produc-
tion of simple 11C radiopharmaceuticals. The synthesis process starts
with the production of [11C]CO2 in the cyclotron (GE PETtrace
16.5MeV) via the 14N(p,α)11C nuclear reaction. The produced [11C]CO2
is delivered into the Methylator, where it first was trapped and sub-
sequently reduced to [11C]CH4 and converted thereafter into
[11C]CH3I and/or [
11C]CH3OSO2CF3. The trapped [
11C]CO2 in the
Methanizer was reduced into a [11C]CH4 with hydrogen on a nickel
catalyst (Shinwasorb) at a rather moderate temperature 350 0C. The
next step was the purification of the [11C]CH4 over a Carboxen 1000
column, with the knowledge that the H2 will flow about 7 times fas-
ter than [11C]CH4 through carbon packing causing the separation of
H2 and CH4. This is one of the most important steps in the produc-
tion process which affects directly the equilibrium reaction which
forms the [11C]CH3I and HI, which is formed in the iodine oven by
the reaction of H2 and I2 as well
Methods: Optimization experiments where performed maximizing
the yield of [11C]CH3I. By changing the time for switching the valve
V04 (see diagram) the effectiveness of the purification was influ-
enced. In ‘Active’ state the formed [11C]CH4 and excess of H2 was di-
rected toward waste, but in ‘Inactive’ state in direction of the Iodine
Oven. If the time was too short the reduced [11C]CH4 would not be
separated thorougly enough from the H2, but when the time was
too long the produced [11C]CH4 would be lost into waste. The first
syntheses were performed with V04 active for 25 sec upon release of
the [11C]CH4, after which it was deactivated. Different timings for
switching the valve were tested and the different yields were
obtained.
Results Our result presented in the Table showed that yield of [11C]
CH3I and [
11C] Choline is purification time depended. By increasing
the time of purification (from 20 to 37 seconds) obtained trapped
[11C] CO2, is more than four time higher and harvested [
11C] CH3I as
well. After 37 seconds we obtained 41% of [11C] CH3I that is directly
reflected to the yield of [11C] Choline (34.6), fitting with our protocol
for synthesis of [11C] Choline.
Conclusion: The module and software give us a big opportunity
and flexibility for testing and optimization of the production
achieving a better yield, and also the development of new 11C
radiopharmaceuticals.Fig. 1 (abstract PP50). See text for descriptionPP51
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Aim: Cancer is the main cause of the deaths in the worldwide.
Among cancer types, lung cancer is the most common one and it is
currently the leading cause of cancer death. 80% to 85% of lung can-
cers compose non-small cell lung cancer (NSCLC) [1]. Combination
therapy in cancer has many advantages including reducing the toxic
effects exists in monotherapy, minimizing multidrug resistance and
ensuring synergistic effect for clinical response in comparison with
monotherapy [2]. Hybrid diagnostic imaging modalities like SPECT/CT
can provide both metabolic, functional and anatomic information
about the diseases. Using specific agents is essential for sufficient
functional information, better diagnosis and effective therapy of
NSCLC. Passively or actively targeted systems such as liposomes have
different interests for either therapy or diagnosis. Recent studies gen-
erally depend on the development of new delivery systems, thera-
nostics, in which diagnosis can be managed together with cancer
therapy by evaluating therapeutic effect.
Methods: Theranostic liposomes were formulated by polyethylene gly-
cole (PEG)ylated, nanosized, either passive or actively (folate conju-
gated) targeted, 99mTc labeled for SPECT/CT imaging and vinorelbine
and paclitaxel encapsulated for NSCLC therapy. Their characterization
studies were conducted.
Results Both passive and active targeted liposomes showed proper
characterization with about 10% encapsulation efficiency of vinorelbine
and 60% encapsulation efficiency of paclitaxel; around 100 nm particle
size of passive targeted liposomes and around 120 nm particle size of
active targeted formulations. All formulations designated a zeta poten-
tial around -10 - -13 mV and phospholipid efficiency of 85%. All formu-
lations designated a stable radiolabeling with 99mTc.
Conclusion: Promising characterization profiles were obtained with
both nanosized, PEGylated passive targeted and active targeted co-
delivery theranostic liposomes for both diagnosis and therapy of
NSCLC. Our studies are continuing.
Funding: This study was supported by the grant of H.U. BAB, Project
No: 12852. Paclitaxel is obtained from Bristol-Meyers Squibb as a gen-
erous gift for our non-clinical research.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, 2012,
Cancer J Clin 65: 87-108.
2. Wu M, Sirota M, Butte AJ, Chen B,2015, Pac Symp Biocomput: 68-79.
PP52
HPLC method for analysis of DOTA-TOC
M. Radzik, A. Jaroń, M. Maurin, P. Garnuszek
National Centre for Nuclear Research Radioisotope Centre POLATOM,
Otwock, Poland
Correspondence: P. Garnuszek
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):PP52
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):7 Page 38 of 38Aim: Main impurities in the 90Y-DOTA-TOC labelling process, apart
from the “free” yttrium-90, are DOTA-TOC complexes with other
metals that could be present in the solution. The most common
method for determination of radiochemical purity (RCP) of labeled
peptides is RP-HPLC. However, the standard gradient HPLC methods
may not allow determination of the DOTA-TOC complexes with
“cold” metals. The information about presence of cold metal com-
plexes might be very important in particular for investigation of rea-
sons of radiolabeling failure and poor RCP. The aim of the study was
to develop a new HPLC method that would be suitable for determin-
ation of RCP as well as for identification and determination of cold
metal complexes that could be present in 90Y-DOTA-TOC.
Methods: The new isocratic RP-HPLC method (Phenomenex Kinetex
150x4.6mm column and isocratic flow of 80% 0.1% TFA in water and
20% of 0.1% TFA in acetonitrile, 1mL/min) has been developed and
validated. Accuracy, repeatability, precision, linearity and range of the
method was checked. DOTA-TOC complexes with “hot” yttrium-90
and lutetium-177 and “cold” complexes with indium, lutetium, yt-
trium, gallium, zinc, copper, iron and lead were evaluated. The forma-
tion of complexes has been confirmed by LC-MS.
Results A very good chromatographic separation of the individual
DOTA-TOC metal complexes has been achieved. Each of the metal
complexes can be easily identified by their characteristic retention
times and could be quantitated using estimated molar absorption
coefficients. The method enabled quantitative determination of un-
labeled peptide in the radioactive preparation in the range of linear-
ity from 10 mcg to 100 mcg of DOTA-TOC (R2 = 0.999).
Conclusion: The developed isocratic HPLC method is suitable for RCP
determination of radiolabeled DOTA-TOC. In single HPLC run both the
RCP and the contribution of DOTA-TOC complexes with cold metals can
be assess, thus reflecting the specific activity of the radiolabeled peptide.
Validation confirmed that the method is accurate, repeatable and precise.
PP53
Radiochemical purity determination of 68Ga-labelled
radiopharmaceuticals. Are the TLC and HPLC results complementary?
P. Garnuszek, M. Maurin, M. Radzik
National Centre for Nuclear Research Radioisotope Centre POLATOM,
Otwock, Poland
Correspondence: P. Garnuszek
EJNMMI Radiopharmacy and Chemistry 2018, 3(Suppl 1):PP53
Aim: European Pharmacopoeia monograph for Gallium (68Ga) edo-
treotide [1] recommends HPLC and TLC as complementary methods
for radiochemical purity (RCP) determination. In TLC [68Ga]gallium in
colloidal form is determined while HPLC separates the free [68Ga]gal-
lium(III) ion and [68Ga]gallium edotreotide. Mobile phases used inthese methods have different pH values. Being aware that gallium
speciation in aqueous solution depends on pH and temperature [2],
the intrinsic questions arise: (1) what 68Ga species are realy deter-
mined, (2) are the TLC results matching the HPLC results? Herein we
are answering these questions based on our experience with 68Ga-la-
belled radiopharmaceutical preparations.
Methods: TLC and HPLC methods for RCP determination of 68Ga-
DOTA-TOC and 68Ga-DOTA-TATE were based on Ph.Eur. [1], for
68Ga-PSMA on the draft monograph [3]. Other TLC mobile phases
were also used: 1M ammonium acetate, 1M sodium acetate/
methanol, 5M sodium acetate/methanol, citrate buffer pH 5.5.
Reference solutions of 68Ga were prepared [2], in HCl (prepared
by addition of 1.5mL of H2O to 1mL of
68Ga eluate in 0.1M HCl)
and in sodium acetate (24mg/ml). RCP in all samples was
assessed by HPLC and TLC followed by calculation of 68Ga
recovery.
Results In HPLC the differences in recovery of 68Ga(III) and 68Ga
in colloidal form, 107%±1.7% and 106.2%±1.3%, respectively,
were not statistically significant. In 68Ga-PSMA11 (n = 12) both
HPLC and TLC revealed very similar results of free 68Ga:
1.64%±0.59% (HPLC) and 1.55%±0.65% (TLC). Similar observations
were made in 68Ga-DOTA-TOC and 68Ga-DOTA-TATE.
Conclusion: Depending on pH of mobile phase, the non-bound
68Ga may exists in various ionic forms. At pH around 2, HPLC
analysis of 68Ga reference sample revealed significant transition
to Ga3+ or Ga(OH)2+ cations, allowing quantitation of free 68Ga
with mobile phase containing 0.1%TFA. TLC results varie depend-
ing on mobile phase composition. Hence, we suggest that TLC is
not to be used as complementary to HPLC but as alternative
method for free 68Ga determination, even though when using 1M
sodium acetate/methanol (50/50) the results of free 68Ga were
consistent with HPLC. It should be stressed that methods for de-
termination of non-bound 68Ga in radiopharmaceutical prepara-
tions do not reflect gallium speciation in aqueous solutions.
Funding: This work was partly financed by grant No. POIR/01.02.00-00-
0041/15 from the National Centre for Research and Development
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